glucose, (beta-d)-isomer has been researched along with dapagliflozin in 1162 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (1.12) | 29.6817 |
| 2010's | 598 (51.46) | 24.3611 |
| 2020's | 551 (47.42) | 2.80 |
| Authors | Studies |
|---|---|
| Biller, SA; Deshpande, PP; Discenza, L; Ellsworth, BA; Flint, OP; Girotra, RN; Hagan, DL; Han, S; Humphreys, WG; Janovitz, EB; Khanna, A; McCann, PJ; Meng, W; Morgan, N; Morrison, EP; Nirschl, AA; Obermeier, MT; Patel, M; Pullockaran, A; Robertson, JG; Sher, PM; Taylor, JR; Wang, A; Washburn, WN; Wetterau, JR; Whaley, JM; Wu, G; Zahler, R | 1 |
| Biller, SA; Hagan, DL; Han, S; Meng, W; Taylor, JR; Washburn, WN; Wetterau, JR; Whaley, JM; Xin, L | 1 |
| Goldstein, BJ; Jabbour, SA | 1 |
| Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V | 1 |
| Donnelly, R; Idris, I | 1 |
| Boulton, D; Geraldes, M; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N | 1 |
| Feng, Y; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N | 1 |
| Kipnes, M | 1 |
| Bastien, A; Fiedorek, FT; List, JF; Norwood, P; T'joen, C; Wilding, JP | 1 |
| Brooks, AM; Thacker, SM | 1 |
| Woo, VC | 1 |
| Calado, J | 1 |
| Discenza, L; Ellsworth, BA; Humphreys, WG; Kasichayanula, S; Khanna, A; Komoroski, B; Koplowitz, B; Li, W; Meng, W; Obermeier, M; Washburn, W; Whaley, JM; Yao, M; Zhu, M | 1 |
| Campbell, RK; Neumiller, JJ; White, JR | 1 |
| Feng, Y; Kasichayanula, S; List, J; Pfister, M; Zhang, L | 1 |
| Sharma, K; Vallon, V | 1 |
| Ferrannini, E; List, JF; Ramos, SJ; Salsali, A; Tang, W | 1 |
| Forst, T; Hanefeld, M | 1 |
| Bailey, CJ; Bastien, A; Gross, JL; List, JF; Pieters, A | 1 |
| Jones, HB; Macdonald, FR; Mayers, RM; Peel, JE; Poucher, SM; Westgate, L; Whaley, JM | 1 |
| Katsiki, N; Mikhailidis, DP; Papanas, N | 1 |
| Arnold, M; Aubry, AF; Cai, J; Couerbe, P; Deng, Y; Gu, H; Magnier, R; Morgan, L; Tirmenstein, M; Wang, B; Xu, X | 1 |
| Cano Megías, M; González Albarrán, O; Pérez López, G | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Boulton, DW; Chang, M; Hasegawa, M; Imai, Y; Kasichayanula, S; LaCreta, FP; Liu, X; Yamahira, N | 1 |
| Gong, N; Wang, YX; Zhang, WB | 1 |
| Aubry, AF; Boulton, DW; Kasichayanula, S; LaCreta, FP; Liu, X; Pfister, M; Reele, SB; Zhang, W | 1 |
| Chao, EC | 2 |
| Cassader, M; Gambino, R; Musso, G; Pagano, G | 1 |
| Kang, SY; Kim, MJ; Lee, J; Lee, JS | 1 |
| Heger, M | 1 |
| Elze, M; Hruba, V; Langkilde, AM; Parikh, S; Strojek, K; Yoon, KH | 2 |
| Basile, J | 1 |
| Del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, MA; Parikh, SJ; Rohwedder, K | 1 |
| Boustany-Kari, CM; Ghosh, A; Haddish-Berhane, N; Kimoto, E; Leininger, MT; Mascitti, V; Maurer, TS; Robinson, RP; Sawant-Basak, A; She, L; Tugnait, M; Yang, X; Zhu, T | 1 |
| Cho, SH; Kang, M; Kim, J; Kim, JY; Lee, J; Lee, JS; Lee, SH; Park, HJ; Song, KS | 1 |
| Kardara, MS; Papazafiropoulou, AK; Pappas, SI | 1 |
| Mansoury, H; Miracle, C; Rieg, T; Singh, P; Thomson, SC; Vallon, V; Whaley, J | 1 |
| Barrio, JR; Ghezzi, C; Hirayama, BA; Hummel, CS; Kepe, V; Liu, J; Loo, DD; Lu, C; Wright, EM | 1 |
| Ernest, P; Jandrain, BJ; Radermecker, RP; Scheen, AJ | 1 |
| Boulton, DW; Kasichayanula, S; LaCreta, FP; Liu, X; Pfister, M; Zhang, W | 1 |
| Bastien, A; Gerich, JE | 1 |
| Bolinder, J; Johansson, L; Kullberg, J; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sugg, J; Wilding, J | 1 |
| Barnett, AH; Bhartia, M; Tahrani, AA | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
| Burki, TK | 1 |
| Diène, C; Digard, E; Farina, V; Gavryushin, A; Gozlan, C; Houpis, IN; Knochel, P; Lemaire, S; Li, J; Liu, R; Wang, Y; Xiao, T | 1 |
| Choksi, R; Deeb, WE; Epstein, BJ; Shah, NK | 1 |
| Cullen, MJ; Devenny, JJ; Godonis, HE; Harvey, SJ; Pelleymounter, MA; Rooney, S | 1 |
| Hennicken, D; Henry, RR; List, JF; Marmolejo, MH; Murray, AV; Ptaszynska, A | 1 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 2 |
| Smith, SA | 1 |
| Anderson, SL; Marrs, JC | 1 |
| List, JF; Rosenstock, J; Salsali, A; Vico, M; Wei, L | 1 |
| Simonyi, G | 1 |
| Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J | 2 |
| Bailey, CJ; Iqbal, N; List, JF; T'joen, C | 1 |
| Arnold, ME; Boulton, DW; Christopher, LJ; Kasichayanula, S; Keung, CF; Lacreta, F; Xu, XS | 1 |
| Boulton, DW; Jabbour, SA; List, JF; Parikh, S; Poucher, SM; Reilly, TP; Saye, J; Tirmenstein, M; Whaley, JM | 1 |
| Shen, JK; Wan, HX | 1 |
| DeFronzo, RA; Lee, T; Liu, JJ | 1 |
| Komala, MG; Mather, A; Panchapakesan, U; Pollock, C | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; Lacreta, FP; Liu, X | 1 |
| Paisley, AJ; Paisley, AN; Rao-Balakrishna, P; Soran, H; Yadav, R; Younis, N | 1 |
| Plosker, GL | 2 |
| Azuma, H; Hayashi, N; Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Matsuoka, O; Parikh, S; Tokudome, T | 1 |
| Boulton, DW; Humphreys, WG; Kasichayanula, S; LaCreta, FP; Liu, X; Pe Benito, M; Pfister, M; Yao, M | 1 |
| Forst, T; Rosak, C | 1 |
| Chen, LH; Leung, PS | 1 |
| Bailey, CJ; Gross, JL; Hennicken, D; Iqbal, N; List, JF; Mansfield, TA | 1 |
| Anthony, S; Bajwa, H; Peter, R | 1 |
| Del Prato, S; Nauck, M | 1 |
| del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K | 1 |
| Anuraj, NS; Jyoti, A; Mukesh, Y; Nishant, S; Prasoona, RK; Shobha, J | 1 |
| Hinneburg, I | 1 |
| de Zeeuw, D; Lambers Heerspink, HJ; Leslie, B; List, J; Wie, L | 1 |
| Bloomgarden, Z | 1 |
| Demaris, KM; White, JR | 1 |
| Boulton, DW; Ching, A; DeFronzo, RA; Griffen, SC; Hompesch, M; Hong, Y; Kasichayanula, S; LaCreta, FP; Leslie, BR; Liu, X; Morrow, LA; Pfister, M | 1 |
| Harris, KB; Riser Taylor, S | 1 |
| Hardy, E; Johnsson, E; List, J; Parikh, S; Ptaszynska, A | 1 |
| Freeman, JS | 1 |
| Abdul-Ghani, MA; DeFronzo, RA | 1 |
| Boulton, DW; Gould, JC; Kasichayanula, S; Shepperly, DC | 1 |
| Boulton, DW; Bui, A; Chang, M; Griffen, SC; Kasichayanula, S; Lacreta, FP; Li, H; Liu, X; Yang, L | 1 |
| Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V | 1 |
| Andrianesis, V; Doupis, J | 1 |
| Kvapil, M | 1 |
| Elisaf, MS; Rizos, EC | 1 |
| Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ | 1 |
| Fioretto, P; Kohan, DE; List, JF; Tang, W | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; Lacreta, F; Liu, X | 1 |
| An, Z; Li, S; Song, H; Wu, B; Zhang, L; Zhang, M | 1 |
| Kirk, R | 1 |
| Kilov, G; Leow, S; Thomas, M | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| le Roux, CW; Miras, AD | 1 |
| Che, WS; Chen, X; Leung, SW; Sun, YN; Zhou, Y | 2 |
| Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S | 1 |
| Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G | 1 |
| Bergenheim, K; McEwan, P; Pompen, M; Roudaut, M; Townsend, R; van Haalen, HG | 1 |
| D'Souza, LJ; Janssen, S; Parkes, DG; Polizzi, C; Tatarkiewicz, K; Villescaz, C; Wang, Y | 1 |
| Gilbert, RE | 2 |
| Mannucci, E; Monami, M; Nardini, C | 1 |
| Ledford, H | 1 |
| Iqbal, N; Ji, L; Li, H; List, JF; Ma, J; Mansfield, TA; Ptaszynska, A; T'joen, CL | 1 |
| Scheen, AJ | 8 |
| Fukazawa, M; Hiramatsu, M; Honda, K; Kawabe, Y; Matsumoto, M; Suzuki, M; Suzuki, Y | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD | 1 |
| García, SD | 1 |
| García, SD; Sanz, AD; Sanz, SD | 1 |
| Mauricio, D | 1 |
| Albarrán, OG; Ampudia-Blasco, FJ | 1 |
| Cefalu, WT | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Traynor, K | 1 |
| Grandy, S; Langkilde, AM; Parikh, S; Sjöström, CD; Sugg, JE | 1 |
| Bakris, GL; Oliva, RV | 1 |
| Kumar, M; Kumar, R; Mahapatra, MK; Malla, P | 1 |
| Balakumar, P; Dhanaraj, SA; Sundram, K | 1 |
| Chen, Z; Chintala, M; Feng, W; Graziano, MP; Li, Q; Shang, J; Wang, M; Wu, W; Wu, Y | 1 |
| Bergenheim, K; Ekman, M; Granström, O; McEwan, P; Sabale, U | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 2 |
| Davis, CS; Fleming, JW; Warrington, LE | 1 |
| Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Tokudome, T; Ueda, N; Yang, J | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Chung, SH; Kim, GW | 1 |
| Eguchi, J; Hatanaka, T; Horiguchi, CS; Makino, H; Nakatsuka, A; Nishii, N; Ogawa, D; Tachibana, H; Takei, K; Terami, N; Wada, J; Yamada, H | 1 |
| Angelopoulos, TP; Doupis, J | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Apanovitch, AM; de Bruin, TW; Johnsson, KM; List, JF; Parikh, SJ; Ptaszynska, A | 1 |
| Chanda, S; Choudhury, SR; Das, S; Datta, A; Pathak, AN | 1 |
| Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A | 1 |
| Burgess, L; de Bruin, TW; Hamer-Maansson, JE; Hruba, V; Korányi, L; Schumm-Draeger, PM | 1 |
| Nauck, MA | 1 |
| Bogle, A; Chalamandaris, AG; Edelman, S; Griffen, SC; Henry, RR; Iqbal, N; Kasichayanula, S; List, J; Mudaliar, S; Rosenstock, J | 1 |
| Mediavilla Bravo, JJ | 1 |
| Lajara, R | 1 |
| Vallon, V | 1 |
| Bennett, H; Bergenheim, K; McEwan, P; Ward, T | 1 |
| Sigler, J | 1 |
| Alkaabi, JM; Hamouda, NN; Howarth, FC; Oz, M; Qureshi, MA; Sydorenko, V | 1 |
| Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P | 1 |
| Navarro, D | 1 |
| Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V | 1 |
| Svačina, S | 1 |
| Davidson, JA; Kuritzky, L | 1 |
| Carnovale, A; Durante, C; Filetti, S; Maranghi, M; Tarquini, G; Tiseo, G | 1 |
| Farrell, K; Ghosh, A; Natarajan, J; Pinheiro, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Hardy, E; Jabbour, S; Parikh, S; Wilding, J | 1 |
| de Bruin, TW; Hamer-Maansson, JE; Parikh, S; Reele, S; Tang, W | 2 |
| Al-Busaidi, N; Rizvi, AA; Rizzo, M | 1 |
| Blau, JE; Rother, KI; Taylor, SI | 1 |
| Narendran, P; Saeed, MA | 1 |
| Almodóvar Carretón, MJ; Escudero Vilaplana, B; Herrero Hernández, S | 1 |
| Abad Paniagua, EJ; Betegón Nicolás, L; Brosa, M; Casado Escribano, P; Fernández Rodriguez, JM; Morales Escobar, FJ; Sánchez-Covisa, J | 1 |
| Cai, W; Jiang, L; Liu, W; Liu, Y; Xie, Y; Zhao, G | 1 |
| Barengo, NC; MacKinnon, I; Sposetti, G | 1 |
| Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K | 1 |
| Davis, PN; Ndefo, UA; Oliver, A | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Arnold, ME; Aubry, AF; Basdeo, S; Boulton, DW; Ji, QC; Liu, G; Liu, J; Ma, E; Mylott, W; Shen, JX; Stouffer, B; Xu, X | 1 |
| Miller, SA; Powell, J; Taylor, JR | 1 |
| Mikhail, N | 1 |
| Vivian, EM | 1 |
| Abdul-Ghani, M; Chavez-Velazquez, A; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Urban McCarthy, S; Xiong, J | 1 |
| Abdul-Ghani, M | 1 |
| Hussar, DA | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Rupprecht, H | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 2 |
| Dutta, D; Kalra, S | 1 |
| Miller, S; Onge, ES; Whalen, K | 1 |
| Abderrahmani, A; Beaucamps, C; Bonner, C; Delalleau, N; Deprez, B; Gmyr, V; Kerr-Conte, J; Malaisse, WJ; Moerman, E; Pattou, F; Popescu, I; Queniat, G; Sener, A; Staels, B; Thévenet, J | 1 |
| Edenhofer, I; Kapoor, S; Mitchell, K; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP | 1 |
| Hashemi, M; Johnsson, E; Ptaszynska, A; Sjöström, CD; Sugg, J | 1 |
| Johansson, P; Johnsson, E; List, J; Ptaszynska, A; Sjöström, CD | 1 |
| Pickl, S | 1 |
| Boulton, DW; Chang, M; Cui, D; Griffen, SC; LaCreta, F; Liang, D; Liu, X; Lubin, S; Quamina-Edghill, D | 1 |
| Banks, P; Bode, BW; Buse, JB; Cefalu, WT; Garg, SK; Heptulla, R; Lapuerta, P; Rendell, M; Rosenstock, J; Sands, AT; Strumph, P; Zambrowicz, BP | 1 |
| Handelsman, Y | 2 |
| Chau, N; Miners, JO; Pattanawongsa, A; Rowland, A | 1 |
| Fath, R | 1 |
| Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J | 1 |
| Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE | 1 |
| Clements, JN; D'Souza, JJ; Gentry, C; Gross, B; Hess, R; Reece, S; Shealy, K; Whitley, HP | 1 |
| Bagger, JI; Knop, FK; Rungby, J; Storgaard, H; Vilsbøll, T | 1 |
| Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S | 1 |
| Hattersley, AT; Thorens, B | 1 |
| Stephens, JW; Williams, DM | 1 |
| Vivian, E | 1 |
| Fioretto, P; Giaccari, A; Sesti, G | 1 |
| Ishii, S; Kato, H; Nagai, Y; Nakamura, Y; Nishine, A; Ohta, A; Tanaka, Y; Terashima, Y | 1 |
| Boulton, DW; Johnsson, E; LaCreta, F; Leil, TA; Tang, W | 1 |
| Okada, J; Okada, S; Osaki, A; Saito, T; Shibusawa, R; Shimoda, Y; Tagaya, Y; Yamada, E; Yamada, M | 1 |
| Grandy, S; Rohwedder, K; Ryden, A; Sternhufvud, C; Sugg, J | 1 |
| Abbas, A; Bustamante, M; Farah, Z; Gosavi, S; Mukherjee, D; Said, S; Shami, W; Syed, SH; Teleb, M | 1 |
| Hu, J; Tan, X | 1 |
| Yacoub, T | 1 |
| Han, P; Iqbal, N; Johnsson, E; Mansfield, T; Min, KW; Ptaszynska, A; T'Joen, C; Wang, B; Yang, W | 1 |
| Hirano, T; Hiromura, M; Kohashi, K; Kushima, H; Mori, Y; Nagashima, M; Terasaki, M; Watanabe, T | 1 |
| Bjourson, AJ; Flatt, PR; Gault, VA; Millar, PJ; Moffett, RC; O'Kane, MJ; Pathak, NM; Pathak, V | 1 |
| Cain, VA; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Alessi, F; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kitaura, C; LaCreta, F; Lubin, S; Pollack, A | 1 |
| Edenhofer, I; Kapoor, S; Kipar, A; Mei, C; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP; Yang, M | 1 |
| Gilbert, RE; Kepecs, DM; Thai, K; Zhang, Y | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Weir, MR | 1 |
| Biagetti, B; Dalama, B; Mesa, J | 1 |
| Miller, EM; Miller, K | 1 |
| Johnsson, E; Johnsson, K; Mansfield, TA; Parikh, SJ; Ptaszynska, A; Yavin, Y | 1 |
| Kamaruddin, NA; Kori, N; Mohd Noor, N; Mustafa, N; Othman, H; Rajoo, S; Sukor, N; Wahab, NA; Wan Seman, WJ | 1 |
| Fioretto, P; Johnsson, K; Kohan, DE; Parikh, S; Ptaszynska, A; Ying, L | 1 |
| Gause-Nilsson, I; Johansson, PA; Johnsson, E; Sonesson, C | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Cain, VA; Gause-Nilsson, I; Heerspink, HJ; Johnsson, E; Sjöström, CD | 1 |
| Geissel, W | 1 |
| Asai, Y; Chiba, Y; Imai, J; Katagiri, H; Kodama, S; Munakata, Y; Nakamura, K; Sawada, S; Shirai, Y; Sugisawa, T; Takahashi, K; Tsukita, S; Uno, K; Yamada, T | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
| Bonnes, H; Katz, A; Skolnik, N; Yeh, H | 1 |
| Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F | 1 |
| Hemmingsen, B; Krogh, J; Metzendorf, MI; Richter, B | 1 |
| Ahmed-Sarwar, N; Nathan, KT; Werner, P | 1 |
| Edelsberger, T | 1 |
| Araki, E; Asano, M; Ekholm, E; Johnsson, E; Kim, H; Onishi, Y; Yajima, T | 1 |
| Valek, R; Von der Mark, J | 1 |
| Kourlaba, G; Maniadakis, N; Tentolouris, N; Tzanetakos, C | 1 |
| Torjesen, I | 1 |
| Boulton, DW; Ismat, FA; LaCreta, F; Tang, W; Tirucherai, GS | 1 |
| Boulton, DW; Hamrén, B; Johansson, CC; Parkinson, J; Tang, W | 1 |
| Kawaguchi, M; Mori, H; Okada, Y; Tanaka, Y | 1 |
| Cain, VA; Fioretto, P; Johnsson, E; Sjöström, CD; Stefansson, BV | 1 |
| Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Faillie, JL | 1 |
| Chang, YK; Choi, DE; Choi, H; Jeong, JY; Lee, KW; Lim, BJ; Na, KR | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Hsu, YH; Li, DD; Song, YQ; Tang, HL; Wang, TS; Zhai, SD; Zhang, JJ | 1 |
| Bloch, MJ | 1 |
| Boulton, DW; Griffen, SC; Hines, C; LaCreta, F; Liu, X; Smith, C; Tejwani, R; Volk, K | 1 |
| Carlson, CJ; Santamarina, ML | 1 |
| Lam, S | 1 |
| Billger, M; Johnsson, E; Johnsson, K; Mellander, A; Träff, AK; Yoshida, S | 1 |
| Batra, M; Chaudhuri, A; Dandona, P; Garg, M; Ghanim, H; Hejna, J; Khan, S; Kuhadiya, ND; Makdissi, A; Mehta, A; Torre, B | 1 |
| Boulton, DW; LaCreta, F; Liang, D; Lubin, S; Marion, AS; Reynolds, L; Vakkalagadda, B | 1 |
| Javor, E; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Ahlstedt, I; El Hachmane, MF; Göpel, SO; Pedersen, MG | 1 |
| Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Norton, L; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Barrio, JR; Ghezzi, C; Hirayama, BA; Huang, SC; Kepe, V; Liu, J; Powell, DR; Satyamurthy, N; Scafoglio, C; Wright, EM; Yu, AS | 1 |
| Cain, VA; Ji, L; Johnsson, KM; Sjöström, CD; Yang, W; Zhou, Z | 1 |
| Del Gobbo, LC; Li, Y; Song, Y; Tang, H; Zhai, S; Zhang, J; Zhang, X | 1 |
| Mudher Mikhael, E | 1 |
| Knop, FK; Rungby, J; Røder, ME; Storgaard, H; Vilsbøll, T | 1 |
| Aschenbrenner, DS | 3 |
| Dalama, B; Mesa, J | 1 |
| Keller, JP; Looger, LL | 1 |
| Gao, G; Li, FF; Li, Q; Ma, JH; Su, XF; Wu, JD; Ye, L; Zhu, HH | 1 |
| Kaku, K; Kaneto, H; Kimura, T; Matsuoka, TA; Obata, A; Okauchi, S; Shimo, N; Shimoda, M | 1 |
| Wise, J | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
| Ahn, YB; Chung, S; Kim, ES; Kim, JW; Kim, MJ; Kim, SJ; Ko, SH; Lee, EM; Moon, SD; Shin, SJ; Yoo, YH | 1 |
| Dong, H; Gu, S; Mu, Y; Zeng, Y; Zhai, S; Zhen, X | 1 |
| Liu, S; Mir, MU; Shao, H; Shi, L; Shi, Q; Zawadzki, NK; Zhai, S; Zou, D | 1 |
| Reed, JW | 1 |
| Mannucci, E; Monami, M | 1 |
| Bennett, C; Christensen, MB; Gluud, LL; Grøndahl, MF; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Gilbert, JD; Goldenberg, RM; Perkins, BA; Verma, S; Zinman, B | 1 |
| Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E | 1 |
| Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T | 1 |
| Chen, L; Efe, O; Klein, JD; LaRocque, LM; Sands, JM; Wang, J | 1 |
| Chan, SP; Lim, LL; Moses, K; Rajadhyaksha, V; Tan, AT | 1 |
| Bonacorsi, SJ; Brailsford, JA; Caceres-Cortes, J; Cao, K; Espina, R; Yao, M | 1 |
| Cefalu, WT; Grove, O; Hsia, DS | 1 |
| Kristensen, FB; Lindberg, MJ; Yildiz, A | 1 |
| Mende, CW | 1 |
| Araki, E; Asano, M; Kim, H; Onishi, Y; Yajima, T | 1 |
| González-Ortiz, M; Martínez-Abundis, E; Méndez-Del Villar, M; Ramírez-Rodríguez, AM | 1 |
| Ayer, A; Cariou, B; Charpentier, F; Dollet, L; Jagu, B; Joubert, M; Le May, C; Magré, J; Manrique, A; Marechal, X; Montaigne, D; Prieur, X; Staels, B; Tesse, A; Toumaniantz, G | 1 |
| Gregus, Z; Németi, B; Poór, M | 1 |
| Almodóvar-Ruiz, F; Feo-Ortega, G; Gorgojo-Martínez, JJ; Sanz-Velasco, A; Serrano-Moreno, C | 1 |
| Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y | 1 |
| Fukui, T; Hayashi, T; Hirano, T; Ito, Y; Nakanishi, N; Ohara, M; Osamura, A; Tomoyasu, M; Yamamoto, S; Yamamoto, T | 1 |
| Cha, BS; Kang, ES; Kim, G; Kim, SR; Lee, BW; Lee, JY; Lee, YH | 1 |
| Dandona, P; Hansen, L; Henry, RR; Mudaliar, S; Pettus, J; Xu, J | 1 |
| Nuffer, WA; Trujillo, JM | 1 |
| Chen, L; Deng, W; Lei, X; Leng, W; Liang, Z; Ouyang, X; Wu, M; Wu, Q | 1 |
| Clar, C; Clegg, A; Colquitt, J; Court, R; Cummins, E; Holt, T; Johnston, R; McGrane, D; O'Hare, JP; Royle, P; Shantikumar, S; Tan, BK; Uthman, O; Waugh, N | 1 |
| Bodegard, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M | 2 |
| Hammar, N; Hankins, M; Kim, J; Tsai, K | 1 |
| Boyland, EJ; Cuthbertson, DJ; Halford, JC; Harrold, JA; Kemp, GJ; Rajeev, SP; Roberts, C; Sprung, VS; Stancak, A; Wilding, JP | 1 |
| Chang, NC; Lee, TM; Lin, SZ | 1 |
| Garnock-Jones, KP | 1 |
| Kazazis, C; Trigkidis, K; Vallianou, NG | 1 |
| Åstrand, A; Baines, DL; Baker, EH; Benjamin, A; Garnett, JP; Gill, S; Groves, H; Lundqvist, AJ; Orogo-Wenn, M; Smith, DM; Taylor, JD; Tregoning, JS; Walters, D; Wingren, C | 1 |
| Bramlage, P; Friedrich, S; Jumar, A; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
| Li, D; Li, Y; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Andrikopoulos, S; Joannides, CN; Lamont, BJ; Mangiafico, SP; Waters, MF | 1 |
| Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
| Avogaro, A; Fioretto, P | 1 |
| Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, SI | 1 |
| Busch, S; Kostev, K; Pscherer, S; Rist, R; Scheerer, MF | 1 |
| Ejskjaer, N; Heinemann, L; Klonoff, D; Pfützner, A; Pickup, J | 1 |
| Dey, J | 1 |
| Buchholt, AT; El Khoury, AC; Kamal, A; Schubert, A; Taieb, V | 1 |
| Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH | 1 |
| Lingvay, I | 1 |
| Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Fadini, GP; Iori, E; Marescotti, MC; Vitturi, N; Zatti, G | 1 |
| Kajiya, S; Kawasoe, M; Kawasoe, S; Kubozono, T; Maruguchi, Y; Miyata, M; Ohishi, M; Uenomachi, H | 1 |
| Rajput, R; Ved, J | 1 |
| Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
| Chen, JM; Deng, JH; Lu, TB; Sun, CC | 1 |
| Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF | 1 |
| Burudpakdee, C; Cai, J; Divino, V | 1 |
| Aoki, C; Aso, Y; Kato, K; Niitani, T; Sagara, M; Suzuki, K; Wakamatsu, S; Yanagi, K | 1 |
| Avogaro, A; Del Prato, S; Fioretto, P; Genovese, S; Giaccari, A; Giorgino, F; Purrello, F | 1 |
| Ahmed, M; Crowley, RK; McKenna, MJ | 1 |
| Chaudhuri, A; Dandona, P | 1 |
| Harindhanavudhi, T; Ruanpeng, D; Sangtian, J; Ungprasert, P | 1 |
| Bajaj, M; Birnbaum, Y; Perez-Polo, JR; Yang, HC; Ye, Y | 1 |
| Tschöpe, D | 1 |
| Dotta, F; Nigi, L; Rossi, C; Santini, E; Sebastiani, G; Solini, A | 1 |
| Arya, N; Birkeland, KI; Bodegård, J; Cavender, MA; Fenici, P; Fu, AZ; Hammar, N; Holl, RW; Jørgensen, ME; Khunti, K; Kosiborod, M; Norhammar, A; Thuresson, M; Wilding, JP | 1 |
| Abbate, A; Baker, WL; Brown, R; Bucheit, JD; Buckley, LF; Carbone, S; Dixon, DL; Kelly, MS; Parod, ED | 1 |
| Fralick, M; Goldberg, N | 1 |
| Ekinci, EI; Hall, V; Johnson, D; Kwong, J | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Gurung, A; Min, T; Plummer, E; Stephens, JW; Wali, L; Williams, DM | 1 |
| Greenfield, JR; Isaacs, M; Tonks, KT | 1 |
| Bailey, C; Blak, B; Emmas, C; Kok, M; Rigney, U; Wilding, J | 1 |
| Chen, S; Davidson, JA; Holland, WL; Lee, Y; Li, J; McCorkle, SK; Roth, MG; Scherer, PE; Unger, RH; Wang, MY; Wang, ZV; Yu, X | 1 |
| Maltezos, E; Pafili, K; Papanas, N | 1 |
| Coady, MJ; Lapointe, JY; Wallendorff, B | 1 |
| Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M | 1 |
| Glodzik, W; Hohendorff, J; Kapusta, M; Kiec-Wilk, B; Klupa, T; Ludwig-Galezowska, A; Malecki, MT; Mrozinska, S; Parpan, T; Platek, T; Skupien, J; Szopa, M; Zapala, B | 1 |
| Bjourson, AJ; Flatt, PR; Gault, VA; Millar, P; Moffett, RC; O'Kane, M; Parthsarathy, V; Pathak, N; Pathak, V | 1 |
| Gadzhanova, S; Pratt, N; Roughead, E | 1 |
| Adamson, KA; Bain, SC; Barnes, DJ; Chowdhury, TA; Chuah, LL; Morris, DS; Robinson, AM; Ryder, REJ; Thong, KY; Yadagiri, M | 1 |
| de J Patiño-Laguna, A; Díaz-Cruz, C; González-Ortiz, M; Grover-Páez, F; López-Murillo, LD; Martínez-Abundis, E | 1 |
| Hirose, T; Ikehara, K; Kanda, E; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Drexler, A | 1 |
| Jabbour, S | 1 |
| Pereyra A, M; Ramírez, C; Román, R | 1 |
| Chen, H; Kang, Q; Kuang, H; Liao, L; Shu, X; Wang, Y | 1 |
| Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M | 2 |
| Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P | 1 |
| Chang, A; Chauhan, K; Coca, SG; Ferket, B; Ferrandino, R; Grams, ME; Nadkarni, GN; Poojary, P; Saha, A; Surapaneni, A | 1 |
| Aronson, R; Brown, RE; Gupta, N | 1 |
| Brown, AJM; Lang, C; McCrimmon, R; Struthers, A | 1 |
| Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H | 1 |
| Coppenrath, VA; Hydery, T | 1 |
| Angelopoulou, A; Avgoustakis, K; Bakandritsos, A; Kolokithas-Ntoukas, A; Voulgari, E | 1 |
| Kruger, DF; Novak, LM | 1 |
| Bailey, CJ; Jabbour, S; Karup, C; Langkilde, AM; Scheen, A; Seufert, J | 1 |
| Avogaro, A; Bonora, E; Consoli, A; Fadini, GP; Sesti, G; Zatti, G | 1 |
| Dear, AE; Gaspari, T; Hu, Y; Liu, H; Simpson, RW; Spizzo, I; Widdop, RE | 1 |
| Barbosa, FT; Lima, FJC; Santos, LL; Sousa-Rodrigues, CF | 1 |
| Adrio, B; Agra, RM; Díaz-Rodríguez, E; Eiras, S; Fernández, ÁL; García-Caballero, T; González-Juanatey, JR | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV | 1 |
| Kaira, K; Katoh, R; Kusano, M; Matsumoto, S; Okada, J; Okada, S; Saito, T; Yamada, E; Yamada, M; Yokoo, H | 1 |
| Bruno, RM; Ghiadoni, L; Giannini, L; Seghieri, M; Solini, A; Taddei, S; Vitolo, E | 1 |
| Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS | 1 |
| Fraser, S; Osgood, S | 1 |
| Advani, A; Advani, SL; Bjornstad, P; Bowskill, BB; Cattran, D; Cham, L; Cherney, DZI; Gibson, IW; Hladunewich, MA; Kabir, MG; Lai, V; Lovshin, JA; Lytvyn, Y; Majumder, S; Rajasekeran, H; Reich, HN; Sood, MM; Tse, J | 1 |
| Chattipakorn, N; Chattipakorn, SC; Sa-Nguanmoo, P; Siri-Angkul, N; Sivasinprasasn, S; Tanajak, P; Thummasorn, S | 1 |
| Brown, F; McColl, T | 1 |
| Abiru, N; Ando, T; Haraguchi, A; Hongo, R; Horie, I; Ito, A; Kawakami, A; Nakamura, T; Natsuda, S; Sagara, I | 1 |
| Bowles, K; Bradshaw, A; Meosky, K; Mospan, C; Mospan, G; Vance, S | 1 |
| Bilezikian, JP; Hanif, W; Keerthy, D; Kotsa, K; Nirantharakumar, K; Tahrani, AA; Thayakaran, R; Thomas, GN; Toulis, KA | 1 |
| Ahlqvist, M; Gilmour, R; Kankkonen, C; Kehr, G; Knerr, L; Sadurní, A; Sjögren, HP; Wernevik, J | 1 |
| Kim, JH; Li, Y; Ma, J; Ptaszynska, A; Yang, W; Zhao, J; Zhou, Z | 1 |
| Chao, YS; Chen, CT; Hsieh, TC; Huang, CY; Huang, YC; Huang, YL; Lee, JC; Song, JS; Wang, MH; Wu, SH; Yao, CH; Yeh, TK; Yuan, MC | 1 |
| Hieshima, K; Jinnouchi, H; Jinnouchi, K; Jinnouchi, T; Kajiwara, K; Kurinami, N; Miyamoto, F; Nishimura, H; Sugiyama, S; Suzuki, T; Yoshida, A | 2 |
| Levi, M; Luo, Y; Myakala, K; Orlicky, DJ; Wang, D; Wang, X; Yang, P | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kishi, S; Kitazawa, H; Okabe, M; Sato, M; Sato, T; Takahashi, M; Yuasa, S | 1 |
| Boemke-Zelch, F; Bosch, A; Kannenkeril, D; Karg, MV; Linz, P; Nagel, AM; Ott, C; Schmieder, RE; Schneider, MP; Striepe, K; Titze, J; Uder, M | 1 |
| Brandjes, DPM; Gerards, MC; Gerdes, VEA; Hageman, IMG; Hoekstra, JBL; Kross, M; Patberg, KW; Potter van Loon, BJ; Snijders, D; Venema, GE; Vriesendorp, TM | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD | 1 |
| Chan, MJ; Hsu, CW; Huang, WH; Weng, CH; Yen, TH | 1 |
| Cain, V; Dekkers, CCJ; Heerspink, HJL; Sjöström, CD; Stefansson, BV; Wheeler, DC | 1 |
| Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M | 1 |
| Cracowski, JL; Khouri, C; Roustit, M | 1 |
| Boulton, DW; Griffen, SC; Leslie, BR; Shen, W; Wilcox, CS | 1 |
| Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF | 1 |
| Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J | 1 |
| Azoulay, L; Filion, KB; Puckrin, R; Reynier, P; Saltiel, MP; Yu, OHY | 1 |
| Bain, SC; Bashir, J; Chudleigh, R; Nalla, P; Peter, R | 1 |
| Geng, X; He, J; Huang, W; Jia, Y; Lei, L; Meng, X; Su, L; Wang, L; Yang, B; Zhang, S; Zhou, H | 1 |
| Bajaj, M; Birnbaum, Y; Yang, HC; Ye, Y | 1 |
| Avogaro, A; Baldi, I; Bottigliengo, D; Consoli, A; Fadini, GP; Giaccari, A; Sesti, G; Zatti, G | 1 |
| Al-Sharea, A; Goldberg, IJ; Hu, Y; Huggins, LA; Murphy, AJ; Nagareddy, PR | 1 |
| Caerels, S; Mathieu, C; Van den Mooter, L | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Bortolozzi, M; Cappellari, R; Ceolotto, G; Fadini, GP; Menegazzo, L; Romanato, F; Scattolini, V; Vigili de Kreutzeberg, S | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Cherney, DZ; Dekkers, CCJ; Gansevoort, RT; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F | 1 |
| Blonde, L; Bookhart, B; Chen, YW; Patel, C; Pfeifer, M; Wu, B | 1 |
| Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N | 1 |
| Bell, KF; Eudicone, JM; Gani, R; Huang, H; Krukas-Hampel, MR; Tugwell, CW | 1 |
| Bell, KF; Enhoffer, DM; Eudicone, JM; Green, JB; Latham, K; Wittbrodt, ET | 1 |
| Battson, ML; Ecton, KE; Gentile, CL; Hou, S; Jarrell, DK; Lee, DM; Weir, TL | 1 |
| Berlie, HD; Bertran, E; Jaber, L; Nixon, A | 1 |
| Alghdban, MK; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| Akturk, HK; Garg, SK; Rewers, A | 1 |
| Íbias, J; Nazarian, A; O'Dell, LE | 1 |
| Jeon, HJ; Ku, EJ; Oh, TK | 1 |
| Forest, CP; Tat, V | 1 |
| Aiello, V; Brancato, D; Di Noto, A; Fleres, M; Provenzano, F; Provenzano, V; Saura, G; Scorsone, A; Spano, L | 1 |
| Hieshima, K; Jinnouch, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Miyamoto, F; Sugiyama, S; Yoshida, A | 1 |
| Christy, J; Erbas, O; Erdogan, A; Erdogan, MA; Solmaz, V; Taskiran, E; Yusuf, D | 1 |
| Fukuhara, A; Nishitani, S; Okuno, Y; Otsuki, M; Shimomura, I; Shin, J | 1 |
| Fuchigami, A; Hirose, T; Kumashiro, N; Shigiyama, F | 1 |
| Bansilal, S; Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IA; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JP; Wiviott, SD | 1 |
| Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, LO; Wanchai, K | 1 |
| Ebenbichler, CF; Kempf, P; Laimer, M; Lunger, L; Mader, JK; Melmer, A; Pieber, TR; Stettler, C; Tilg, H | 1 |
| Chou, YM; Goh, ZNL; Lin, CC; Seak, CJ; Seak, CK; Seak, JC | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| Deng, L; Li, Z; Liang, R; Liao, R; Xu, X; Zhang, B; Zhang, L | 1 |
| Chiba, Y; Katagiri, H; Yamada, T | 1 |
| de Albuquerque Rocha, N; McCullough, PA; McGuire, DK; Neeland, IJ; Toto, RD | 1 |
| Eriksson, JW; Forsberg, GB; Jansson, PA; Johansson, L; Kvarnström, M; Lind, L; Lundkvist, P; Miliotis, T; Moris, L; Oscarsson, J; Risérus, U | 1 |
| Connelly, KA; Desjardins, JF; Gilbert, RE; Thai, K; Zhang, Y | 1 |
| Engel, SS; Kaufman, KD; Lam, RLH; Morgan, J; O'Neill, EA; Raji, A; Scott, R; Zimmer, Z | 1 |
| Furukawa, E; Furukawa, S; Hiasa, Y; Matsuura, B; Miyake, T; Niiya, T; Sakai, T; Senba, H; Yamamoto, S | 1 |
| Atkin, SL; Butler, AE; Katsiki, N; Sahebkar, A; Yaribeygi, H | 1 |
| Athyros, V; Doumas, M; Imprialos, K; Patoulias, D; Stavropoulos, K | 1 |
| Benigni, A; Buelli, S; Cassis, P; Cerullo, D; Corna, D; Locatelli, M; Morigi, M; Remuzzi, G; Villa, S; Zanchi, C; Zoja, C | 1 |
| Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Cappellari, R; Fadini, GP | 1 |
| Henry, RR; McCrimmon, RJ | 1 |
| Lu, W; Wang, M; Wang, S; Yao, D | 1 |
| Anichini, R; Avogaro, A; Del Prato, S; Fadini, GP; Gatti, A; Manca, ML; Penno, G; Solini, A | 1 |
| Aronson, R; Bajaj, HS; Bhullar, L; Brown, RE; Kalra, S; Sohi, N | 1 |
| González-Ortiz, M; Martínez-Abundis, E; Ramírez-Rodríguez, AM | 1 |
| Akyol, PY; Karakaya, Z; Payza, U; Topal, F; Topal, FE | 1 |
| Aso, Y; Hiraishi, H; Iijima, M; Iijima, T; Jojima, T; Kato, K; Murohisa, T; Shimizu, M; Suzuki, K; Takekawa, H; Usui, I | 1 |
| Gong, S; Guo, T; Li, L; Xu, S; Zhang, C | 1 |
| Henry, RR; Katz, A; Klein, D; Mansfield, T; Pettus, J; Shi, L; Strange, P; Zhou, R; Zhuplatov, SB | 1 |
| Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK | 1 |
| Abdul-Ghani, M; DeFronzo, RA; Fawaz, M; Jayyousi, A; Megahed, A; Migahid, O; Singh, R | 1 |
| Asahara, SI; Furubayashi, A; Kanno, A; Kawamura, M; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Ogawa, W; Okada, Y; Suzuki, E; Takai, T; Tsuchiya, S | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Omori, K; Takase, T | 1 |
| Dandona, P; Hansen, L; Langkilde, AM; Mathieu, C; Phillip, M; Thorén, F; Tschöpe, D; Xu, J | 1 |
| Cain, VA; Hallow, MK; Heerspink, HJL; Inzucchi, SE; Rossing, P; Sartipy, P; Sjöström, CD; Stefansson, BV | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Kakizaki, S; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Sasaki, T; Suga, T; Takeuchi, K; Wada, E; Yamada, M; Yokota-Hashimoto, H | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P | 1 |
| Olgar, Y; Turan, B | 1 |
| Akkus, E; Degirmenci, S; Durak, A; Olgar, Y; Tuncay, E; Turan, B | 1 |
| Boulton, DW; Parkinson, J; Penland, RC; Sokolov, V; Tang, W; Ueda, S; Yakovleva, T | 1 |
| Cefalu, WT; Riddle, MC | 1 |
| Chao, YS; Chen, CT; Chu, KF; Hsieh, TC; Huang, CY; Lee, JC; Song, JS; Wang, MH; Wu, SH; Yao, CH; Yeh, TK | 1 |
| Lim, GB | 4 |
| Araki, E; Asano, M; Boulton, DW; Kim, H; Shiramoto, M; Tang, W; Thorén, F; Ueda, S; Watada, H; Yajima, T | 1 |
| Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
| Ares, J; Delgado, E; Maciá, C; Menéndez, E; Pujante, P; Rodriguez Escobedo, R | 1 |
| Bhatt, DL; Connelly, KA; Verma, S | 1 |
| Assaf, N; El-Yamany, MF; Ghoneim, HA; Oraby, MA; Safar, MM | 1 |
| Edmonston, D; Wolf, M | 1 |
| Akkuş, G; Akkuş, O; Kaypaklı, O | 1 |
| Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H | 1 |
| Bell, C; Biela, LM; Grimm, NC; Luckasen, GJ; Melby, CL; Newman, AA; Schoenberg, HM; Trikha, SRJ; Wilburn, JR | 1 |
| Loewen, ME; Subramaniam, M; Weber, LP | 1 |
| Culha, C; Gursoy, K; Kocer, U; Kuskonmaz, SM; Onder, CE | 1 |
| Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J | 1 |
| Abdul Rashid, AM; Adams, L; Agah, R; Ahmad Saad, FF; Akay, S; Appiah-Opong, R; Aronson, RD; Asbun, H; Ashong, Y; Ayi, I; Baez, P; Bar-Ad, V; Bay, JL; Bello-Pagan, M; Blackbourn, LAK; Bolan, C; Brierley, L; Cannaday, S; Cannon, TL; Caparrotta, TM; Capitano, M; Colhoun, HM; Coppola, D; Crees, ZD; Crites, D; Devaraj, K; Dumashie, E; Edil, BH; Endo, K; Ferrone, CR; Forcione, DG; Ford, J; Fortuna, D; Garcia, M; Gilad, GM; Gomez, V; Gonzalez, C; Gwira, TM; Han, JY; Hanaki, T; Hardacre, JM; Hester, D; Hidalgo, M; Hirschler, V; Hodul, PJ; Ikeguchi, M; Intersimone, P; Jang, JH; Ji, Z; Johnson, T; Kandel, P; Koh, R; Lee, G; Lee, IG; Leese, GP; Li, J; Liu, X; Lopez, MJ; Maccallini, G; Macdonald, DB; Malek, R; Maley, WR; Martel, G; McCrimmon, RJ; McGurnaghan, SJ; McKeigue, PM; McKnight, JA; Md Noh, MSF; Miao, Y; Mody, K; Molinari, C; Monroe, JF; Mora, HA; Morton, SM; Moyana, TN; Munoz-Jordan, J; Nakamura, S; Neaterour, P; Orcutt, ST; Palmer, JD; Paniccia, A; Park, J; Pearson, ER; Perez, NP; Petrie, JR; Pyatibrat, S; Rademacher, N; Raimondo, M; Ranasinha, N; Reyes, N; Richardson, LC; Ritter, AW; Rivera, A; Rivera-Garcia, B; Rosemurgy, AS; Ross, SB; Sama, A; Sattar, N; Sawata, T; Schulick, RD; Shang, D; Sharp, TM; Shimizu, T; Şirin, B; Sloboda, DM; So, E; Song, X; Srour, SA; Stauffer, J; Suzuki, K; Taguchi, T; Takawira, C; Torphy, R; Trump, DL; Tuffour, I; Ünsal, B; Van Dyne, EA; Vickers, MH; Vitulli, PL; Wallace, MB; Wang-Gillam, A; Waterman, SH; Wei, J; Weinstein, JC; Wild, SH; Williams, N; Winter, J; Woodward, TA; Wu, ES; Wu, J; Yeo, CJ; Yeo, TP; Yeung, V; Zhang, JB | 1 |
| Adam, J; Ashcroft, FM; Asterholm, IW; Benrick, A; Briant, LJB; Chibalina, MV; Gribble, FM; Hamilton, A; Hastoy, B; Knudsen, JG; Ramracheya, R; Reimann, F; Rorsman, NJG; Rorsman, P; Salehi, A; Spiliotis, II; Tarasov, A; Vergari, E; Wu, Y; Zhang, Q | 1 |
| Donnan, K; Segar, L | 1 |
| Asseburg, C; Neslusan, C; Willis, M | 1 |
| Han, S; Jin, K; Paek, JH; Park, H; Park, SB; Park, WY; Yeo, SM | 1 |
| Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W | 1 |
| Attalla, B; Bédard, A; Billger, M; Chang, J; Haile, S; Kirk, J; Söderberg, M | 2 |
| Jiang, A; Li, F; Shi, L; Wang, S; Zhu, D | 1 |
| Cardone, RL; Kibbey, RG; Perry, RJ; Rabin-Court, A; Shulman, GI; Song, JD; Wang, Y | 1 |
| Åstrand, M; Boulton, DW; Ekholm, E; Hamrén, B; Melin, J; Parkinson, J; Tang, W | 1 |
| Chattipakorn, N; Chattipakorn, S; Gunaparn, S; Jaiwongkam, T; Kumfu, S; Phrommintikul, A; Wongcharoen, W | 1 |
| Garg, SK; Giordano, D | 1 |
| Bindels, RJM; de Baaij, JHF; de Galan, BE; Gault, VA; Hoenderop, JGJ; Ma, C; Millar, PJ | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Kishi, H; Maejima, Y; Sakurai, S; Shimizu, M; Shimomura, K; Usui, I | 1 |
| Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
| Chin, KL; Hird, TR; Liew, D; Magliano, DJ; Ofori-Asenso, R; Si, S; Zoungas, S | 1 |
| McMurray, JJV; Verma, S | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Desai, AS; Furtado, RHM; Gause-Nilsson, I; Goto, S; Johanson, P; Johansson, PA; Kato, ET; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Furtado, RHM; Gause-Nilsson, IAM; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Raz, I; Ruff, CT; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Bittencourt, RJ; Figueiredo, IR; Freire, NB; Patrocínio, MS; Pierdoná, N; Rose, SCP | 1 |
| Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 2 |
| De Ponti, F; Marchesini, G; Poluzzi, E; Raschi, E | 1 |
| Chu, C; Hocher, B; Lu, YP; Yin, L | 1 |
| Fernández-Ruiz, I | 2 |
| Dandona, P; Hansen, L; Langkilde, AM; Lind, M; Mathieu, C; Oron, T; Phillip, M; Thorén, F; Xu, J | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| Tuttle, KR | 3 |
| Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC | 1 |
| Abdel Hamid, MA; Ahmed, HM; Batakoushy, HA; Omar, MA | 3 |
| Abdelaziz, H; Al AdAwi, RM; Elgaily, D; Jassim, Z; Mohamed Ibrahim, MI; Sree, B | 1 |
| Baglioni, P | 1 |
| Akinci, B | 2 |
| Raz, I; Sabatine, MS; Wiviott, SD | 1 |
| Guo, L; Li, J; Li, L; Li, X; Liu, H; Liu, R; Luo, Y; Mou, H; Yang, G; Yang, M; Zhang, C; Zhang, X; Zhang, Y | 1 |
| Habib, EK; Hamouda, MA; Khairy, E; Mohamed, DI; Saad, SST | 1 |
| Biester, T; Boulton, D; Busse, D; Danne, T; Parkinson, J; Scheerer, M; Sokolov, V; Tang, W | 1 |
| Kondo, H; Takahashi, N | 1 |
| Boeder, S; Edelman, SV | 1 |
| Oliveira, PA; Seixas, F | 1 |
| Furukawa, S; Hiasa, Y; Matsuura, B; Miki, T; Miura, T; Ohnishi, H; Sato, T; Tanno, M | 1 |
| Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS | 1 |
| Aoshima, S; Arai, H; Inoue, T; Kosugi, R; Nakatani, E; Okamoto, K | 1 |
| Bingöl Özakpınar, Ö; Cam, ME; Cilingir, OT; Ercan, F; Kingir, ZB; Okuyan, B; Özdemir Kural, ZN; Ozsavci, D; Sancar, M; Şekerler, T | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Karagiannis, A; Loutradis, C; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, M | 1 |
| Biancalana, E; Bruno, RM; Dardano, A; Ghiadoni, L; Giannini, L; Parolini, F; Rossi, C; Seghieri, M; Solini, A; Taddei, S | 1 |
| Gilbert, JD; Goldenberg, RM; Hramiak, IM; Woo, VC; Zinman, B | 1 |
| de Boer, IH | 1 |
| Atsumi, T; Cho, KY; Hatanaka, KC; Kameda, H; Kitao, N; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takagi, R; Takahashi, K; Terauchi, Y | 1 |
| Bi, J; Cheng, X; Dai, F; Hao, L; Huang, F; Liu, Y; Wang, C; Xu, K | 1 |
| Dhillon, S | 1 |
| Barakat, GH; Elkady, EF; Hassib, ST; Taha, EA | 1 |
| Elshahed, MS; Lotfy, HM; Mohamed, D | 1 |
| Darshi, M; Heerspink, HJL; Kim, JJ; Laverman, GD; Mulder, S; Pena, MJ; Sharma, K | 1 |
| Boulton, DW; Dayton, B; Engman, H; Tang, W; Zhu, Y | 1 |
| Bastie, CC; Kaira, K; Maeshima, A; Nakajima, Y; Okada, S; Shibusawa, R; Yamada, E; Yamada, M | 1 |
| Katsiki, N; Mantzoros, C; Perakakis, N | 1 |
| Briand, F; Galsgaard, ED; Nørgaard, SA; Sand, FW; Sulpice, T; Søndergaard, H; Sørensen, DB | 1 |
| Blak, BT; Fenici, P; Medina, J; Nolan, ST; Rigney, U; Wilding, JPH | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 1 |
| Feng, M; Fu, S; Lv, H; Lyu, W; Wang, J; Xu, X | 1 |
| Shah, PA; Sharma, V; Shrivastav, PS; Yadav, MS | 1 |
| Bailey, CJ; Del Prato, S; Reyner, D; Saraiva, G; Wei, C | 1 |
| Cain, V; Chertow, GM; Goldenberg, R; Sartipy, P; Sjöström, CD; Stefánsson, BV; Toto, RD | 1 |
| Bodegard, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Rikner, K; Thuresson, M | 1 |
| Packer, M | 3 |
| Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
| Bonner, C; Bousquet, C; Coddeville, A; Daoudi, M; Delalleau, N; Gmyr, V; Hubert, T; Kerr-Conte, J; Martineau, Y; Moerman, E; Pasquetti, G; Pattou, F; Quenon, A; Saponaro, C; Staels, B; Thévenet, J; Vantyghem, MC | 1 |
| Boulton, DW; Cain, V; Dekkers, CCJ; Greasley, PJ; Heerspink, HJL; Sjöström, CD | 1 |
| Candido, R; Cucinotta, D; Graziano, G; Manicardi, V; Nicolucci, A; Rocca, A; Rossi, MC; Tuccinardi, F | 1 |
| Avogaro, A; Bonora, BM; Fadini, GP; Vigili de Kreutzenberg, S | 1 |
| Dykhoff, HJ; Karaca-Mandic, P; McCoy, RG; Montori, VM; Ross, JS; Sangaralingham, L; Shah, ND | 1 |
| Cayón Blanco, M; Gómez-Fernández, P; Hidalgo Santiago, JC; López Saez, JB; Maraver Delgado, J | 1 |
| Feng, B; Ma, X; Sun, K; Xu, G; Zhang, N; Zhou, Y | 1 |
| Al-Huniti, N; Dunyak, J; Higashimori, M; Ichikawa, K; Nagase, M; Ueda, S | 1 |
| Aoki, K; Azushima, K; Hanaoka, M; Haruhara, K; Hosokawa, S; Inazumi, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, R; Kobayashi, Y; Kondo, Y; Misumi, T; Ohki, K; Ono, S; Orime, K; Osada, U; Sasaki, H; Shibasaki-Kurita, T; Tamura, K; Terauchi, Y; Wakui, H; Yamada, T; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Gippini, A; Prado, A | 1 |
| Baldi, S; DeFronzo, RA; Ferrannini, E; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD | 1 |
| Iizuka, K; Kato, T; Liu, Y; Mizuno, M; Nonomura, K; Takao, K; Yabe, D; Yasuda, M | 1 |
| Adler, AI; Dent, R; Latimer, N; Ting, S | 1 |
| Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC | 1 |
| Avogaro, A; Cazzetta, G; Devangelio, E; Fadini, GP; Felace, G; Li Volsi, P; Poli, M | 1 |
| Austin, B; Drazner, MH; Fong, MW; Givertz, MM; Gordon, RA; Husain, M; Inzucchi, SE; Jermyn, R; Katz, SD; Khariton, Y; Kosiborod, M; Lamba, S; Lanfear, DE; LaRue, SJ; Lindenfeld, J; Malone, M; Margulies, K; McGuire, DK; Mentz, RJ; Mutharasan, RK; Nassif, ME; Pitt, B; Pursley, M; Scirica, BM; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Fang, JC | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Cowen, J; Leader, R; Rajeev, SP | 1 |
| Chan, YY; Chang, KC; Chen, HY; Hung, MJ; Kao Yang, YH; Lai, EC; Shao, SC; Yang, NI | 1 |
| Huynh, K | 2 |
| Burchell, R; Burton, SE; Gal, A; Jacob, A; Lopez-Villalobos, N; Malabu, U; Singh, P; Weidgraaf, K | 1 |
| Limova, M; Mattis, DM; Mully, T | 1 |
| Moist, L | 1 |
| Kato, ET; Sabatine, MS; Wiviott, SD | 1 |
| Elghazaly, H; Hajiev, S; Singh, P | 1 |
| Bai, XY; Sun, Q; Tang, Y; Zhang, M; Zhou, QL; Zhou, YF | 1 |
| Ferrannini, E; Gastaldelli, A; Guja, C; Han, J; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Kang, ES; Kim, JH; Ko, HY; Lee, H; Wang, HJ; Yun, M | 1 |
| Bhatt, DL; Braunwald, E; Verma, S | 1 |
| Butler, J; Vaduganathan, M | 1 |
| Asrih, M; Gariani, K | 1 |
| Detsch, JM; Lacerda, CS; Marino, EC; Marques, K; Pechmann, LM; Polesel, MG; Sanches, CP; Scharf, M; Vianna, AGD | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Tanaka, M; Yamakage, H | 1 |
| Albrecht, M; Boomsma, M; Hollmann, MW; Homayr, A; Juni, RP; Kerindongo, R; Koolwijk, P; Preckel, B; Spin, EL; Uthman, L; van Hinsbergh, VWM; Weber, NC; Zuurbier, CJ | 1 |
| Bengtsson, O; Chiang, CE; DeMets, DL; Dutkiewicz-Piasecka, M; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Felker, GM | 1 |
| Bengtsson, O; DeMets, DL; Diez, M; Docherty, KF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; Niklasson, A; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Cain, V; Correa-Rotter, R; Heerspink, HJL; Sartipy, P; Scholtes, RA; Sjöström, CD; Stefánsson, BV; Toto, RD; van Raalte, DH | 1 |
| Araki, E; Asano, M; Fujii, H; Kim, H; Langkilde, AM; Ohashi, H; Okabe, T; Thoren, F; Tomonaga, O; Uchigata, Y; Watada, H; Yajima, T | 1 |
| Cho, H; Park, JH; Seo, I; Shim, HM | 1 |
| Collins, SP; Tromp, J | 1 |
| Cahn, A; Cernea, S; Raz, I | 1 |
| Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L | 2 |
| Arcidiacono, B; Brunetti, A; Brunetti, FS; Caroleo, P; Chiefari, E; Corigliano, DM; Foti, DP; Mirabelli, M; Puccio, L; Vero, R | 1 |
| Agra-Bermejo, RM; Couselo-Seijas, M; Eiras, S; Fernández, AL; González-Juanatey, JR; Martínez-Cereijo, JM; Rozados-Luis, A; Sierra, J; Soto-Pérez, M | 1 |
| Elshazly, SM; Nasr, AM; Rezq, S; Shaheen, A | 1 |
| Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH | 1 |
| Canivell, S; Franch-Nadal, J; Gratacòs, M; Mata-Cases, M; Mauricio, D; Real, J; Vlacho, B | 1 |
| Ambrosio, G; Anker, S; Bauersachs, J; Chioncel, O; Coats, AJS; Cosentino, F; De Boer, RA; Filippatos, G; Hill, L; Huelsmann, M; Jhund, PS; Komajda, M; Lopatin, Y; Lund, LH; Lyon, A; Metra, M; Mullens, W; Petrie, MC; Piepoli, M; Polovina, MM; Ponikowski, P; Rosano, GMC; Sari, I; Seferović, J; Seferović, PM; Thum, T; Volterrani, M | 1 |
| Davids, M; Herrema, H; Kramer, MHH; Nieuwdorp, M; van Bommel, EJM; van Raalte, DH | 1 |
| Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Verma, S | 1 |
| Coates, PT; Salehi, T | 1 |
| Choi, SH; Jang, HC; Lee, YK; Lim, HL; Oh, HN; Oh, TJ; Park, KS; Sul, WJ | 1 |
| Acosta-Montalvo, A; Bonner, C; Cnop, M; Coddeville, A; Delalleau, N; Gmyr, V; Kerr-Conte, J; Moerman, E; Mühlemann, M; Pasquetti, G; Pattou, F; Piron, A; Saponaro, C; Staels, B; Thévenet, J | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV; Solomon, SD | 1 |
| Bjornstad, P; Nelson, RG; Pavkov, ME | 1 |
| Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H | 1 |
| Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H | 2 |
| Broo, A; Corkill, D; Coward, S; Goodman, J; Houvenagel, S; Jermutus, L; Jones, I; Lainé, AL; Petrone, M; Rose, J; Sandinge, AS; Santos, ALGD | 1 |
| Al-Bazz, DY; Wilding, JP | 1 |
| Fourlanos, S; Neoh, SL; Nolan, BJ; Varadarajan, S | 1 |
| Abraham, NG; Arad, M; Aravot, D; Arow, M; Freimark, D; Hochhauser, E; Kornowski, R; Nudelman, V; Shainberg, A; Waldman, M; Yadin, D | 1 |
| Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ | 1 |
| Baer, PC; Freitag, J; Geiger, H; Koch, B; Schubert, R | 1 |
| Abd El Fattah, MA; Ahmed, MAE; Eid, NI; Gamal El Din, AA; Gamil, NM; Maklad, YA | 1 |
| Chen, C; Chen, Y; Cowley, MA; Huang, L; Huang, Z; Qi, X; Veldhuis, JD; Wang, C; Zhang, Y; Zhu, S | 1 |
| Nakajima, Y; Okada, J; Okada, S; Osaki, A; Ozawa, A; Pessin, JE; Saito, T; Shimoda, Y; Yamada, E; Yamada, M; Yokoo, H | 1 |
| Heerspink, HJL; Koomen, JV; Kroonen, MYAM; Laverman, GD; Petrykiv, SI; Stevens, J | 1 |
| Slomski, A | 5 |
| Jang, K; Jeon, JY; Kim, MG; Moon, SJ | 1 |
| Cumhur Cure, M; Cure, E | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Astapova, II; Campbell, JE; Capozzi, ME; Coch, RW; D'Alessio, DA; Douros, JD; El, K; Encisco, SE; Finan, B; Herman, MA; Koech, J; Sloop, KW; Wait, JB | 1 |
| Hirota, Y; Komada, H; Miura, H; Morita, Y; Nakamura, T; Ogawa, W; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Tamori, Y; Yamada, T | 1 |
| Ackermans, MT; Bouter, KEC; Dallinga-Thie, GM; Jansen, H; Nieuwdorp, M; Schierbeek, H; Schimmel, AWM; Serlie, MJ; van Bommel, EJM; van Harskamp, D; van Raalte, DH | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC | 1 |
| Bennett, H; Bergenheim, K; Evans, M; McEwan, P; Tank, A | 1 |
| Chan, YY; Chang, KC; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, YH; Shao, SC | 1 |
| Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Ghanim, H; Green, K; Hejna, J; Makdissi, A | 2 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C | 1 |
| Boulton, DW; Chu, L; Greasley, PJ; Helmlinger, G; Johansson, S; Penland, RC; Peskov, K; Sokolov, V; Tang, W; Yakovleva, T | 1 |
| Sullivan, K; Van Spall, HGC | 1 |
| Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH | 1 |
| Bajaj, HS; Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Erskine, D | 1 |
| Wilcox, CS | 1 |
| Aizawa, Y; Fujita, S; Ikeda, Y; Okabe, M; Sato, T; Yuasa, S | 1 |
| Eriksson, JW; Greasley, PJ; Hammarstedt, A; Hedberg, J; Heerspink, HJL; Ju, W; Mulder, S; Nagaraj, SB; Nair, V; Oscarsson, J | 1 |
| Balogh, DB; Besztercei, B; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lenart, L; Sparding, N; Szabo, AJ; Wagner, LJ | 1 |
| Casella, R; Casiraghi, C; Cazzaniga, A; Colombo, G | 1 |
| Borghi, C; Cicero, AFG | 1 |
| Dau, NQ; Peled, H | 1 |
| Mehra, MR; Vieira, JL | 1 |
| Docherty, KF; Jhund, PS; McMurray, JJV | 1 |
| Abdalla, O; Dessouki, A; Kilany, O; Sasaki, K; Sayed, N; Shimoda, M; Yoshida, T | 1 |
| Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Jsg-Nafld, JSGON; Kamada, Y; Kawaguchi, T; Kawanaka, M; Koseki, M; Nakajima, A; Nozaki, Y; Okanoue, T; Ono, M; Sumida, Y; Takahashi, H; Tokushige, K; Yoneda, M; Yoshida, Y | 1 |
| Fernandez-Fernandez, B; Ortiz, A; Porrini, E; Soler, MJ | 1 |
| van Bommel, EJM; van Raalte, DH | 1 |
| Arnott, C; Neal, B | 1 |
| Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Bengtsson, O; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Vinh, PN | 1 |
| Bhatt, DL; Bonaca, M; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Hadjadj, S; Jermendy, G; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D | 1 |
| Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K | 1 |
| Chatsudthipong, V; Kongkaew, A; Lungkaphin, A; Thongnak, L | 1 |
| Altay, H; Cahn, A; Çavuşoğlu, Y; Celik, A; Demir, S; Kılıçaslan, B; Nalbantgil, S; Raz, I; Temizhan, A; Yıldırımtürk, Ö; Yılmaz, MB | 1 |
| Granger, CB; Mahaffey, KW | 1 |
| Chopey, IV; Debreceni, KO; Feysa, SV; Griadil, TI; Hechko, MM; Mykhalko, YO | 1 |
| Carballo, D; Carballo, S; Darbellay Farhoumand, P; Garin, N; Serratrice, J; Stirnemann, J | 1 |
| Heerspink, HJL; Koomen, JV; Stevens, J | 1 |
| Araki, E; Arya, N; Dandona, P; Iqbal, N; Lind, M; Mathieu, C; Phillip, M; Rudofsky, G; Scheerer, MF; Thorén, F | 1 |
| Adams, LG; Hanson, B; Jennings-Gee, J; Kock, ND; Saenkham, P; Subashchandrabose, S | 1 |
| Ghosal, S; Sinha, B | 1 |
| Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Yang, HC; Ye, Y | 1 |
| Diaz, LJ; Eickhoff, MK; Faber, J; Frimodt-Møller, M; Jensen, MT; Olsen, FJ; Persson, F; Rossing, P | 1 |
| Arıkan, AA; Baycelebi, G; Gokosmanoglu, F; Onmez, A | 1 |
| Fonseca, VA; Shao, H; Shi, L | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P; Wintzell, V | 1 |
| Gra-Menendez, S; Iacobellis, G | 1 |
| Liu, PY; So, EC; Wu, SN | 1 |
| Gabay, L; Nakhleh, A; Shehadeh, N; Zloczower, M | 1 |
| Flatt, PR; Irwin, N; Moffett, RC; Tanday, N | 1 |
| Eleftheriadis, T; Liakopoulos, V; Nikolaou, E; Pissas, G; Stefanidis, I; Tsogka, K | 1 |
| Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A | 1 |
| Aronson, R; Gerstein, HC; Hall, S; Harris, S; Hramiak, I; Liu, YY; McInnes, N; Sigal, RJ; Sultan, F; Woo, V | 1 |
| Bottino, R; Bouchi, Y; Calcutt, MW; Dai, C; Dean, ED; Greiner, DL; Hart, NJ; Jacobson, DA; McGuinness, OP; Poffenberger, G; Powers, AC; Shostak, A; Shultz, LD; Walker, JT | 1 |
| Avogaro, A; Consoli, A; Fadini, GP; Morieri, ML; Purrello, F; Sesti, G | 1 |
| Ahn, DJ; Lee, IH | 1 |
| Alexander, GC; Heyward, J; Mansour, O; Olson, L; Singh, S | 1 |
| Heerspink, HJL; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Ruiter, D; Smits, MM; Touw, DJ; van Bommel, EJM; van Raalte, DH | 1 |
| El-Domiaty, H; El-Nabi, SH; Fayez Ewida, S; Hanna, G; Saleh, S; Shabaan, A | 1 |
| Cho, JH; Kim, H; Kim, HS; Lee, H; Lee, SH; Yim, HW; Yoon, KH | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Chopra, VK; DeMets, DL; Dewan, P; Dukát, A; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkely, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vinh, PN | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Lahnwong, S; Palee, S; Sriwichaiin, S | 1 |
| Bobade, PS; Dhote, AM; Ganorkar, SB; Patil, MR; Sharma, SS; Shirkhedkar, AA | 1 |
| Bakris, GL; Sternlicht, HK | 1 |
| Kim, HJ; Kim, JJ; Seong, JM; Sohn, HS | 1 |
| Brown, AJM; Gandy, S; Houston, JG; Lang, CC; McCrimmon, R; Struthers, AD | 1 |
| Ameloot, K; Ceyssens, W; Dauw, J; Dupont, M; Forouzan, O; Kockaerts, V; Luwel, E; Martens, P; Mullens, W; Vercammen, J | 1 |
| Rasouli, N | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Ebrahim, TM; ElMahdy, MK; Helal, MG | 1 |
| Choi, YH; Jeong, IK; Kwon, HS; Lee, BW; Lee, SH; Min, KW; Yoo, SJ; Yoon, KH | 1 |
| Hara, K; Hatano, M; Hayashino, Y; Iida, S; Ikegami, Y; Isshiki, M; Ito, D; Kitazato, H; Noda, M; Saito, D; Sakuma, I; Satoh-Asahara, N; Shimada, A; Shiojima, I; Sumita, T; Takahashi, K | 1 |
| Costantino, S; Hamdani, N; Paneni, F | 1 |
| Chappard, D; Gault, VA; Mabilleau, G; Mieczkowska, A; Millar, P | 1 |
| Bengtsson, O; Claggett, BL; Desai, AS; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjostrand, M; Solomon, SD | 1 |
| El-Sahar, AE; El-Yamany, MF; Rastanawi, AA; Saad, MA | 1 |
| Gazewood, JD; Tingen, J | 1 |
| Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Boulton, DW; Chopra, VK; de Boer, RA; DeMets, DL; Dewan, P; Docherty, KF; Dukát, A; Greasley, PJ; Howlett, JG; Inzucchi, SE; Jackson, AM; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S | 1 |
| Birkenfeld, AL; Dandona, P; Hansen, TK; Iqbal, N; Mathieu, C; Phillip, M; Repetto, E; Scheerer, MF; Thoren, F; Xu, J | 1 |
| Jackson, K; Moseley, KF | 1 |
| Cui, X; Feng, J; Gu, L; Hong, T; Lang, S; Le, Y; Liu, J; Wang, H; Wei, R; Wei, T; Yang, J; Yang, K | 1 |
| Chen, R; Li, N; Liu, K | 1 |
| Banham-Hall, E; Bond, S; Cheriyan, J; Cope, A; Fisk, M; Galloway, J; Hall, F; Jayne, D; Kadyan, S; Kostapanos, M; Kulkarni, S; Lu, IN; Norton, S; Wilkinson, IB | 1 |
| Nekeman, S; Uyl-de Groot, CA; Van der Linden, N; Van Olst, S | 1 |
| Bergenheim, K; Böhm, M; Darlington, O; Docherty, KF; Jhund, PS; McEwan, P; McMurray, JJV; Petrie, MC; Qin, L | 1 |
| Raj, GM; Wyawahare, M | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Heerspink, HL; Helmlinger, G; Nieves, EH; Penland, RC; van Raalte, DH | 1 |
| Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Ahmad, T; Desai, NR | 1 |
| Krittayaphong, R; Permsuwan, U | 1 |
| Basu, S; Hallow, KM; Yu, H | 1 |
| Lester, S; Van Klompenburg, E | 1 |
| Cowie, MR | 1 |
| Díaz-Cruz, C; Díaz-Cruz, K; González-Ortiz, M; Martínez-Abundis, E; Patiño-Laguna, AJ; Ramírez-Rodríguez, ZG; Rosales-Rivera, LY | 2 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Anand, IS; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Diez, M; Docherty, KF; Dukát, A; Ge, J; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Feng, X; Gao, G; Gu, Q; Li, Q; Yuan, L; Zhang, Y | 1 |
| Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Kooy, A; Langkilde, AM; Leiter, LA; Litwak, L; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I | 1 |
| Boogerd, CJ; de Boer, RA; Dokter, MM; Lam, CSP; Markousis-Mavrogenis, G; Meems, LMG; Schouten, EM; Silljé, HHW; Voors, AA; Westenbrink, BD; Withaar, C | 1 |
| Chen, P; Jiang, J; Lin, L | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Ofstad, AP; Packer, M; Pfarr, E; Pocock, SJ; Zannad, F | 1 |
| Anand, I; Bengtsson, O; Böhm, M; de Boer, RA; DeMets, DL; Desai, AS; Docherty, KF; Drozdz, J; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S | 1 |
| Antoine, N; Augustin, R; Bensellam, M; Broca, C; Brusa, D; Chae, H; Gatineau, E; Gilon, P; Gribble, FM; Herrera, PL; Khattab, F; Klein, H; Lai, BK; Mark, M; Mayoux, E; Piemonti, L; Pieper, M; Reimann, F; Rita, N; Ruiz, L; Singh, B; Stierstorfer, B; Wojtusciszyn, A | 1 |
| Chen, F; Chen, ZQ; Li, L | 1 |
| Raz, I; Sabatine, MS; Wiviott, SD; Zelniker, TA | 1 |
| Cosentino, F; Savarese, G | 1 |
| Brown, A; Gandy, S; Houston, JG; Lang, CC; McCrimmon, R; Mordi, IR; Ramkumar, PG; Struthers, AD | 1 |
| Petrie, JR | 1 |
| Cain, V; Correa-Rotter, R; Greasley, PJ; Heerspink, HJL; Sartipy, P; Sjöström, CD; Stefánsson, BV; Wheeler, DC | 1 |
| Zuurbier, CJ | 1 |
| Anker, SD; Butler, J; Fonarow, GC; Handelsman, Y; Hernandez, AF; Khan, MS; Kosiborod, MN; McGuire, DK; McMurray, JJV; Rosenstock, J; Vaduganathan, M; Verma, S | 1 |
| Kosiborod, MN; McGuire, DK; Verma, S | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD | 1 |
| Cui, L; Hao, Z; Li, G; Liu, Y; Sun, Y; Wen, Y | 1 |
| Sotirakos, S | 1 |
| Hui, Y; Xu, Y; Yang, C; Yin, D | 1 |
| Anand, IS; Bengtsson, O; Böhm, M; Chopra, V; de Boer, RA; Desai, AS; Docherty, KF; Ge, J; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkley, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Shou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
| Boomsma, M; Hermanides, J; Hollmann, MW; Kessler, J; Kuschma, M; Preckel, B; Römer, G; Uthman, L; Weber, NC; Zuurbier, CJ | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D | 1 |
| Chen, G; Chen, J; Ding, XF; Liang, Y; Ma, HL; Yu, SJ; Zhang, Q; Zhou, J; Zhu, J | 1 |
| Dronamraju, N; Erlandsson, F; Goldwater, R; Han, D; Johansson, S; Johnsson, E; Oscarsson, J; Parkinson, J; Stack, AG | 1 |
| Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Penland, RC; Tang, W; Yu, H | 1 |
| Brunton, S; Chilton, R | 1 |
| Khong, TK; Magavern, E | 1 |
| Chang, WT; Chen, ZC; Cheng, JT; Fisch, S; Hong, CS; Kang, NW; Lin, YW; Shih, JY | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Araki, E; Arya, N; Bergenstal, R; Dandona, P; di Bartolo, P; Hansen, L; Heller, S; Iqbal, N; Lind, M; Mathieu, C; Phillip, M; Scheerer, MF; Thoren, F; Xu, J | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Haynes, R; Judge, PK | 1 |
| Butler, J; Greene, SJ; Khan, MS | 1 |
| Bengtsson, O; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE | 1 |
| Dashora, U; Dhatariya, K; Gregory, R; Macklin, A; Nagi, D; Patel, DC; Rayman, G; Rowles, S; Winocour, P | 1 |
| Blonde, L; Bookhart, B; Chen, YW; Patel, C; Pericone, CD; Wu, B | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Held, C; Hou, FF; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Karagiannis, A; Kotsa, K; Loutradis, C; Minopoulou, I; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, MP; Tsapas, A; Tzatzagou, G; Zografou, I | 1 |
| Cho, I; Cho, IJ; Ha, JW; Han, G; Hong, GR; Jang, Y; Kang, SM; Lee, CJ; Lhagvasuren, P; Seo, J; Shim, CY | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Bakker, SJL; Danser, AHJ; Ferrannini, E; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Post, A; Touw, DJ; van Berkel, M; van Bommel, EJM; van Raalte, DH | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Chang, WT; Chen, ZC; Ho, CH; Lin, YW; Liu, PY; Shih, JY | 1 |
| Atlas, E; Battelino, T; Biester, T; Bratina, N; Danne, T; Dovc, K; Kordonouri, O; Muller, I; Nimri, R; Phillip, M; Scheerer, MF; von dem Berge, T | 1 |
| Balzer, MS; Bartosova, M; Haller, H; Nordlohne, J; Rong, S; Schmidt, S; Schmitt, CP; Shushakova, N; Stapel, B; von Vietinghoff, S; Zemtsovski, JD | 1 |
| Habu, M; Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Node, K; Tanaka, A | 1 |
| Karagiannis, A; Kotsa, K; Loutradis, C; Papadopoulou, E; Sarafidis, P; Theodorakopoulou, MP; Tsapas, A; Tzanis, G; Tzatzagou, G; Zografou, I | 1 |
| Aguilar-Ballester, M; Burks, DJ; González-Navarro, H; Herrero-Cervera, A; Martínez-Hervás, S; Real, JT; Taberner-Cortés, A; Vinué, Á | 1 |
| Ding, LL; Qiu, M; Zhang, M; Zhou, HR | 1 |
| Khunti, K | 1 |
| Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ | 1 |
| Arya, N; Greasley, PJ; Hammarstedt, A; Heerspink, HJL; Hesp, AC; Karlsson, C; Muskiet, MHA; Scholtes, RA; van Baar, MJB; van Raalte, DH | 1 |
| Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
| Pan, H; Shen, J; Zhao, B; Zhao, J | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Ahmad, A; Alanazi, FK; Aldughaim, MS; Alqahtani, A; Alqahtani, AS; Kazi, M; Noman, OM | 1 |
| Elkind-Hirsch, KE; Harris, R; Seidemann, E | 1 |
| Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; de Boer, RA; Diez, M; Docherty, KF; Dukát, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Bergenheim, K; Bhatt, DL; Boyce, R; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Leiter, LA; McEwan, P; Morgan, AR; Mosenzon, O; Wilding, JPH | 1 |
| Bengtsson, O; de Boer, RA; Desai, AS; Dewan, P; Docherty, KF; Drozdz, J; Hawkins, NM; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Boulton, D; Parkinson, J; Penland, RC; Shah, M; Sokolov, V; Stolbov, L; Tang, W; Yakovleva, T | 1 |
| Aberle, J; Birkenfeld, AL; Jaeckel, E; Menzen, M; Rohwedder, K; Scheerer, MF; Schmid, SM; Tang, W; Terkamp, C; Xu, J | 1 |
| Acharya, Y; Dahal, R; Mukherjee, D | 1 |
| Bouchi, R; Fukuda, T; Itoh, J; Kishimoto, J; Ogawa, Y; Ono, Y; Sonoda, N; Takeuchi, T; Yamada, T | 1 |
| Guyatt, G; Hao, Q | 1 |
| Al-Shorbagy, MY; Arab, HH; Saad, MA | 1 |
| Chen, MB; Cui, WY; Wang, H; Xu, HL; Zheng, QH | 1 |
| Cao, Z; Guo, X; Ma, Y; Shao, Y; Sun, X; Yuan, G; Zhang, J | 1 |
| Boulton, DW; Jo, H; Parkinson, J; Pilla Reddy, V; Tang, W | 1 |
| Chatzigeorgiou, A; Cholongitas, E; Chrysavgis, L; Papatheodoridi, AM | 1 |
| Azushima, K; Haruhara, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, Y; Kondo, Y; Misumi, T; Osada, U; Tamura, K; Terauchi, Y; Wakui, H; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Fukuda, S; Ishii, Y; Kemmochi, Y; Kuroki, F; Miyajima, K; Nakae, D; Ohta, T; Sano, R; Sasase, T; Sugimoto, M; Yamanaka, M; Yasui, Y | 1 |
| Nakamoto, K; Tsubakimoto, M; Yabiku, K | 1 |
| Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C | 1 |
| Vogt, L | 1 |
| Isobe, S; Yasuda, H | 1 |
| Heerspink, HJL; Langkilde, AM; Wheeler, DC | 1 |
| Abu-Zaid, A; Alhabeeb, H; Alomar, S; Altowairqi, AK; Baradhwan, A; Bhagavathul, AS; Dissanayaka, T; Oganesyan, A; Tom, S | 1 |
| LeMaistre, FI; Molony, DA | 1 |
| Araújo, I; Cunha, GJL; Fonseca, C; Guerreiro, R; Henriques, C; Maltês, S; Presume, J; Rocha, BML; Rodrigues, C | 1 |
| Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y | 1 |
| Arab, HH; Safar, MM; Shahin, NN | 1 |
| Bengtsson, O; Böhm, M; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kristensen, SL; Køber, L; Langkilde, AM; Lindholm, D; Martinez, MFA; McMurray, JJV; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Shen, L; Sjöstrand, M; Solomon, SD | 1 |
| El Fayoumi, HM; Elkazzaz, SK; Khodeer, DM; Moustafa, YM | 1 |
| Htun, KT; Intachai, N; Jaikumkao, K; Kothan, S; Lungkaphin, A; Promsan, S; Swe, MT; Tapanya, M; Thongnak, L | 1 |
| Bairaktari, E; Bletsa, E; Chasapi, S; Dafopoulos, P; Dimou, A; Ferrannini, E; Filippas-Dekouan, S; Kostara, C; Koutsovasilis, A; Pappa, E; Spyroulias, G; Tsimihodimos, V | 1 |
| Bengtsson, O; Butt, JH; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Li, P; Xu, SZ; Zaibi, N | 1 |
| Austin, B; Fong, MW; Hartupee, J; Husain, M; Inzucchi, SE; Khariton, Y; Kosiborod, MN; LaRue, SJ; Malik, AO; McGuire, DK; Nassif, ME; Ogunniyi, MO; Pitt, B; Scirica, BM; Tang, F; Umpierrez, G; Wenger, NK; Windsor, SL | 1 |
| Bolli, GB; Fanelli, CG; Lucidi, P; Porcellati, F | 1 |
| Davies, M; Fielding, BA; Garesse, R; Herring, RA; Jackson, N; Johnsen, S; Mendis, A; Russell-Jones, DL; Shojaee-Moradie, F; Stevenage, M; Umpleby, AM | 1 |
| Abd Elmaaboud, MA; Arab, HH; Kabel, AM | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, I; Herrera, M; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Merlini, P; Mosenzon, O; Murphy, SA; O'Donoghue, ML; Raz, I; Sabatine, MS; Šmahelová, A; Tankova, T; Wilding, JPH; Wiviott, SD | 1 |
| Anand, IS; Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Araki, E; Arya, N; Asano, M; Ikeda, H; Iqbal, N; Maeda, H; Mathieu, C; Shiraiwa, T; Thoren, F | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 3 |
| Imai, Y; Kaneto, M; Nakatou, T; Senoo, M; Shimomura, Y; Teshigawara, S; Tone, A; Watanabe, S | 1 |
| Huang, J; Lin, M; Tang, Z; Wei, G; Wu, S; Yang, F; Yu, W; Zeng, F | 1 |
| Diogo, V; Gourzoulidis, G; Ioannidis, I; Karpouzos, G; Kourlaba, G; Papageorgiou, G; Tsimihodimos, V; Tzanetakos, C | 1 |
| Drożdż, J; Gackowski, A; Gumprecht, J; Jankowska, EA; Kaźmierczak, J; Kukulski, T; Lelonek, M; Leszek, P; Nessler, J; Ponikowski, P; Rozentryt, P; Rubiś, P; Siniarski, A; Witkowski, A | 1 |
| Larmour, K; Levin, A | 1 |
| Adler, AI; Douch, E; Dunning, L; Elliott, N | 1 |
| Li, S; Si, Z; Wang, D; Xue, Y; Yang, Y; Zhang, Z | 1 |
| Bourron, O; Hartemann, A; Jeannin, AC; Laroche, S; Phan, F | 1 |
| Chang, CP; Chang, WT; Chen, CY; Chen, ZC; Cheng, BC; Fisch, S; Ho, CH; Lin, MT; Lin, YW; Shih, JY | 1 |
| Hadova, K; Klimas, J; Kralova, E; Krenek, P; Marusakova, M | 1 |
| Barreto, J; Bonilha, I; Breder, I; Breder, JC; Carvalho, LSF; Cavalcante, P; Cintra, RMR; de Lima-Junior, JC; do Carmo, HRP; Kimura-Medorima, ST; Moreira, C; Moura, FA; Munhoz, DB; Nadruz, W; Oliveira, DC; Quinaglia, T; Soares, AAS; Sposito, AC | 1 |
| Cai, Z; Cheng, H; Hu, X; Huang, H; Li, X; Liao, D; Tan, Z; Wang, C; Wang, Y; Wu, C; Wu, M; Xie, Y; Xu, F; Yin, K; Zeng, J; Zhao, W; Zhou, S; Zhou, X; Zhu, Y | 1 |
| Au Yeung, J; Khong, TK | 1 |
| Bengtsson, O; Butt, JH; Diez, M; Docherty, KF; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Ogunniyi, MO; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Floege, J; Marx, N | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Kosiborod, M; Kurlyandskaya, R; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC | 1 |
| Bengtsson, O; Böhm, M; Chiang, CE; Desai, AS; Docherty, KF; Gasparyan, SB; Howlett, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Chon, J; Chun, MH; Han, CS; Kang, JH; Kim, DW; Kim, JY; Oh, DW; Park, CW; Rhee, YS; Shin, DH | 1 |
| Barratt, J; Floege, J | 1 |
| Ishikawa, K; Kumagai, J; Maezawa, Y; Matumoto, A; Ochiai, H; Ohno, T; Ono, H; Takeda, K; Yokoh, H; Yokote, K | 1 |
| Kabel, AM; Salama, SA | 1 |
| Albiero, M; Amendolagine, FI; Avogaro, A; Cappellari, R; D'Anna, M; Fadini, GP; Migliozzi, L; Rosato, A; Tedesco, S; Zuccolotto, G | 1 |
| Loutradis, C; Sarafidis, PA; Theodorakopoulou, MP | 1 |
| Choi, H; Lim, S; Shin, Y | 1 |
| Kohn, OF | 1 |
| Brand, SB; Cragin, L; Fahrbach, K; Gandhi, PK; Kansal, AR; Pfarr, E; Reifsnider, OS; Ustyugova, A | 1 |
| Greenhill, C | 1 |
| Bellido, D; Bellido, V; Botana, MA; Caballero, I; Goñi, F; Mangas, MÁ; Morales, C; Palomares, R; Sevillano, C; Soto, A; Tejera, C | 1 |
| Anastasiou, G; Hatziagelaki, E; Liberopoulos, E | 1 |
| Ahmed, AAE; El-Rous, MA; Raafat, EM; Saber, S | 1 |
| Baines, DL; Dockrell, MEC; Pan, X; Phanish, MK | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Niitani, T; Sagara, M; Tomaru, T; Usui, I | 1 |
| Ang, L; Dillon, B; Fang, F; Kidwell, KM; Leone, V; Mizokami-Stout, K; Pop-Busui, R; Reiss, J | 1 |
| Chew, DS; Mark, DB | 1 |
| Goldhaber-Fiebert, JD; Heidenreich, PA; Khush, KK; Parizo, JT; Salomon, JA; Sandhu, AT; Spertus, JA | 1 |
| Choutka, J; Parkan, K; Pohl, R; Rahm, M; Vaňková, K | 2 |
| Claggett, B; de Boer, RA; DeMets, D; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Öhrn, F; Petersson, M; Shah, SJ; Solomon, SD; Wilderäng, U | 1 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
| Kato, M; Kuribayashi, N; Nagayama, D; Ohashi, H; Ohira, M; Saiki, A; Suzuki, D; Tatsuno, I; Uchida, D; Watanabe, Y; Yamaguchi, T | 1 |
| Haberbosch, L; Spranger, J | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| Jafar, TH | 1 |
| Chai, D; Chen, X; Chu, Y; Du, H; Lin, J; Lin, X; Liu, J; Ma, K; Ruan, Q; Xie, H; Xu, C; Zeng, J; Zhang, H; Zhang, Y | 1 |
| Barreto, J; Breder, I; Cintra, RM; de Carvalho, LSF; Guerra-Júnior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Dabal, TD; Jackson, CD; Patrick, SA | 1 |
| Buranapin, S; Chattipakorn, N; Euathrongchit, J; Leerapun, A; Phrommintikul, A; Phrueksotsai, S; Pinyopornpanish, K; Thongsawat, S | 1 |
| Belosludtsev, KN; Belosludtsev, MN; Belosludtseva, NV; Dubinin, MV; Mikheeva, IB; Starinets, VS | 1 |
| An, F; Jin, T; Liu, D; Liu, M; Pan, J; Suo, M; Tian, J; Wang, X; Zhang, M | 1 |
| Bajaj, HS; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Persson, F; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Wheeler, DC | 1 |
| Cazorla-Bak, MP; Chin, K; Connelly, KA; Evans, RG; Gilbert, RE; Hare, GMT; Jacobs, E; Mazer, CD; Nghiem, L; Thai, K; Vinogradov, SA; Wilson, DF; Zhang, Y | 1 |
| Cui, S; Dong, X; Gao, W; Liu, Y; Ren, L; Yin, X; Yu, L | 1 |
| Albrecht, M; Hermanides, J; Hollmann, MW; Kerindongo, RP; Li, X; Preckel, B; Römer, G; Weber, NC; Zuurbier, CJ | 1 |
| Chen, Y; Ding, Y; Luo, J; Niu, Y; Sun, P; Wang, Y; Xie, W; Xu, N; Zhang, Y | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Ye, Y | 1 |
| Chen, SY; Chen, WT; Lee, CC; Lee, TM | 1 |
| Ding, Y; Du, B; Fu, H; Li, L; Liu, Y; Wang, F; Yin, Y; Yu, S; Yue, Z; Zhang, Z; Zhao, R | 1 |
| Ghazal Asswad, R; Nicholson, MK; Wilding, JP | 1 |
| Borges, JI; Cora, N; Lymperopoulos, A; Sizova, A | 1 |
| Aboudara, M; Akin, EE; Ambery, P; Barroso, WKS; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Feitosa, ADM; Fonseca, A; Furtado, RHM; Garla, V; Gasparyan, SB; Gordon, RA; Gosch, K; Hoffmann Filho, CR; Jaeger, CP; Javaheri, A; Koch, GG; Kosiborod, MN; Langkilde, AM; Lazcano Soto, JR; Leaes, PE; Martinez, F; Moia, DDF; Mukhtar, O; Nassif, M; Nigro Maia, L; Oscarsson, J; Pursley, M; Silveira, FS; Soares, RVP; Tang, F; Verma, S; Windsor, SL | 1 |
| Caimari, F; Rossello, X | 1 |
| Bellows, BK; Calvachi, P; Garan, AR; Gavin, MC; Hernandez, I; Isaza, N; Kazi, DS; Liu, CL; Raber, I; Shen, C | 1 |
| Bengtsson, O; Claggett, B; Docherty, KF; Ferreira, JP; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| de Galan, BE; Tack, CJ; van Meijel, LA | 1 |
| Chew, DP; Chong, W; De Pasquale, C; De Pasquale, CG; Hecker, T; Horsfall, M; Ilyas, F; Jones, L; Mangoni, AA; Selvanayagam, JB; Stranks, S; Swan, A; Tee, SL; Thomas, S; Wollaston, F | 1 |
| Beddhu, S; Fouque, D; Kalantar-Zadeh, K; Kovesdy, CP; Kramer, HJ | 1 |
| AboGresha, NM; Ahmed, AAM; El-Sayed, N; El-Sayed, NM; Mahmoud, IZ; Mostafa, YM | 1 |
| Fan, H; Liu, J; Ma, J; Zhao, Y | 1 |
| Ademi, Z; Kompa, AR; Liew, D; Owen, AJ; Savira, F; Tonkin, A; Wang, BH; Zomer, E; Zoungas, S | 1 |
| Kuo, WH; Lee, CT; Lee, WC; Leung, FF; Ng, HY | 1 |
| Carbone, S; daSilva-deAbreu, A; Lavie, CJ | 1 |
| Bhatt, DL; Cahn, A; Diaz, R; Gause-Nilsson, IAM; Goudev, A; Kuder, J; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Oyama, K; Park, KS; Raz, I; Sabatine, MS; Špinar, J; Wilding, JPH; Wiviott, SD | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Solomon, SD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Bengtsson, O; Curtain, JP; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Abdelaziz, MA; Belal, F; El-Domany, RA; Shaldam, M | 1 |
| Abdalla, O; Dessouki, A; Kilany, O; Murata, I; Sasaki, K; Sayed, N | 1 |
| Mendoza, VL; Punzalan, FER; Tumanan-Mendoza, BA | 1 |
| Jiang, LL; Li, FF; Liu, BL; Ma, JH; Yan, RN; Ye, L; Zhang, P | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
| Arieta, CEL; Barreto, J; Breder, I; Breder, JC; Carvalho, LSF; Chaves, FRP; Cintra, RMR; Fernandes, VHR; Kimura-Medorima, ST; Munhoz, DB; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC | 1 |
| Bai, L; Ding, Y; Fan, Y; Fatima, M; Gao, J; Han, T; Wang, C; Zhang, Y | 1 |
| Cherney, D; Chertow, GM; Correa-Rotter, R; Dwyer, JP; Greene, T; Heerspink, HJL; Kosiborod, M; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Karabulut, D; Karabulut, U; Keskin, K; Yiğit, E; Yiğit, Z | 1 |
| Raja, UY; Saravanan, P | 1 |
| Aiwale, A; Ghag, S; Pawar, R; Trailokya, AA; Zalke, A; Zargar, AH | 1 |
| Chan-Jiang, E; de Diego, M; Godoy, R; Mennickent, S; Vergara, C | 1 |
| Belosludtsev, KN; Belosludtseva, NV; Starinets, VS | 1 |
| Anker, SD; Butler, J; Sattar, N; Verma, S | 1 |
| Chang, HY; Chang, WT; Hua, YM; Kuo, FH; Lee, MC; Liao, CT; Ou, HT; Strong, C; Tang, HJ; Toh, HS; Yang, CT | 1 |
| Faridvand, Y; Jodati, A; Nejabati, HR; Nemati, M; Nouri, M; Nozari, S; Safaie, N; Zamani, ARN; Zamani-Gharehchamani, E | 1 |
| Lo, KB; Mathew, RO; Rangaswami, J; Vaduganathan, M | 1 |
| Blair, HA | 1 |
| Al-Kali, A; Alkhateeb, H; Gangat, N; Pardanani, A; Szuber, N; Tefferi, A | 1 |
| Chen, G; Wang, H; Zhang, W; Zhou, J | 1 |
| Boulton, DW; Chang, R; Naagaard, MD; Någård, M; Tang, W | 1 |
| Chan, YY; Chang, KC; Chang, SH; Hung, MJ; Lai, EC; Lin, SJ; Shao, SC | 1 |
| Abu-Assi, E; Amat-Santos, IJ; Blas, SG; Cruz-Gonzalez, I; de la Torre Hernandez, JM; Diez-Gil, JL; Gheorge, L; Ibáñez, B; Iñiguez-Romo, A; Lopez-Otero, D; Melendo-Viu, M; Muñoz-Garcí, AJ; Nombela-Franco, L; Raposeiras-Roubín, S; Romaguera, R; Sánchez-Luna, JP; Sánchez-Recalde, Á | 1 |
| García, Á; Gil-Rojas, Y; Lasalvia, P | 2 |
| Borlaug, BA; Chandra, L; Chaudhry, SP; Chow, CH; Clemson, BS; Fong, M; Gordon, RA; Joseph, SM; Kanwar, MK; Khan, SS; Khariton, Y; Khumri, T; Kitzman, DW; Kosiborod, MN; Lamba, S; Lewis, GD; Malik, AO; Nassif, ME; Pursley, M; Ryan, JJ; Shah, SJ; Sharma, K; Siraj, ES; Tang, F; Umpierrez, G; Windsor, SL | 1 |
| Hamaoka, T; Hirai, T; Inoue, O; Kato, T; Kawashiri, MA; Mukai, Y; Murai, H; Sakata, K; Sugimoto, H; Takamura, M; Takashima, S; Takata, S; Usui, S | 1 |
| Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK | 1 |
| Anand, IS; Berg, DD; Chopra, V; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Langkilde, AM; Lindholm, D; McMurray, JJV; Morrow, DA; Nicolau, JC; O'Meara, E; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Welsh, P | 1 |
| Han, Y; He, SM; Wang, DD; Wang, TY; Wang, YM | 1 |
| Giannakoulas, G; Kotsa, K; Koufakis, T; Zebekakis, P | 1 |
| Bengtsson, O; Böhm, M; Butt, JH; de Boer, RA; Desai, AS; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V | 3 |
| Adamson, C; Bengtsson, O; Butt, JH; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lindholm, D; Maria Langkilde, A; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Barreto, J; Bonilha, I; Breder, I; Cintra, RM; Coelho-Filho, OR; Cunha, JS; de Carvalho, LSF; Guerra-Junior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Kuo, WH; Lee, CT; Lee, WC; Leung, FF; Ng, HY; Tain, YL | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Nowicki, M; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC; Wittmann, I | 1 |
| Chen, QY; Guan, X; Jiang, YN; Lai, TF; Li, L; Ren, FF; Xie, ZY | 1 |
| Chen, H; Li, J; Liang, B; Sun, J; Yang, L; Zhang, X; Zhang, Z | 1 |
| Doumas, M; Karagiannis, A; Kassimis, G; Papadopoulos, C; Patoulias, D; Vassilikos, V | 1 |
| Boeder, SC; Giovannetti, ER; Gregory, JM; Pettus, JH | 1 |
| Bansiya, V; Boughton, CK; Evans, ML; Raj, A | 1 |
| Jiang, L; Ke, Q; Luo, J; Lv, Y; Shi, C; Wang, L; Yang, J; Zhou, Y | 1 |
| Kellum, JA; Ostermann, M; Reis, T; Ronco, C; Zarbock, A | 1 |
| Berwanger, O; Esterline, R; Furtado, RHM; Gasparyan, SB; Kosiborod, MN; Oscarsson, J; Verma, S | 1 |
| Amarume, J; Feng, Z; Kusunoki, M; Nakamura, T; Nishina, A; Sato, D; Yano, M | 1 |
| Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L | 1 |
| Chatsudthipong, V; Lungkaphin, A; Pengrattanachot, N; Phengpol, N; Promsan, S; Sutthasupha, P; Thongnak, L | 1 |
| Anand, IS; Bengtsson, O; Desai, AS; Diez, M; Docherty, KF; Howlett, JG; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Nicolau, JC; O'Meara, E; Ogunniyi, MO; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Chen, YC; Jandeleit-Dahm, K; Peter, K | 1 |
| Bosch, A; Fromm, MF; Gemeinhardt, A; Gessner, A; Kannenkeril, D; Maas, R; Mayr, A; Schmieder, RE; Staerk, C | 1 |
| Ali, DA; Hazem, RM; Ibrahim, AZ; Moustafa, YM | 1 |
| Bhatt, DL; Gause-Nilsson, I; Kolkailah, AA; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Abdollahi, E; Delbandi, AA; Falak, R; Hajimiresmaiel, SJ; Keyhanfar, F; Shafiei, M | 1 |
| Abd El-Fattah, EE; Alsharidah, M; Amin, NA; Cavalu, S; El-Ahwany, E; Ghanim, AMH; Kaddah, MMY; Mourad, AAE; Saad, AS; Saber, S; Sami, HM; Shata, A; Yahya, G | 1 |
| Deerochanawong, C; Permsuwan, U; Pojchaijongdee, N; Thongsuk, D; Vareesangthip, K | 1 |
| Dai, C; Fang, J; Huang, H; Kong, B; Qin, T; Shuai, W; Xiao, Z | 1 |
| Albai, A; Braha, A; Cipu, D; Potre, O; Timar, B; Timar, R; Vasiluță, L | 1 |
| de Sousa, C; Pinto, FJ | 1 |
| de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Abdelsalam, RM; El-Safty, H; El-Sahar, AE; Ismail, A; Saad, MA | 1 |
| Abdulrahman, N; Eldassouki, H; Gadeau, AP; Imran, Z; Ismail, R; Moustafa, DA; Mraiche, F; Rayan, M | 1 |
| El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS | 1 |
| Bengtsson, O; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Simpson, J; Sjöstrand, M; Solomon, SD | 1 |
| Artola Arita, V; Rienstra, M; Van Veldhuisen, DJ | 1 |
| Fan, X; Guo, F; Huang, F; Liu, Y; Qin, G; Song, Y; Zhao, L | 1 |
| Jardine, MJ; O'Hara, DV | 1 |
| Barkhof, F; IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Schrantee, A; van Bloemendaal, L; van Ruiten, CC; Veltman, DJ | 1 |
| Aluri, KZ; Chertow, GM; Cusick, MM; Goldhaber-Fiebert, JD; Handley, TJ; Joyner, AKC; Owens, DK; Salomon, JA; Tisdale, RL | 1 |
| Balogh, DB; Barczi, A; Fekete, A; Fintha, A; Hodrea, J; Molnar, A; Saeed, A; Szabo, AJ; Wagner, LJ | 1 |
| Capel, M; Escobar, C; Morales, C; Pérez-Alcántara, F; Pomares, E; Simón, S | 1 |
| Egan, EM; Remedi, MS; Shyr, ZA; Ustione, A; Yan, Z | 1 |
| Arima, H; Fujita, Y; Horibe, K; Ida, S; Itoh, R; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Tanaka-Mizuno, S; Ugi, S; Yanagimachi, T; Yoshimura, M | 1 |
| Ge, J; He, K; Jing, Z; Li, J; Sun, J; Xi, W | 1 |
| Huang, WJ; Liang, G; Lin, K; Luo, W; Qian, JF; Shan, PR; Xu, DY; Yang, N; Ye, SJ; Yuan, CX; Zhu, WW | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Amarume, J; Feng, Z; Kusunoki, M; Nakamura, T; Nishina, A; Sato, D; Tsutsumi, K; Umehara, Y; Yano, M | 1 |
| Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z | 1 |
| Ansari, IA; Bhatt, SP; Dutta, K; Ghosh, A; Gupta, R; Mahajan, H; Misra, A; Pandey, RM; Pandey, S; Tyagi, K; Venugopal, VK | 1 |
| Cho, HJ; Cho, JH; Choi, HG; Kim, Y; Woo, MR | 1 |
| Joshi, D; Narula, S; Rohilla, R; Singh, H; Singh, J; Singla, M | 1 |
| Faridvand, Y; Jodati, A; Kazemzadeh, H; Maroufi, NF; Mirzajanzadeh, P; Nejabati, HR; Nouri, M; Pezeshkian, M; Safaie, N; Vahedian, V | 1 |
| Seki, H; Watanabe, H; Yorozu, T | 1 |
| Birnie, E; Burggraaf, B; Castro Cabezas, M; de Herder, WW; Fernández Arroyo, S; Huisbrink, J; Mulder, MT; Pouw, NMC; Rensen, PCN; van de Geijn, GM; van der Zwan, EM; van Vark-van der Zee, LC | 1 |
| Davies, M; Fielding, BA; Herring, RA; Jackson, N; Mendis, J; Middleton, B; Parsons, I; Russell-Jones, DL; Shojaee-Moradie, F; Stevenage, M; Umpleby, AM | 1 |
| Aijaz, SS; Iqbal, Y; Zafar, Y | 1 |
| Deng, C; Gu, Y; He, Y; Shi, J; Sun, L; Yang, L | 1 |
| Heni, M; Hummel, J; Kullmann, S | 1 |
| Chan, ATP; Tang, SCW | 1 |
| Xu, W; Xu, X; Yan, Y; Zhuo, Q | 1 |
| Asseri, SM; Ebrahim, HA; El-Agawy, MSE; El-Shafey, M; El-Sherbiny, M; Eldosoky, M; Elsherbini, DMA; Elsherbiny, NM | 1 |
| Isganaitis, E; Karlsson, C; Laffel, LM; Norjavaara, E; Ratnayake, J; Shehadeh, N; Tamborlane, WV; Van Name, M | 1 |
| Bjornstad, P; Nelson, RG; Tommerdahl, KL | 1 |
| Cao, F; Chen, G; Guo, X; Huang, X; Qiao, Y; Tang, C; Wang, D; Yan, G; Yao, Y; Zhang, W; Zhang, Y | 1 |
| Boulton, DW; Hamrén, B; Melin, J; Parkinson, J; Penland, RC; Rekić, D; Tang, W | 1 |
| Fu, Q; He, J; Li, M; Peng, J; Tan, S; Tang, M; Tang, Y; Xie, W; Xu, X; Zhang, Q; Zhang, Y; Zheng, Z; Zhu, T | 1 |
| Alegete, P; Boodida, S; Vankalapati, KR | 1 |
| Chang, WT; Chen, ZC; Hong, CS; Kan, WC; Lin, TH; Lin, YW; Shih, JY | 1 |
| Adamson, C; Bengtsson, O; Damman, K; de Boer, RA; Docherty, KF; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC | 1 |
| Belohlávek, J; Bengtsson, O; Butt, JH; Chiang, CE; Dewan, P; Docherty, KF; Drożdż, J; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Bengtsson, O; Boulton, DW; Docherty, KF; Greasley, PJ; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Petrie, MC; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Yeoh, SE | 1 |
| IJzerman, RG; Kok, MD; Kramer, MHH; Nieuwdorp, M; Serné, EH; Smits, MM; van Raalte, DH; van Ruiten, CC | 1 |
| IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Ten Kulve, JS; van Ruiten, CC; Veltman, DJ; Wijdeveld, M | 1 |
| Damas-Fuentes, M; Fernández-Valero, A; Martínez-Montoro, JI; Pinzón-Martín, JL; Tinahones, FJ | 1 |
| Aylward, P; Bhatt, DL; Cahn, A; Dalby, AJ; Dellborg, M; Dimulescu, D; Furtado, RHM; Gause-Nilsson, I; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Oude Ophuis, AJM; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Benson, L; Cosentino, F; Dahlström, U; Ferrannini, G; Lund, LH; McMurray, JJV; Mellbin, L; Savarese, G; Thorvaldsen, T | 1 |
| Bello, E; Bhatwadekar, AD; Dhami, H; Leley, SP; Luo, Q; Mathew, D | 1 |
| Chi, PJ; Hsieh, YJ; Hsu, BG; Lee, CJ; Lu, CW | 1 |
| Hiramoto, K; Horikawa, T; Ooi, K; Tanaka, S | 1 |
| Facharztmagazine, R | 1 |
| IJzerman, RG; Nieuwdorp, M; van Ruiten, CC; Veltman, DJ | 1 |
| Dai, W; Peng, Q | 1 |
| Fu, Z; Husain, M; Ilkayeva, O; Inzucchi, SE; Javaheri, A; Jones, P; Kosiborod, MN; Kwee, LC; Lanfear, DE; Margulies, KB; McGuire, DK; Mentz, RJ; Nassif, ME; Newgard, CB; Pitt, B; Scirica, BM; Selvaraj, S; Shah, SH; Windsor, SL | 1 |
| He, L; Li, Y; Song, H; Song, Z; Xu, D; Zhang, D | 1 |
| Ananicheva, N; Andreev, D; Bogdanova, A; Charaya, K; Dyachuk, I; Kuzub, A; Mesitskaya, D; Poltavskaya, M; Shchekochikhin, D; Tarasenko, S | 1 |
| Chen, C; Chen, X; Cowley, M; Cui, L; Geng, F; Huang, L; Huang, Z; Roelfsema, F; Tan, C; Wang, W; Wu, M | 1 |
| Abegaz, TM; Ali, AA; Diaby, V; Sherbeny, F | 1 |
| Huh, Y; Kim, YS | 1 |
| Bezan Petric, U; Fukazawa, A; Hu, MC; Ishizawa, R; Kim, HK; Mizuno, M; Smith, SA; Vongpatanasin, W; Wang, Z | 1 |
| Chen, HC; Yang, AY | 1 |
| Cao, X; Song, X; Tran, J; Yan, P; Yuan, H; Zhao, G; Zhou, R | 1 |
| Chen, J; Huang, Y; Li, T; Lin, X; Lin, Y; Lu, H; Xian, J; Yang, Z; Zhang, Q | 1 |
| Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H | 1 |
| Akdeniz, CS; Belen, E; Canbolat, IP; Cetinarslan, Ö; Erbas, O; Karaca, M; Sönmez, M; Yigittürk, G | 1 |
| Chen, X; Fan, ZG; Ji, MY; Ma, GS; Xu, Y | 1 |
| Almengló, C; Durán, D; Eiras, S; Fernández, ÁL; Flores-Arias, MT; Fu, X; González-Juanatey, JR; Martínez-Cereijo, JM; Rodríguez-Mañero, M; Viñuela, JE | 1 |
| Kurata, Y; Nangaku, M | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Leiter, LA; McGuire, DK; Mosenzon, O; Oyama, K; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD | 1 |
| Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D | 1 |
| Bengtsson, O; Biering-Sørensen, T; Butt, JH; DeFilippis, EM; Dewan, P; Docherty, KF; Fiuzat, M; Jhund, PS; Johansen, ND; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD; Vaduganathan, M | 1 |
| Bellante, R; Berra, C; Bolla, A; Chebat, E; Cimino, V; D'Addio, F; Desenzani, P; Fiorina, P; Folli, F; Franzetti, I; Gandolfi, A; Gazzaruso, C; Genovese, S; Ghelardi, R; Girelli, A; Lazzaroni, E; Loretelli, C; Lunati, ME; Manfrini, R; Montefusco, L; Morpurgo, PS; Muratori, F; Muratori, M; Nasr, MB; Orsi, E; Pastore, I; Plebani, L; Rossi, A; Scaranna, C; Tinari, C; Vallone, L | 1 |
| Huang, K; Liu, J; Sun, S; Wang, Y; Xie, X; Zhou, W; Zhu, D; Zhu, Q | 1 |
| Matsumoto, K; Tsuboi, N; Ueda, H; Yokoo, T | 1 |
| Abdallah, DM; Ahmed, KA; El-Abhar, HS; Fleifel, AM; Soubh, AA | 1 |
| Bin-Meferij, MM; Eissa, H; El-Baz, AM; El-Kott, AF; El-Sokkary, MMA; Elgharabawy, RM; Hassan, HM; Khalaf, EM; Khodir, AE; Nouh, NA; Saleh, S; Shata, A; Yousef, ME | 1 |
| Aksu, E; Aykan, AÇ; Balcıoğlu, AS; Çelik, E; Göçer, K; Şahin, M | 1 |
| Liu, Z; Zhang, H | 1 |
| Bengtsson, O; De Boer, RA; Docherty, KF; Hammarstedt, A; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Little, DJ; Martinez, FA; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S; Welsh, P | 1 |
| Huang, B; Wen, W; Ye, S | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Heerspink, HJL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Schechter, M; Wilding, JPH; Wiviott, SD; Yanuv, I; Zelniker, TA | 1 |
| Ferry, A | 1 |
| Al Habeeb, W; Alcocer-Gamba, MA; Bachus, E; Belohlavek, J; Borleffs, CJW; Cabrera Honorio, JW; Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Dobreanu, D; Drozdz, J; Fang, JC; Han, Y; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Merkely, B; O'Meara, E; Petersson, M; Pham, VN; Saraiva, JFK; Shah, SJ; Solomon, SD; Tereshchenko, SN; Thierer, J; Vaduganathan, M; Vardeny, O; Verma, S; Wilderäng, U; Zaozerska, N | 1 |
| Bachus, E; Belohlávek, J; Butt, JH; Chiang, CE; Claggett, BL; de Boer, RA; Desai, AS; Drożdż, J; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Lam, CSP; Lindholm, D; Maria Langkilde, A; Martinez, F; McMurray, JJV; Merkely, B; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U | 1 |
| Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Katova, T; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Peikert, A; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O; Wilderäng, U | 1 |
| Bengtsson, O; Butt, JH; Claggett, BL; de Boer, RA; DeMets, D; Desai, AS; Docherty, KF; Gasparyan, SB; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kondo, T; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Petersson, M; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ | 1 |
| Claggett, BL; Cunningham, JW; de Boer, RA; DeMets, D; Desai, AS; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Kulac, IJ; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McGrath, MM; McMurray, JJV; O'Meara, E; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U | 1 |
| Capece, U; Cinti, F; Cocchi, C; Crea, F; D'Amario, D; Ferraro, PM; Giaccari, A; Giordano, A; Gugliandolo, S; Guzzardi, MA; Indovina, L; Iozzo, P; Leccisotti, L; Lorusso, M; Mezza, T; Sorice, GP | 1 |
| Grätzel von Grätz, P | 1 |
| Choi, D; Hong, GR; Jeon, OH; Kim, C; Kim, D; Kim, JS; Lee, CJ; Lee, HJ; Lee, JJ; Lee, OH; Lee, SG; Lee, SJ; Lee, YH; Lee, YJ; Moon, RK; Oh, J; Park, S | 1 |
| Ando, J; Kodera, S; Komuro, I; Morita, H; Nishi, H; Takeda, N | 1 |
| Chan, SH; Cheng, HC; Chou, WC; Chu, PM; Hsieh, PL; Huang, YT; Tsai, KL | 1 |
| Bachir, N; Boukabous, A; Terki, A; Zaoui, N | 1 |
| Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A | 1 |
| Chen, K; Liu, J; Qin, S; Qin, Y; Wang, C; Wu, X; Xiao, W; Yang, Y; Zhang, X | 1 |
| Ji, Y; Sun, L; Wang, FF; Yan, XJ; Zhang, JL; Zhu, Y | 1 |
| Ma, F; Wang, H; Wu, Y; Zhang, J | 1 |
| Doumas, M; Karagiannis, A; Katsimardou, A; Papadopoulos, C; Patoulias, D; Zografou, I | 1 |
| Chang, R; Cui, B; Fan, Z; Hiram, R; Huang, C; Huang, H; Liu, T; Shi, S; Su, X; Tang, Y; Wu, G; Wu, J; Xiong, F; Yan, M; Zhang, W | 1 |
| Claggett, BL; de Boer, RA; Desai, AS; Hegde, SM; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, F; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Ma, H; Ma, Y | 1 |
| Bai, Z; Chen, L; Chen, Z; Liu, T; Luo, J; Xiao, Y; Xie, T; Yu, L; Zhang, C; Zhao, X | 1 |
| Cui, Y; Dong, Z; Fu, Y; He, X; Li, Y; Ma, Y; Xun, X | 1 |
| Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE | 1 |
| Bergenheim, K; Briggs, A; Darlington, O; Garcia Sanchez, JJ; Heerspink, HJL; McEwan, P; McMurray, JJV; Miller, R; Wheeler, DC | 1 |
| Khine, A; Lin, E | 1 |
| Claggett, BL; de Boer, RA; Desai, AS; Docherty, K; Fang, J; Hernandez, AF; Inzucchi, SE; Jhund, P; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, F; Mc Causland, FR; McGrath, MM; McMurray, JJV; Petersson, M; Saraiva, JFK; Shah, SJ; Solomon, SD; Vaduganathan, M; Verma, S | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Rossing, P; Sjöström, CD; Wheeler, DC | 1 |
| Bhatt, DL; Cahn, A; Gause-Nilsson, IAM; Goodrich, EL; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Pollack, R; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Drozdz, J; Fang, JC; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; O'Meara, E; Petersson, M; Solomon, SD; Vaduganathan, M; Vardeny, O; Zieroth, S | 1 |
| Atlım, HT; Aydemir, M; Doğruel, H; Sarı, R; Yılmaz, N | 1 |
| Bayes-Genis, A; Núñez, J | 1 |
| Bartholdy, KV; Biering-Sørensen, T; Bressendorff, I; Christensen, J; Feldt-Rasmussen, B; Hansen, D; Haynes, R; Jensen, J; Johansen, ND; Køber, L; Landler, N; Persson, F; Rossing, P; Schou, M; Skaarup, KG; Solomon, S; Vaduganathan, M; Zannad, F | 1 |
| Beernink, JM; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Laverman, GD; McMurray, JJV; Persson, F; Rossing, P; Sjöström, CD; Toto, RD; Wheeler, DC | 1 |
| Iijima, Y; Ito, R; Manda, N; Miwa, T; Nakayama, M; Odawara, M; Shikuma, J; Tanaka, A; Tomiyama, H; Yakou, F | 1 |
| Borleffs, CJW; Claggett, BL; de Boer, RA; Desai, AS; Dobreanu, D; Hernandez, AF; Inzucchi, SE; Janssens, SP; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Solomon, SD; Vaduganathan, M; Vinh, PN | 1 |
| Melenovsky, V; Monzo, L | 1 |
| Kosiborod, MN; Selvaraj, S; Shah, SH | 1 |
| Iwata, Y; Kawamura, Y; Mitani, W; Morimoto, M; Notsu, S; Tamai, S; Yamato, M | 1 |
| Butt, JH; McMurray, JJV; Solomon, SD | 1 |
| Chertow, GM; Heerspink, HJL; Jongs, N; Langkilde, AM; Vart, P; Wheeler, DC | 1 |
| Wiley, T; Williams, L | 1 |
| Khong, TK; Sylvester, RD | 1 |
| Desai, RJ; Everett, BM; Fu, EL; Levin, R; Patorno, E; Schneeweiss, S; Solomon, SD; Vaduganathan, M | 1 |
| Bachus, E; Booth, D; Chen, J; Comin-Colet, J; Davis, JA; De Boer, RA; McEwan, P; McMurray, JJV; Solomon, SD | 1 |
| Anand, I; Berg, DD; de Boer, RA; Docherty, KF; Hammarstedt, A; Jarolim, P; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Osmanska, J; Ponikowski, P; Sabatine, MS; Sattar, N; Schou, M; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Chertow, GM; Heerspink, HJL; Schechter, M | 1 |
| Patoulias, D | 1 |
| Choi, YJ; Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lim, J; Na, JO; Park, JB; Rhee, TM | 1 |
| Greenberg, B; Park, JJ | 1 |
| Rawat, R; Varshney, A | 1 |
| Mukherjee, D | 1 |
| Cui, C; Guo, X; Liu, J; Qiao, Q; Shi, M; Wang, J; Wang, Q; Wang, W; Wang, Y; Xu, J; Zhang, C; Zhang, H; Zhang, X | 1 |
211 review(s) available for glucose, (beta-d)-isomer and dapagliflozin
| Article | Year |
|---|---|
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2008 |
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin: an emerging treatment option in type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Discovery; Drug Tolerance; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Delivery Systems; Glucosides; Humans; Hypoglycemic Agents; Life Style; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Dapagliflozin: BMS 512148; BMS-512148.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drugs, Investigational; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Topics: Absorption; Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Dapagliflozin: more than just another oral glucose-lowering agent?
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2010 |
[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Topics: Absorption; Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; Double-Blind Method; Gluconeogenesis; Glucose; Glucosides; Glycosuria, Renal; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Kidney Tubules, Proximal; Mice; Phlorhizin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
[Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Topics: Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Thiophenes | 2012 |
A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Gluconeogenesis; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2011 |
Challenges for the treatment of diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Bile Acids and Salts; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucokinase; Glucosides; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Patents as Topic; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2011 |
SGLT-2 inhibitors in development for type 2 diabetes treatment.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phlorhizin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Topics: Benzhydryl Compounds; Biological Transport; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
[Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Molecular Structure; Monosaccharides; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2012 |
Sodium glucose cotransporter 2 and the diabetic kidney.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glipizide; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[Dapagliflozin. Lowering blood glucose levels by increasing glucosuria].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Drug Interactions; Glucosides; Glycosuria; Humans; Hypoglycemic Agents | 2013 |
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Effects of dapagliflozin on cardiovascular risk factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transport Proteins | 2013 |
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney | 2013 |
The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus; Gluconeogenesis; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
[New drugs in type 2 diabetes mellitus therapy].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Venoms | 2013 |
Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Topics: Animals; Benzhydryl Compounds; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2014 |
SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Female; Fructose; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Homeostasis; Humans; Islet Amyloid Polypeptide; Lactones; Male; Minimally Invasive Surgical Procedures; Obesity, Morbid; Orlistat; Phentermine; Receptors, Glucagon; Topiramate; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome; Urinary Tract Infections | 2014 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
Topics: Bariatric Surgery; Benzhydryl Compounds; Causality; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Disease Management; Evidence-Based Medicine; Exercise Therapy; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Obesity; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2013 |
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycemic Index; Glycosuria; Humans; Hypoglycemic Agents; Male; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Dapagliflozin: glucuretic action and beyond.
Topics: Animals; Benzhydryl Compounds; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Weight Gain | 2014 |
Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Disease Management; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; United States | 2014 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2014 |
Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Feeding Behavior; Glucosides; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Nanotechnology; Prevalence; Risk Reduction Behavior; Stem Cell Transplantation; Urbanization | 2014 |
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
[How are changing the therapy options in obese diabetic type 2 patients].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Obesity, Morbid | 2014 |
Dapagliflozin: a review of its use in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biological Availability; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transport Proteins; Treatment Outcome | 2014 |
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Treatment Outcome | 2015 |
Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; Thiophenes; United States | 2014 |
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2014 |
[Dapagliflozin, a novel oral antidiabetic with an uncertain future].
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2014 |
Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Discovery; Glucosides; Glycosides; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Monosaccharides; Phlorhizin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2015 |
Dapagliflozin: drug profile and its role in individualized treatment.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents | 2015 |
Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2015 |
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Topics: Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Pharmacovigilance; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Urinary Tract Infections | 2015 |
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents | 2016 |
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; United States; Weight Loss | 2015 |
Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Dapagliflozin combination therapy in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Treatment Outcome | 2016 |
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Primary Health Care; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transport Proteins; Treatment Outcome | 2016 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2016 |
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Pharmacological aspects of the safety of gliflozins.
Topics: Animals; Benzhydryl Compounds; Fractures, Bone; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Lipids; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Incidence; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Topics: Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Incidence; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2017 |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Magnesium; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
[Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Topics: Animals; Antihypertensive Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
Topics: Animals; Benzhydryl Compounds; Bone Density; Canagliflozin; Drug Labeling; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Parathyroid Hormone; Risk; Sodium-Glucose Transporter 2 Inhibitors; United States; United States Food and Drug Administration; Vitamin D | 2017 |
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Drug Therapy, Combination; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Incretins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Regression Analysis; Reproductive Tract Infections; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2017 |
Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
Topics: Asian People; Benzhydryl Compounds; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Membrane Transport Modulators; Middle Aged; Reproducibility of Results; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Linagliptin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Econometric; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Hypoglycemic Agents | 2017 |
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
.
Topics: Angiotensins; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Protective Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction | 2017 |
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Renal Insufficiency; Reproducibility of Results; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Arab Emirates | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Consensus; Delphi Technique; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Circadian Rhythm; Diabetes Mellitus; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Dapagliflozin for the treatment of type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hyperuricemia; Hypoglycemia; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets | 2018 |
Bolstering your armamentarium with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Topics: Adult; Aged; Amputation, Surgical; Benzhydryl Compounds; Blood Volume; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Double-Blind Method; Female; Fractures, Spontaneous; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections | 2018 |
Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2017 |
Current practices and future outlook on the integration of biomarkers in the drug development process.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Guidelines as Topic; Humans; Leukemia, Myeloid; Retinoic Acid Receptor alpha | 2017 |
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Hypoglycemic Agents; Infections; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
The role of SGLT2 inhibitors in managing type 2 diabetes.
Topics: Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
[Dapagliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, Acutely Reduces Energy Expenditure in Brown Adipose Tissue via Neural Signals in Mice].
Topics: Adipose Tissue, Brown; Animals; Benzhydryl Compounds; Energy Metabolism; Gene Expression; Glucosides; Humans; Liver; Mice; Midbrain Raphe Nuclei; Nerve Net; Norepinephrine; Oxygen Consumption; Proto-Oncogene Proteins c-fos; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System; Thermogenesis; Uncoupling Protein 1; Vagus Nerve | 2018 |
Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2018 |
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT inhibitor adjunct therapy in type 1 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemic Agents; International Cooperation; Multicenter Studies as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1 | 2018 |
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholesterol; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
New Medications for the Treatment of Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2019 |
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Topics: Animals; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiotonic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Protective Agents; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Pregnancy; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding Treatment | 2020 |
Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Quality-Adjusted Life Years; United Kingdom | 2020 |
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchangers | 2020 |
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Non-alcoholic Fatty Liver Disease | 2020 |
Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Pharmaceutical Preparations | 2020 |
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Humans; Lower Extremity; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Risk; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Topics: Accidental Falls; Benzhydryl Compounds; Bone Density; Bone Remodeling; Calcium; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Phosphates; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Topics: Aged; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Body Mass Index; Case-Control Studies; Cause of Death; Clinical Trials as Topic; Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Patient Outcome Assessment; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.
Topics: Amputation, Surgical; Bayes Theorem; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2021 |
The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
An update on dapagliflozin for the treatment of heart failure.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2021 |
[Practical approach of dapagliflozin for the treatment of heart failure. Role of primary care physician].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Physicians, Primary Care; Stroke Volume; Ventricular Function, Left | 2021 |
Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Brachial Artery; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Vasodilation | 2022 |
Dapagliflozin no longer licensed for type 1 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Safety-Based Drug Withdrawals | 2022 |
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID
Topics: Angiotensin-Converting Enzyme 2; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; COVID-19; Double-Blind Method; Drug Repositioning; Glucosides; Heart Diseases; Humans; Kidney Diseases; Mitochondria; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Receptors, Virus; Renin-Angiotensin System; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Humans; Prospective Studies; Risk Assessment | 2022 |
Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Cholesterol, HDL; Glucosides; Humans; Non-alcoholic Fatty Liver Disease | 2022 |
Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Multicenter Studies as Topic | 2022 |
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cholesterol, LDL; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic | 2022 |
The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2022 |
Dapagliflozin for the treatment of chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Network Meta-Analysis | 2022 |
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Heart Failure; Humans; Sodium; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin in people with chronic kidney disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2023 |
314 trial(s) available for glucose, (beta-d)-isomer and dapagliflozin
| Article | Year |
|---|---|
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult | 2009 |
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2009 |
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Tolerance Test; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2009 |
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Treatment Outcome; Young Adult | 2009 |
In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzhydryl Compounds; Biological Availability; Biotransformation; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucosides; Half-Life; Hepatocytes; Humans; Hypoglycemic Agents; Isoenzymes; Kinetics; Macaca fascicularis; Male; Membrane Transport Modulators; Mice; Mice, Inbred BALB C; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2010 |
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet Therapy; Double-Blind Method; Exercise Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Placebos; Treatment Outcome | 2010 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Treatment Outcome | 2011 |
Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Biological Availability; Diet; Dietary Fats; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2011 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2011 |
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Glipizide; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Topics: Adult; Benzhydryl Compounds; Female; Glucosides; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Sodium-Glucose Transport Proteins | 2011 |
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2012 |
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Osteoporosis; Time Factors; Treatment Outcome | 2012 |
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
Topics: Benzhydryl Compounds; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; India; Male; Mexico; Middle Aged; Puerto Rico; Russia; South Africa; Treatment Outcome; United States; Weight Loss | 2012 |
Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Biological Availability; Chromatography, Liquid; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucosides; Humans; Male; Mass Spectrometry; Middle Aged; Sodium-Glucose Transport Proteins; White People; Young Adult | 2013 |
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Topics: Adolescent; Adult; Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Glucosides; Glucuronosyltransferase; Humans; Hypoglycemic Agents; Male; Mefenamic Acid; Middle Aged; Rifampin; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2013 |
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Kidney Function Tests; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2013 |
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Treatment Outcome | 2013 |
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Long-Term Care; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2013 |
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transport Proteins | 2013 |
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
Topics: Benzhydryl Compounds; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Kidney; Male; Occupational Exposure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Topics: Administration, Oral; Adolescent; Adult; Benzhydryl Compounds; China; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2013 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2014 |
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Quality-Adjusted Life Years; Severity of Illness Index | 2014 |
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Topics: Adult; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Time Factors | 2014 |
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Time Factors | 2014 |
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Topics: Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Fasting; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Feasibility Studies; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; South Africa | 2015 |
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Postprandial Period; Thiophenes | 2015 |
Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Drug Administration Schedule; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2015 |
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Topics: Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Treatment Outcome | 2015 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2015 |
Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Topics: Adult; Benzhydryl Compounds; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2015 |
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2015 |
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diagnostic Self Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Surveys and Questionnaires; Treatment Outcome | 2016 |
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos | 2016 |
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Blood Pressure Determination; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Hemorheology; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Renin-Angiotensin System; Systole; Uric Acid | 2016 |
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Brazil; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Fasting; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2016 |
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Tolerance Test; Glucosides; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Young Adult | 2016 |
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2016 |
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged | 2016 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System | 2016 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Biological Availability; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2016 |
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Topics: Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome | 2016 |
[Effect of dapagliflozin on cardiovascular risk factors].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Patient Satisfaction; Sodium-Glucose Transport Proteins; Treatment Outcome | 2016 |
Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2016 |
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Diet, High-Fat; Drug Compounding; Fasting; Female; Food-Drug Interactions; Glucosides; Hot Temperature; Humans; Male; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2016 |
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Prognosis; Young Adult | 2016 |
Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
Topics: Adamantane; Administration, Oral; Adult; Benzhydryl Compounds; Cross-Over Studies; Dipeptides; Drug Interactions; Female; Glucosides; Half-Life; Humans; Male; Young Adult | 2016 |
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Calorimetry, Indirect; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Glucagon; Glucosides; Humans; Insulin; Insulin Resistance; Ketones; Lipid Metabolism; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2016 |
Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Topics: Aged; Asia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos | 2017 |
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Oxidative Stress | 2016 |
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Time Factors; Treatment Outcome | 2017 |
Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipids; Male; Metabolic Syndrome; Middle Aged; Weight Loss | 2018 |
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Lipoproteins, HDL2; Male; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins | 2017 |
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Topics: 3-Hydroxybutyric Acid; Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects | 2017 |
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Topics: Adipose Tissue; Benzhydryl Compounds; Body Composition; Body Fat Distribution; Brain; Calorimetry, Indirect; Cross-Over Studies; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Energy Metabolism; Feeding Behavior; Food; Functional Neuroimaging; Glucosides; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Liver; Magnetic Resonance Imaging; Organ Size; Proton Magnetic Resonance Spectroscopy | 2017 |
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin Resistance; Laser-Doppler Flowmetry; Male; Microcirculation; Microvessels; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Topics: Adolescent; Adult; Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Placebos; Reproducibility of Results; Treatment Outcome; Young Adult | 2017 |
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss | 2017 |
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Male; Middle Aged; Particle Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Benzhydryl Compounds; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Male; Pilot Projects; Young Adult | 2017 |
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Germany; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Internationality; Male; Middle Aged; Mortality; Norway; Registries; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Treatment Outcome; United Kingdom; United States | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors | 2017 |
Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes.
Topics: Adipose Tissue; Arterial Pressure; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Viscera | 2017 |
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Progression; Double-Blind Method; Glucosides; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Magnetic Resonance Imaging; Proof of Concept Study; Prospective Studies; Research Design; Risk Factors; Scotland; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Topics: Adult; Benzhydryl Compounds; Blood Volume; Bumetanide; Diuresis; Diuretics; Drug Combinations; Drug Interactions; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Osmolar Concentration; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Water-Electrolyte Imbalance; Young Adult | 2018 |
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
Topics: Adult; Animals; Arterioles; Benzhydryl Compounds; Disease Models, Animal; Female; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Kidney; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Proteinuria; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vasoconstriction | 2018 |
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Asia; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2018 |
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Humans; Male; Middle Aged; Muscle, Skeletal; Prospective Studies; Skin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Aged; Benzhydryl Compounds; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Glucose; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Length of Stay; Male; Middle Aged; Monitoring, Ambulatory; Prednisone; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Tissue | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Bumetanide; Drug Interactions; Female; Glucosides; Healthy Volunteers; Humans; Hyperuricemia; Male; Middle Aged; Natriuresis; Renal Elimination; Risk Assessment; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Uric Acid; Young Adult | 2018 |
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo.
Topics: Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Extracellular Traps; Female; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Neutrophils | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Topics: Acute Kidney Injury; Adult; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hepatitis A Virus Cellular Receptor 1; Humans; Inflammation Mediators; Interleukin-6; Kidney Glomerulus; Kidney Tubules; Netherlands; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects.
Topics: Adult; Appetite; Benzhydryl Compounds; Cross-Over Studies; Energy Intake; Female; Glucosides; Healthy Volunteers; Humans; Male; Single-Blind Method; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Topics: Adamantane; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Male; Middle Aged | 2018 |
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Japan; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Topics: Aged; Benzhydryl Compounds; Cerebral Infarction; Diabetes Mellitus, Type 2; Diuresis; Drug Monitoring; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Administration Schedule; Glucosides; Humans; Insulin Resistance; Ketone Bodies; Male; Middle Aged; Pilot Projects; Postprandial Period | 2018 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Carboxylic Acids; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids; Female; Glucose; Glucosides; Hepatocytes; Humans; Inflammation; Lipid Metabolism; Liver Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Sweden | 2018 |
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Least-Squares Analysis; Male; Middle Aged; Postprandial Period; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome | 2018 |
The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Obesity; Sleep Apnea Syndromes; Treatment Outcome; Young Adult | 2018 |
Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Cells, Cultured; Cohort Studies; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Stem Cells; Young Adult | 2018 |
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Placebos; Prediabetic State; Treatment Outcome | 2020 |
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Elasticity Imaging Techniques; Female; Glucosides; Humans; Lipid Metabolism; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; Young Adult | 2018 |
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome | 2018 |
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Exenatide; Female; Glucosides; Humans; Insulin; Ketones; Male; Middle Aged; Pioglitazone; Qatar; Treatment Outcome | 2019 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Substitution; Energy Metabolism; Female; Glucosides; Humans; Male; Middle Aged; Pioglitazone; Treatment Outcome | 2019 |
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Placebos; Treatment Outcome; Weight Loss | 2018 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glucuronides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training.
Topics: Adaptation, Physiological; Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Endurance Training; Exercise Therapy; Female; Glucosides; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Physical Endurance; Sedentary Behavior; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2019 |
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2 | 2019 |
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Young Adult | 2019 |
Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Inflammation Mediators; Lipids; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Troponin T; Vildagliptin | 2019 |
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; gamma-Glutamyltransferase; Glucosides; Hepatitis; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat; Weight Loss | 2019 |
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cause of Death; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Topics: Aged; Benzhydryl Compounds; Brain Ischemia; Cause of Death; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Time Factors; Treatment Outcome | 2019 |
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.
Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Epigenesis, Genetic; Female; Glomerular Filtration Rate; Glucosides; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Italy; Male; MicroRNAs; Middle Aged; Prognosis; Renal Circulation; Sodium-Glucose Transporter 2 Inhibitors; Statistics, Nonparametric; Treatment Outcome; Up-Regulation | 2019 |
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Ketone Bodies; Male; Metabolome; Metabolomics; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
Topics: Adamantane; Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Drug Combinations; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2019 |
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prediabetic State; Reference Values; Registries; Treatment Outcome | 2019 |
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Magnesium; Magnesium Deficiency; Middle Aged; Placebos; Randomized Controlled Trials as Topic | 2019 |
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Plasma Volume; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiography, Impedance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart; Hemodynamics; Humans; Italy; Male; Middle Aged; Predictive Value of Tests; Single-Blind Method; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes st
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Japan; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2019 |
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2020 |
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2019 |
The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cats; Cross-Over Studies; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Male; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sleep; Sleep Apnea, Obstructive; Treatment Outcome | 2019 |
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Exenatide; Fibrosis; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2019 |
Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged | 2020 |
Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Topics: Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Glucosides; Humans; Japan; Male; Middle Aged; Monokines; Muscle, Skeletal; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebo Effect; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Ventricular Function, Left; Young Adult | 2020 |
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Odds Ratio; Placebo Effect; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2020 |
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan | 2020 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Vasoconstriction; Vasodilation | 2020 |
Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Feces; Female; Gastrointestinal Microbiome; Gliclazide; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2020 |
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss | 2020 |
Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Fasting; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Pyrimidines; Therapeutic Equivalency; Thiazolidinediones; Young Adult | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Topics: Anti-Infective Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Erythropoiesis; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Hepcidins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Middle Aged; Obesity; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult | 2020 |
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin | 2020 |
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Brain Ischemia; Diabetes Mellitus, Type 2; Glucosides; Humans; Stroke | 2020 |
The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Pericardium; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Kidney; Metabolomics; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2020 |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans | 2020 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2020 |
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
Topics: Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exercise; Female; Glucosides; Glycated Hemoglobin; Healthy Lifestyle; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Recurrence; Remission Induction; Secondary Prevention; Time Factors; Treatment Outcome | 2020 |
Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Gliclazide; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Vascular Stiffness | 2020 |
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2; Stroke Volume; Ventricular Function, Left | 2020 |
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged | 2020 |
Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring.
Topics: Benzhydryl Compounds; Glucosides; Hemodynamic Monitoring; Humans; Pulmonary Artery; Stroke Volume; Ventricular Function, Left | 2020 |
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin | 2021 |
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Europe; Glucosides; Heart Failure; Humans; North America; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2020 |
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume | 2020 |
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.
Topics: Benzhydryl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosides; Humans; Immunologic Factors; Intensive Care Units; Pandemics; Phenylpropionates; Pneumonia, Viral; Pyridazines; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Standard of Care | 2020 |
Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial.
Topics: Benzhydryl Compounds; Blood Pressure; Double-Blind Method; Glucosides; Humans; Prediabetic State; Prehypertension | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2020 |
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Brain Ischemia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Stroke; Treatment Outcome | 2021 |
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Incretins; Liraglutide; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Glucosides; Heart Failure; Humans; Outpatients; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged | 2020 |
Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Prediabetic State; Treatment Outcome | 2021 |
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Female; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Naphthalenes; Propionates; Pyridines; Treatment Outcome; United States; Uric Acid; Uricosuric Agents; Young Adult | 2021 |
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Triglycerides; Waist Circumference; Weight Loss | 2021 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
Topics: Aged; Benzhydryl Compounds; Biomarkers; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypoglycemic Agents; Pulse Wave Analysis; Treatment Outcome | 2021 |
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2021 |
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrates; Diabetes Mellitus, Type 2; Electrolytes; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Humans; Hydrogen-Ion Concentration; Ketones; Kidney Tubules; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Topics: Adolescent; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome; Young Adult | 2021 |
Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Glucosides; Humans; Treatment Outcome | 2021 |
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Natriuretic Agents; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary | 2021 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; Hypoglycemic Agents; Metformin; Overweight; Pregnancy; Prospective Studies; Single-Blind Method | 2020 |
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Male; Pulmonary Disease, Chronic Obstructive; Stroke Volume | 2021 |
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Treatment Outcome | 2021 |
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Hematocrit; Humans; Insulin; Male; Middle Aged; Reticulocyte Count | 2020 |
Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Body Composition; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Muscle, Skeletal; Organ Size; Resistance Training; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
Topics: Administration, Oral; Adolescent; Antibiotics, Antitubercular; Area Under Curve; Benzhydryl Compounds; Child; Child, Preschool; Computer Simulation; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Glucosides; Glucuronosyltransferase; Healthy Volunteers; Hepatic Insufficiency; Humans; Infant; Infant, Newborn; Male; Mefenamic Acid; Models, Biological; Predictive Value of Tests; Renal Insufficiency; Rifampin; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2021 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stroke Volume; Ventricular Function, Left | 2021 |
Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Greece; Humans; Male; Metabolome; Metformin; Middle Aged; Treatment Outcome; Urinalysis | 2021 |
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2021 |
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2021 |
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Lung; Quality of Life | 2021 |
Effect of dapagliflozin on anaemia in DAPA-HF.
Topics: Anemia; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume | 2021 |
Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Single-Blind Method; Treatment Outcome | 2021 |
Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Prospective Studies | 2021 |
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vasodilation | 2021 |
Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients.
Topics: Anemia; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume | 2022 |
Effect of dapagliflozin in patients with heart failure.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Topics: Aged; Benzhydryl Compounds; Disease Progression; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adiponectin; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Prospective Studies; Treatment Outcome | 2021 |
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left | 2021 |
A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin.
Topics: Aged; Anthropometry; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Proteins; Female; Glucosides; Humans; Insulin; Male; Middle Aged; Muscle, Skeletal; Organ Size; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glyburide; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Non-alcoholic Fatty Liver Disease | 2021 |
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Benzhydryl Compounds; Cardiometabolic Risk Factors; COVID-19; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Multiple Organ Failure; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Topics: Aged; Benzhydryl Compounds; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Survival Rate; Time Factors; Ventricular Function, Left | 2021 |
Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.
Topics: Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2021 |
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic | 2021 |
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
Topics: Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Death, Sudden, Cardiac; Glucosides; Heart Arrest; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left | 2021 |
Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
Topics: Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Retina; Treatment Outcome | 2021 |
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Incidence; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prospective Studies; Stroke Volume; Transcatheter Aortic Valve Replacement; Treatment Outcome; Ventricular Function, Left | 2022 |
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Exercise; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2021 |
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Topics: Adiponectin; Adiposity; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity | 2022 |
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucosides; Glycemic Control; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2022 |
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2022 |
Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Insulin; Lipid Metabolism; Male | 2022 |
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Topics: Adolescent; Benzhydryl Compounds; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Prospective Studies; Treatment Outcome; Young Adult | 2022 |
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Ventricular Dysfunction, Left | 2022 |
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Frailty; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2022 |
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
Topics: Benzhydryl Compounds; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Glucosides; Humans; Life Style; Lipids; Middle Aged; Obesity; Waist Circumference | 2022 |
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
Topics: Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Pilot Projects; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss | 2022 |
Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Glycolipids; Humans; Liraglutide; Metabolic Syndrome; Quality of Life; Stroke Volume; Uric Acid; Ventricular Function, Left | 2022 |
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Humans | 2022 |
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Topics: Benzhydryl Compounds; Biomarkers; Ferritins; Glucosides; Heart Failure; Hepcidins; Humans; Iron; Iron Deficiencies; Receptors, Erythropoietin; Receptors, Transferrin; Stroke Volume; Transferrins | 2022 |
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Myocardial Infarction; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume | 2022 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Topics: Aged; Aged, 80 and over; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Hospitalization; Humans; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function.
Topics: Benzhydryl Compounds; Blood Glucose; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2022 |
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Calcium; Connexin 43; Disease Models, Animal; Fura-2; Glucose; Glucosides; Heart Failure; Monocrotaline; Pulmonary Arterial Hypertension; Rats; Sodium; Ventricular Dysfunction, Right; Ventricular Remodeling | 2022 |
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Topics: Aged; Female; Glucosides; Heart Failure; Humans; Male; Stroke Volume; Ventricular Function, Left | 2022 |
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Topics: Aged; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Kidney; Male | 2023 |
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin; Insulin, Regular, Human; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Ventricular Function, Left | 2022 |
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.
Topics: Benzhydryl Compounds; Echocardiography; Glucosides; Humans; Renal Insufficiency, Chronic | 2023 |
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; White | 2023 |
Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Interleukin-6; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha | 2023 |
637 other study(ies) available for glucose, (beta-d)-isomer and dapagliflozin
| Article | Year |
|---|---|
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism | 2008 |
Molecule of the month. Dapagliflozin.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Delivery Systems; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2007 |
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Topics: Adipocytes; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Cloning, Molecular; Glucose; Glucosides; Humans; Rats; Rats, Zucker; Reference Values; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2008 |
Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Hyperglycemia; Islets of Langerhans; Obesity; Pancreas; Rats; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma.
Topics: Acetonitriles; Animals; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Disease Models, Animal; Enzyme Inhibitors; Glucosides; Mass Spectrometry; Rats; Rats, Zucker; Reproducibility of Results; Sensitivity and Specificity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Solid Phase Extraction; Water | 2010 |
Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Cyclization; Drug Design; Glucosides; Inhibitory Concentration 50; Molecular Structure; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2011 |
New diabetes drugs go beyond insulin to flush out excess sugar.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Thiophenes | 2011 |
Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Biological; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Topics: Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship; Thiophenes | 2011 |
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Disease Models, Animal; Feedback, Physiological; Glomerular Filtration Rate; Glucosides; Homeostasis; Kidney Glomerulus; Kidney Tubules; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2012 |
Structural selectivity of human SGLT inhibitors.
Topics: Benzhydryl Compounds; Biological Transport; Diabetes Mellitus; Glucose; Glucosides; HEK293 Cells; Humans; Kidney; Molecular Structure; Patch-Clamp Techniques; Phlorhizin; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Substrate Specificity | 2012 |
[Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transport Proteins | 2011 |
Dapagliflozin--redefining treatment of T2DM?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Drugs in traffic: the road to approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abiraterone Acetate; Adenine; Androstadienes; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Benzhydryl Compounds; Bevacizumab; Drug Approval; Drug Industry; Glucosides; Hydroxyprogesterones; Indans; Morpholines; Natriuretic Peptide, Brain; Organophosphonates; Protein C; Recombinant Proteins; Rivaroxaban; Tenofovir; Thiophenes | 2011 |
FDA rejects novel diabetes drug over safety fears.
Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins; United States; United States Food and Drug Administration | 2012 |
Stereoselective C-glycosylation reactions with arylzinc reagents.
Topics: Benzhydryl Compounds; Glucosides; Indicators and Reagents; Molecular Structure; Stereoisomerism | 2012 |
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Topics: 3-Hydroxybutyric Acid; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Blood Glucose; Caloric Restriction; Diet; Dose-Response Relationship, Drug; Drinking; Energy Intake; Glucosides; Hyperphagia; Insulin; Male; Obesity; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Respiration; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss | 2012 |
Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Sodium-Glucose Transport Proteins | 2012 |
Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Models, Biological; Permeability; Sodium-Glucose Transporter 2 Inhibitors | 2012 |
Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.
Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors.
Topics: Algorithms; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Inhibitory Concentration 50; Quantitative Structure-Activity Relationship; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Dapagliflozin (Forxiga) for type 2 diabetes?
Topics: Adult; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United Kingdom; Weight Loss | 2013 |
Diabetes: Efficacy of dapagliflozin associated with renal function.
Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins | 2013 |
The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Sodium-Glucose Transport Proteins; Weight Gain | 2013 |
Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Exenatide; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Male; Mice; Mice, Inbred NOD; Peptides; Venoms | 2014 |
Diabetes drugs ride a bumpy road.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Glucosides; Heart Diseases; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Candida albicans; Candidiasis; Disease Progression; Female; Glucosides; Glycosuria; Kidney; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
[Introduction].
Topics: Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Insulin; Male; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin approved for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United States; United States Food and Drug Administration | 2014 |
Dapagliflozine (Farxiga) for type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
The perils of clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Male | 2014 |
Zucker Diabetic Fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Benzhydryl Compounds; Blood Coagulation; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Factor Xa Inhibitors; Female; Glucosides; Hypoglycemic Agents; Platelet Aggregation; Pyrazoles; Pyridones; Rats; Rats, Zucker; Thrombophilia; Thrombosis | 2014 |
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality-Adjusted Life Years; Scandinavian and Nordic Countries; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2015 |
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Blood Glucose; Body Weight; Cells, Cultured; Diabetic Nephropathies; Disease Models, Animal; Gene Expression; Glomerular Mesangium; Glucose; Glucosides; Homeostasis; Inflammation; Insulin-Secreting Cells; Kidney; Kidney Cortex; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Isoindoles; Niacinamide; Rats; Rats, Zucker; Streptozocin | 2015 |
[Contributions of SGLT-2 and new drugs under investigation].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2014 |
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom | 2015 |
Drug updates and approvals: 2014 in review.
Topics: Allergens; Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Drug Approval; Dry Powder Inhalers; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Lactones; Nurse Practitioners; Phleum; Plant Extracts; Pollen; Pyrazoles; Pyridines; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2014 |
Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Calcium; Diabetes Mellitus, Experimental; Glucose; Glucosides; Heart Ventricles; Humans; Myocytes, Cardiac; Patch-Clamp Techniques; Rats; Streptozocin | 2015 |
A report from the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) (September 15-19, 2014 - Vienna, Austria).
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Linagliptin | 2014 |
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Lipids | 2015 |
Possible adverse effects of SGLT2 inhibitors on bone.
Topics: Benzhydryl Compounds; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
[Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Models, Econometric; Spain | 2015 |
What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Formularies as Topic; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies.
Topics: Acetates; Analytic Sample Preparation Methods; Benzhydryl Compounds; Blood Chemical Analysis; Glucosides; Humans; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2015 |
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin | 2015 |
New drugs 2015, part 1.
Topics: Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Dibenzazepines; Drug Approval; Estrogens, Conjugated (USP); Glucosides; Humans; Indoles; Nitriles; Pyridones; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Topics: Administration, Oral; Adult; Animals; Benzhydryl Compounds; Blood Glucose; Cell Separation; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Gene Silencing; Glucagon; Glucagon-Secreting Cells; Gluconeogenesis; Glucosides; Hepatocyte Nuclear Factor 4; Humans; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; RNA, Small Interfering; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 | 2015 |
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biopsy; Body Weight; Cell Proliferation; Cyclic AMP; Disease Models, Animal; Disease Progression; Diuresis; Electrolytes; Epithelial Cells; Glucosides; Kidney; Kidney Function Tests; Male; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transport Proteins; Ultrasonography | 2015 |
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
[Weight also counts for patients].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
In brief: ketoacidosis with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.
Topics: Benzhydryl Compounds; Canagliflozin; Drug Interactions; Enzyme Inhibitors; Glucosides; Glucuronosyltransferase; HEK293 Cells; Humans; Microsomes, Liver; UDP-Glucuronosyltransferase 1A9 | 2015 |
[Positive experience with SGLT-2 inhibitor in general practice].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2015 |
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney Tubules, Proximal; Male; Medication Therapy Management; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Topics: Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Cell Count; Colonic Neoplasms; Diabetes Mellitus, Type 2; Glucosides; Glucuronosyltransferase; HCT116 Cells; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2015 |
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sodium-Glucose Transport Proteins; State Medicine; United Kingdom | 2015 |
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Foam Cells; Gene Expression; Glucose Tolerance Test; Glucosides; Hyperglycemia; Hypoglycemic Agents; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Bone Density; Diabetes Mellitus, Experimental; Diet, High-Fat; Energy Metabolism; Fasting; Gastric Inhibitory Polypeptide; Glucosides; Homeostasis; Insulin; Islets of Langerhans; Male; Mice; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Urea Nitrogen; Diuresis; Female; Glucosides; Glycosuria; Kidney; Kidney Function Tests; Male; Organ Size; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urodynamics | 2015 |
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Disease Progression; Fibrosis; Gene Expression; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Treatment Failure | 2016 |
[Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Topics: Age Factors; Aged; Benzhydryl Compounds; Blood Pressure; Blood Urea Nitrogen; Diuresis; Female; Fractures, Bone; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Hypotension, Orthostatic; Hypovolemia; Incidence; Male; Middle Aged; Osmosis; Placebos; Polyuria; Randomized Controlled Trials as Topic; Risk Factors; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice.
Topics: Adipose Tissue, Brown; Animals; Benzhydryl Compounds; Carbohydrate Metabolism; Energy Metabolism; Gene Expression Regulation; Glucosides; Glycogen; Ion Channels; Liver; Male; Mice; Midbrain Raphe Nuclei; Mitochondrial Proteins; Proto-Oncogene Proteins c-fos; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Synaptic Transmission; Thermogenesis; Uncoupling Protein 1; Vagus Nerve | 2016 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies | 2016 |
Gliflozins: ketoacidosis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents | 2016 |
[XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transport Proteins | 2016 |
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Greece; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Three new treatments for diabetes recommended by NICE.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Practice Guidelines as Topic | 2016 |
A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transport Proteins | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections | 2016 |
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; bcl-2-Associated X Protein; Benzhydryl Compounds; Cell Hypoxia; Cell Line; Diabetic Nephropathies; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Glucosides; Hypoxia-Inducible Factor 1; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Reperfusion Injury; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Metformin; Off-Label Use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phenylpropionates; Pyrroles | 2016 |
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
Topics: Animals; Benzhydryl Compounds; Cells, Cultured; Electric Stimulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Mice; Models, Theoretical; Sodium-Glucose Transporter 2 | 2016 |
Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
Topics: Animals; Benzhydryl Compounds; Female; Glucosides; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 | 2017 |
Stronger Warning for Two Diabetes Drugs.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Labeling; Glucosides; Humans; Hypoglycemic Agents; United States; United States Food and Drug Administration | 2016 |
The Oscillating Stimulus Transporter Assay, OSTA: Quantitative Functional Imaging of Transporter Protein Activity in Time and Frequency Domains.
Topics: Anion Transport Proteins; Benzhydryl Compounds; Benzopyrans; Biological Assay; Biological Transport; Cell Membrane; Chloride-Bicarbonate Antiporters; Endoplasmic Reticulum; Excitatory Amino Acid Transporter 2; Fluorescent Dyes; Glucose Transporter Type 2; Glucosides; Glutamate Plasma Membrane Transport Proteins; HEK293 Cells; Humans; Optical Imaging; Plasmids; Salicylic Acid; Sodium-Bicarbonate Symporters; Sodium-Glucose Transporter 2; Sulfate Transporters; Transfection | 2016 |
NICE recommends new triple therapy option for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Practice Guidelines as Topic; Sulfonylurea Compounds; United Kingdom | 2016 |
Diabetes News.
Topics: Benzhydryl Compounds; Congresses as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Peptides; Treatment Outcome; Venoms | 2017 |
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Topics: Aldosterone; Animals; Benzhydryl Compounds; Chymosin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hyperglycemia; Kidney; Lipid Peroxidation; Male; Rats, Inbred OLETF; Renin-Angiotensin System; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
Topics: Acarbose; Benzhydryl Compounds; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2017 |
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
Topics: Animals; Aquaporin 2; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucosides; Glycosuria; Kidney; Male; Membrane Transport Proteins; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Solute Carrier Family 12, Member 1; Urea Transporters; Water-Electrolyte Balance | 2016 |
Synthesis of unlabelled and stable-isotope-labelled glucuronide metabolites of dapagliflozin and synthesis of stable-isotope-labelled dapagliflozin.
Topics: Benzhydryl Compounds; Chemistry Techniques, Synthetic; Glucosides; Glucuronides; Isotope Labeling; Stereoisomerism | 2017 |
[Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Glucosides; GTP-Binding Protein gamma Subunits; Heart; Heterotrimeric GTP-Binding Proteins; Hyperglycemia; Hypoglycemic Agents; Lipodystrophy; Magnetic Resonance Imaging; Mice; Mice, Knockout; Myocardium; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Ventricular Dysfunction, Left; Ventricular Function | 2017 |
Effects of phosphate binders on the gastrointestinal absorption of arsenate and of an SGLT2 inhibitor drug on the urinary excretion of arsenite in mice.
Topics: Aluminum Hydroxide; Animals; Arsenates; Arsenites; Benzhydryl Compounds; Female; Gastrointestinal Absorption; Glucosides; Kidney; Lanthanum; Liver; Mice; Phosphates; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spain; Time Factors; Treatment Outcome; Weight Loss | 2017 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Incidence; Kidney; Kidney Diseases; Male; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2017 |
Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies | 2017 |
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Bone Marrow; Diabetes Complications; Diabetes Mellitus, Experimental; Glucose; Glucosides; Inflammasomes; Interleukin-18; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Registries; Risk Factors; Sweden | 2017 |
Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; General Practitioners; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2017 |
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Topics: Animals; Benzhydryl Compounds; Fibrosis; Gene Expression Regulation; Glucosides; Humans; Interleukin-10; Macrophages; Myocardial Infarction; Myocardium; Rats; Reactive Oxygen Species; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; STAT3 Transcription Factor | 2017 |
Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Bronchoalveolar Lavage Fluid; Diabetes Mellitus, Experimental; Glucosides; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Sodium-Glucose Transport Proteins | 2017 |
Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Topics: Adipose Tissue, White; Adiposity; Animals; Benzhydryl Compounds; Cell Size; Gene Expression Regulation; Glucose Clamp Technique; Glucose Intolerance; Glucose Transporter Type 4; Glucosides; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Membrane Transport Modulators; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); Rats, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2017 |
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins | 2017 |
Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged; Primary Health Care; Retrospective Studies | 2017 |
Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2017 |
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left | 2017 |
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Topics: Adult; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Obesity; Plasma Volume; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Real world points to SGLT-2 blockers advantage.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Abnormalities; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin.
Topics: Benzhydryl Compounds; Citric Acid; Crystallization; Drug Liberation; Drug Stability; Glucosides; Humidity; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Solubility; Tablets; Temperature | 2017 |
Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Canagliflozin; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Retrospective Studies; United States; Young Adult | 2017 |
DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Education as Topic; Patient Selection; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; CARD Signaling Adaptor Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fibroblasts; Fibrosis; Glucosides; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Obese; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Function, Left | 2017 |
Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus - Is it empaglifozin or the class?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
Topics: Animals; Benzhydryl Compounds; Cell Line; Cells, Cultured; Gene Silencing; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Mice; Signal Processing, Computer-Assisted; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Somatostatin | 2017 |
Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Urinary Bladder Neck Obstruction; Urinary Tract Infections | 2017 |
Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Humans; Kidney Diseases; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Practice Patterns, Physicians'; Primary Health Care; Time Factors; Treatment Outcome; United Kingdom; Weight Loss | 2017 |
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rodentia; Signal Transduction; Sodium-Glucose Transporter 2 | 2017 |
Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na
Topics: 3-O-Methylglucose; Animals; Benzhydryl Compounds; Biological Transport; Dose-Response Relationship, Drug; Galactose; Glucose; Glucosides; Humans; Kidney; Kinetics; Membrane Potentials; Membrane Proteins; Methylglucosides; Phlorhizin; Renal Reabsorption; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Xenopus laevis | 2017 |
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Creatinine; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Glucokinase; Glucosides; Glycosuria; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Male; Middle Aged; Mutation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Liraglutide; Male; Mice; Neurons; Neuroprotective Agents | 2017 |
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
Topics: Australia; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Female; General Practice; Glucosides; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2017 |
Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.
Topics: Aged; Benzhydryl Compounds; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Medical Audit; Middle Aged; Mycoses; Odds Ratio; Recurrence; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; United Kingdom | 2018 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Can we go beyond surrogates?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
Topics: Adolescent; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin | 2017 |
Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose; Glucosides; Humans; Kidney; Kidney Neoplasms; Mice, Nude; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden | 2018 |
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Apoptosis; Benzhydryl Compounds; Brain; Cognition Disorders; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Insulin; Insulin Resistance; Long-Term Potentiation; Male; Malondialdehyde; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neuroprotective Agents; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2017 |
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Topics: Acute Kidney Injury; Aged; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hemoglobins; Humans; Hypoglycemic Agents; Incidence; Kidney; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2017 |
Magnetic Nanoparticles for the Delivery of Dapagliflozin to Hypoxic Tumors: Physicochemical Characterization and Cell Studies.
Topics: A549 Cells; Benzhydryl Compounds; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Liberation; Glucosides; Humans; Magnetite Nanoparticles; Nanomedicine; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tumor Hypoxia | 2018 |
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Crowdsourcing; Data Mining; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2017 |
Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; NF-kappa B; Plasminogen Activator Inhibitor 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vasodilation | 2018 |
Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
Topics: Adipogenesis; Adipokines; Adipose Tissue, White; Benzhydryl Compounds; Chemokines; Endothelial Cells; Glucose; Glucosides; Humans; Inflammation Mediators; Insulin; Insulin Resistance; Paracrine Communication; Pericardium; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat | 2018 |
Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Carcinoembryonic Antigen; Cetuximab; Colonic Neoplasms; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucosides; Humans; Kidney; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness | 2017 |
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Resistance; Ketosis; Middle Aged; Young Adult | 2018 |
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury.
Topics: Animals; Benzhydryl Compounds; Cardiotonic Agents; Cytoprotection; Diet, High-Fat; Glucosides; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Function, Left; Vildagliptin | 2018 |
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.
Topics: Abdominal Pain; Anorexia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2; Vomiting | 2018 |
Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Energy Intake; Female; Glucosides; Humans; Hyperphagia; Male; Middle Aged; Sodium-Glucose Transport Proteins; Sugars; Surveys and Questionnaires; Young Adult | 2018 |
Drug updates and approvals: 2017 in review.
Topics: Adamantane; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Benzylamines; Dipeptides; Drug Approval; Drug Combinations; Glucosides; Humans; Oxymetazoline; Primary Health Care; United States; United States Food and Drug Administration | 2017 |
Initiation of dapagliflozin and treatment-emergent fractures.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors | 2018 |
Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fluorine; Glucosides; Glycosylation; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
Topics: Administration, Intravenous; Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Monosaccharides; Oximes; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2018 |
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Topics: Adipose Tissue; Adiposity; Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Prospective Studies | 2018 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, Western; Glucosides; Inflammation; Insulin Resistance; Kidney Diseases; Kidney Glomerulus; Lipids; Liver; Liver Cirrhosis; Liver Diseases; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Topics: Adipose Tissue; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Multidetector Computed Tomography; Pericardium; Plasminogen Activator Inhibitor 1; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Dapagliflozin associated ketoacidosis: A must know fact for nephrologists.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus; Female; Glucosides; Humans; Ketosis; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States | 2018 |
SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Foot; Glucosides; Humans; Hypoglycemic Agents; Leg; Male; Middle Aged; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
Topics: Alanine; Benzhydryl Compounds; Canagliflozin; Cell Death; Cell Line; Citric Acid Cycle; Electron Transport Complex I; Epithelial Cells; Glucosides; Glutamate Dehydrogenase; Glutamic Acid; Glutamine; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Metabolomics; Mitochondria | 2018 |
A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors.
Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2018 |
Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Gluconeogenesis; Glucose; Glucose Tolerance Test; Glucosides; Insulin; Kidney; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microscopy, Electron, Transmission; ROC Curve; Signal Transduction | 2018 |
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Topics: Adamantane; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammasomes; Inflammation Mediators; Kidney; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Italy; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cholesterol, Dietary; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heparin; Hyperlipidemias; Lipoproteins; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Phlorhizin; Proteoglycans; Receptors, LDL; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2018 |
Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins | 2018 |
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin; Insulin Resistance; Kidney; Kidney Diseases; Male; Metformin; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction; Sodium-Glucose Transporter 2 | 2018 |
A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
Topics: Benzhydryl Compounds; Canagliflozin; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Practice Patterns, Physicians'; Propensity Score; Research Design; Retrospective Studies; United States | 2018 |
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Topics: Abdominal Fat; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammation Mediators; Irbesartan; Kidney; Male; Organ Size; Oxidative Stress; Protective Agents; Rats, Wistar; Tetrazoles | 2018 |
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2018 |
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gastrointestinal Microbiome; Glucosides; Intestines; Male; Mice; Muscle, Smooth, Vascular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Stiffness; Vasodilation | 2018 |
Insulin dependent and independent normalization of blood glucose levels reduces the enhanced rewarding effects of nicotine in a rodent model of diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Conditioning, Psychological; Diabetes Mellitus, Experimental; Female; Glucosides; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Nicotine; Nicotinic Agonists; Reward | 2018 |
Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged | 2018 |
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Subcutaneous Fat, Abdominal; Treatment Outcome | 2018 |
Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Epilepsy; Glucosides; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes.
Topics: 3-Hydroxybutyric Acid; Adiponectin; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Gene Expression Profiling; Glucosides; Metabolome; Metabolomics; Mice; Mice, Inbred NOD; Microarray Analysis; Sodium-Glucose Transporter 2 Inhibitors; Transcriptome; Up-Regulation | 2018 |
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Progression; Endoplasmic Reticulum Stress; Glucosides; Inflammation; Kidney; Kidney Diseases; Male; Prediabetic State; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
Topics: Abdominal Pain; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dyspnea; Fatigue; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Nausea; Vomiting | 2018 |
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
Topics: Adenosine Diphosphate; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; Glucosides; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Molecular Structure; Nitric Oxide; Platelet Aggregation; Rabbits; Structure-Activity Relationship; Venous Thrombosis | 2018 |
Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Topics: Animals; Benzhydryl Compounds; Carbonates; Disease Models, Animal; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Myocardium; Rats, Inbred F344; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2018 |
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Cell Line; Disease Models, Animal; Glucosides; Humans; Injections, Intraperitoneal; Male; Mice; Podocytes; Proteinuria; Renal Insufficiency, Chronic; RNA, Small Interfering; Serum Albumin, Bovine; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States | 2019 |
Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway.
Topics: Benzhydryl Compounds; Cell Line, Tumor; Glucosides; HMGB1 Protein; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Kidney Tubules, Proximal; NF-kappa B; Oxidative Stress; Protective Agents; Receptor for Advanced Glycation End Products; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Italy; Kidney; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Treatment Outcome | 2019 |
SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Benzhydryl Compounds; Canada; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Registries; Retrospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Coma; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Effect of Dapagliflozin on Intestinal Flora in MafA-deficient Mice.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gastrointestinal Microbiome; Glucosides; Maf Transcription Factors, Large; Male; Mice; Mice, Inbred ICR; Streptozocin | 2018 |
Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Topics: Aged; Albumins; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2019 |
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Pancreatitis; Propensity Score; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Urinary Tract Infections; Venous Thromboembolism | 2018 |
A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Topics: Animals; Benzhydryl Compounds; Biological Transport; Endoplasmic Reticulum; Gene Expression Regulation; Glucosides; Insulin; Insulin Resistance; Male; Matrix Metalloproteinases; Metabolic Syndrome; Myocytes, Cardiac; Oxidative Stress; Proteolysis; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Zinc | 2019 |
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Blood Glucose; Disease Models, Animal; Glucosides; Heart Rate; Heart Ventricles; Insulin; Insulin Resistance; Male; Membrane Potential, Mitochondrial; Metabolic Syndrome; Mitochondria, Heart; Myocytes, Cardiac; Potassium Channels, Voltage-Gated; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Voltage-Gated Sodium Channels | 2018 |
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; United States; Young Adult | 2019 |
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
Topics: Animals; Benzhydryl Compounds; CHO Cells; Cricetulus; Glucosides; Humans; Indoles; Molecular Structure; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2019 |
Dapagliflozin DECLAREd safe.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2018 |
Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fructose; Glucosides; Male; Pilot Projects; Random Allocation; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2019 |
Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology.
Topics: Benzhydryl Compounds; Fibroblast Growth Factor-23; Glucosides; Homeostasis; Humans; Male; Nephrology; Phosphates; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Electrocardiography; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Male; Middle Aged; Retrospective Studies | 2019 |
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2019 |
Intestinal electrogenic sodium-dependent glucose absorption in tilapia and trout reveal species differences in SLC5A-associated kinetic segmental segregation.
Topics: Animals; Benzhydryl Compounds; Cecum; Gene Expression; Glucose; Glucosides; In Vitro Techniques; Intestinal Absorption; Kinetics; Oncorhynchus mykiss; Phlorhizin; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Species Specificity; Tilapia | 2019 |
Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fournier Gangrene; Glucosides; Humans; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Research Design; Sweden; Treatment Outcome | 2019 |
Topics: Adult; Aged; Animals; Antigens, Helminth; Apoptosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Carcinogenesis; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cell Proliferation; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Endosonography; Feces; Female; Glomerular Filtration Rate; Glucosides; Glutathione; Humans; Logistic Models; Male; Middle Aged; Ovum; Oxidative Stress; Pancreas; Pancreatic Elastase; Pancreatitis, Chronic; Patient Safety; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Prospective Studies; Prostate; Risk Factors; Schistosoma; Schistosomiasis; Scotland; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Systole; Treatment Outcome | 2017 |
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Glucagon-Secreting Cells; Glucosides; Humans; Hypoglycemia; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Insulin; Receptors, Somatostatin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Somatostatin | 2019 |
Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Ketosis; Renal Replacement Therapy; Saline Solution; Sodium Bicarbonate; Young Adult | 2019 |
A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Butylhydroxybutylnitrosamine; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Male; Rats; Rats, Sprague-Dawley; Urinary Bladder Neoplasms | 2019 |
Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Topics: Animals; Benzhydryl Compounds; Blotting, Western; Cardiomyopathies; Disease Models, Animal; Echocardiography; Fibrosis; Glucosides; Heart Ventricles; Hypertrophy, Left Ventricular; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2019 |
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
Topics: Animals; Benzhydryl Compounds; Dehydration; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucocorticoids; Glucose; Glucosides; Humans; Insulin; Ketosis; Lipolysis; Liver; Male; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Glucosides; Male; Membrane Transport Proteins; Mice; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Potassium-Exchanging ATPase; Streptozocin | 2019 |
Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Metformin; Probability | 2019 |
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Canagliflozin; Creatine; Glucosides; Humans; Hypoglycemic Agents; Molecular Structure; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Structure-Activity Relationship | 2019 |
Stratifying the effects of SGLT2i.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.
Topics: Adamantane; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Glucosides; Humans; Incretins; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2019 |
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
New spectrofluorimetric analysis of dapagliflozin after derivatization with NBD-Cl in human plasma using factorial design experiments.
Topics: Benzhydryl Compounds; Fluorescence; Glucosides; Humans; Hypoglycemic Agents; Limit of Detection; Plasma; Spectrometry, Fluorescence | 2019 |
Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Qatar; Treatment Outcome | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Circulating complement-1q tumor necrosis factor-α-related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin.
Topics: Benzhydryl Compounds; Biomarkers; Case-Control Studies; Collagen; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Insulin Resistance; Male; Middle Aged; Prognosis; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs.
Topics: Acute Kidney Injury; Animals; Apoptosis; Benzhydryl Compounds; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Gentamicins; Glucosides; Kidney Function Tests; Male; MicroRNAs; Oxidative Stress; Rats; Rats, Wistar | 2019 |
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
Topics: Adolescent; Age Factors; Benzhydryl Compounds; Blood Glucose; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Re: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Glucosides; Rats; Urinary Bladder Neoplasms | 2019 |
Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucosides; Humans; Longitudinal Studies; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction | 2019 |
Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Glucosides; Rats; Urinary Bladder Neoplasms | 2019 |
Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Energy Intake; Female; Fibroblast Growth Factors; Glucosides; Humans; Male; Middle Aged | 2019 |
Effects of dapagliflozin in experimental sepsis model in rats.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Oxidative Stress; Rats; Sepsis; Tissue Distribution | 2019 |
The expanding résumé of SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Topics: Animals; Benzhydryl Compounds; Fatty Acids; Gene Expression; Glucose Intolerance; Glucosides; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2019 |
A novel SGLT2 inhibitor, SU-011, improves glycaemic control in rodents without the risk of hypoglycaemia and weight gain.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Glucosides; HEK293 Cells; Humans; Interleukin-1beta; Male; Mice; Peptide Fragments; Pyrans; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Tumor Necrosis Factor-alpha | 2019 |
Validated Liquid Chromatographic Method for the Determination of (Canagliflozin, Dapagliflozin or Empagliflozin) and Metformin in the Presence of (1-Cyanoguanidine).
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Guanidines; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Novel univariate spectrophotometric determination of the recently released solid dosage form comprising dapagliflozin and saxagliptin via factorized response spectra: Assessment of the average content and dosage unit uniformity of tablets.
Topics: Adamantane; Benzhydryl Compounds; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Limit of Detection; Sodium-Glucose Transporter 2 Inhibitors; Spectrophotometry; Tablets | 2019 |
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Cell Death; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Epithelial Cells; Glucose; Glucosides; Humans; Kidney; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Topics: Animals; Benzhydryl Compounds; Glucose; Glucosides; Insulin Glargine; Mice; Non-alcoholic Fatty Liver Disease; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetic Nephropathies; Diet, High-Protein; Disease Progression; Gene Expression Regulation; Glucosides; Kidney; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2019 |
Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Primary Health Care; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; United Kingdom | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS.
Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Chromatography, Liquid; Glucosides; Humans; Limit of Detection; Metformin; Plasma; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Solid Phase Extraction; Tandem Mass Spectrometry | 2019 |
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2019 |
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Topics: Benzhydryl Compounds; Blood Volume; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics; Glucose; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Multicenter Studies as Topic; Myocardial Infarction; Natriuresis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stroke; Stroke Volume | 2019 |
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Glucagon; Glucosides; Humans; Liraglutide; Male; Mice; Somatostatin | 2019 |
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
Topics: Adult; Age Factors; Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Medicare; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Statistics, Nonparametric; Vascular Stiffness | 2020 |
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Topics: Animals; Aorta; Benzhydryl Compounds; Biomarkers; Blood Pressure; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytokines; Disease Models, Animal; Female; Fibrosis; Glucosides; Heart Failure; Hypertension; Inflammation Mediators; Lipids; Nitric Oxide; Norepinephrine; Sodium-Glucose Transporter 2 Inhibitors; Sus scrofa; Sympathetic Nervous System; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Optimal designs for regional bridging studies using the Bayesian power prior method.
Topics: Bayes Theorem; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Development; Glucosides; Humans; Models, Statistical; Research Design; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Global Health; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome | 2019 |
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sarcopenia; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Topics: Benzhydryl Compounds; Consensus; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Heart-Failure Therapy - New Drugs but Old Habits?
Topics: Benzhydryl Compounds; Glucosides; Habits; Heart Failure; Humans; Stroke Volume | 2019 |
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hyperglycemia; Kidney Tubules, Proximal; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2019 |
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2019 |
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Dapagliflozin-induced sweet syndrome.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Sweet Syndrome | 2019 |
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2019 |
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2019 |
Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.
Topics: Benzhydryl Compounds; Gluconeogenesis; Glucose; Glucosides; Kidney Tubules, Proximal; Liver; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT-2 inhibitors in heart failure: a new therapeutic avenue.
Topics: Benzhydryl Compounds; Death, Sudden, Cardiac; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Topics: Benzhydryl Compounds; Coronary Vessels; Down-Regulation; Endothelial Cells; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Nitric Oxide; Nitric Oxide Synthase Type III; Permeability; Reactive Oxygen Species; Signal Transduction; Sodium-Glucose Transporter 2; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2019 |
Second-derivative synchronous spectrofluorimetric assay of dapagliflozin: Application to stability study and pharmaceutical preparation.
Topics: Benzhydryl Compounds; Calibration; Drug Stability; Glucosides; Hydrogen-Ion Concentration; Molecular Conformation; Spectrometry, Fluorescence | 2020 |
Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renin-Angiotensin System; Risk Factors; Uric Acid | 2020 |
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Lipolysis; Male; Melatonin; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin in heart failure: new frontiers.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2019 |
SGLT2 inhibitors for primary prevention of cardiovascular events.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Prevention; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeogenesis; Glucosides; Glycosuria; Insulin Resistance; Liver; Male; Metformin; Obesity; Pancreas; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Duration of Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Italy; Male; Middle Aged; Patient Safety; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment.
Topics: Adipose Tissue; Benzhydryl Compounds; Coronary Artery Disease; Glucose; Glucosides; Humans; Lactic Acid; Pericardium; Sodium-Glucose Transport Proteins | 2020 |
Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Topics: Acute Kidney Injury; Animals; Benzhydryl Compounds; Blood Pressure; Dinoprostone; Down-Regulation; Doxazosin; Extracellular Signal-Regulated MAP Kinases; Glucosides; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney; Male; Nitric Oxide Synthase Type II; Random Allocation; Rats; Reperfusion Injury; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin for HFrEF - improved outcomes across all ages.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eligibility Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Reproducibility of Results; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2019 |
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiology; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Disease Progression; Glucosides; Heart Failure; Humans; Incidence; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Class effect: dapagliflozin reduces cardiovascular and kidney events.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Kidney Diseases | 2020 |
Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment.
Topics: Adipose Tissue; Animals; Benzhydryl Compounds; Butyric Acid; Disease Models, Animal; Gastrointestinal Microbiome; Glucose; Glucosides; Liver; Mice; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2019 |
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
Topics: Antibodies; Benzhydryl Compounds; Blood Glucose; Databases, Nucleic Acid; Glucagon; Glucose; Glucosides; HEK293 Cells; Humans; Islets of Langerhans; RNA, Small Interfering; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction; Vasodilation; Young Adult | 2020 |
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Japan; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2020 |
Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic properties.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Benzhydryl Compounds; Blood Glucose; CHO Cells; Cricetulus; Drug Combinations; Drug Compounding; Excipients; Gastrointestinal Absorption; Glucosides; Hypoglycemic Agents; Injections, Subcutaneous; Male; Peptides; Protein Aggregates; Protein Structure, Secondary; Rats; Sodium-Glucose Transporter 2 Inhibitors; Solubility | 2020 |
Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
Topics: Aged; Autoantibodies; Benzhydryl Compounds; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketosis; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Calcium Channels, L-Type; Calcium Signaling; Cells, Cultured; Diabetes Mellitus; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Rats, Sprague-Dawley; Sodium-Calcium Exchanger; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Ventricular Function, Left | 2020 |
Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2020 |
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
Topics: Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Epithelial Cells; Gene Expression Regulation; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Kidney; Kidney Tubules, Proximal; Oxidative Stress; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Food, Fortified; Glucose Transporter Type 2; Glucosides; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Lansoprazole; Male; Oxidative Stress; Pancreas; PPAR gamma; Random Allocation; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin restores insulin and growth hormone secretion in obese mice.
Topics: Animals; Benzhydryl Compounds; Body Composition; Diabetes Mellitus, Type 2; Energy Metabolism; Gene Expression; Glucosides; Growth Hormone; Humans; Insulin; Insulin Resistance; Insulin Secretion; Mice, Inbred C57BL; Mice, Knockout; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Benzhydryl Compounds; Carcinoembryonic Antigen; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Collagen Type IV; Colonic Neoplasms; Diabetes Mellitus, Type 2; Discoidin Domain Receptor 1; Fibronectins; Gene Knockdown Techniques; Glucosides; Glucuronosyltransferase; Humans; Laminin; Membrane Proteins; Phosphorylation; RNA, Small Interfering; Sodium-Glucose Transporter 2 Inhibitors; Vitronectin | 2020 |
Dapagliflozin Cut Risk of Worsening Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Comment on: "High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment".
Topics: Benzhydryl Compounds; Coronary Artery Disease; Glucosides; Humans; Lactic Acid | 2020 |
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Epinephrine; Food Deprivation; Gene Expression Regulation; Glucagon; Glucosides; Insulin; Lipolysis; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucosides; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Benzhydryl Compounds; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Male; Plasma; Triglycerides | 2020 |
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Observational Studies as Topic; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Models, Biological; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Systems Biology | 2020 |
Dapagliflozin reduced worsening HF or CV death in HF with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Gluconeogenesis; Glucose-6-Phosphatase; Glucosides; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Proteins; Intracellular Signaling Peptides and Proteins; Kidney; Male; Metformin; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar | 2020 |
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Approval; Europe; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Reduced
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cell Hypoxia; Cell Line; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fibronectins; Fibrosis; Glucosides; Glycosylation; Humans; Kidney Tubules, Proximal; Male; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2020 |
Dapagliflozin in patients with heart failure and reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Male; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2i and postglomerular vasodilation.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
The authors reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
A Novel Cardioprotective Therapy That Also Improves Glycemia.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Glucosides; Heart Failure; Humans | 2020 |
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
Topics: Angiotensin Receptor Antagonists; Benzhydryl Compounds; Diuretics; Glucosides; Heart Failure; Humans | 2020 |
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2020 |
Effects of dapagliflozin and statins attenuate renal injury and liver steatosis in high-fat/high-fructose diet-induced insulin resistant rats.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Benzhydryl Compounds; Blotting, Western; Dietary Carbohydrates; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Fructose; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Rats; Rats, Wistar | 2020 |
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy].
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Diuresis; Female; Glucosides; Glycosuria; Heart Failure; Heart Ventricles; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Myocardium; Natriuresis; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Walk Test | 2020 |
Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Comparison of the effect of dapagliflozin on contrast to standard therapy of the patients with type 2 diabetes mellitus and concomitant obesity, their effect on laboratory and anthropometric parameters.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Treatment Outcome | 2020 |
Prognosis of patients eligible for dapagliflozin in acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzhydryl Compounds; Cause of Death; Cohort Studies; Eligibility Determination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Patient Readmission; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Hyperglucosuria induced by dapagliflozin augments bacterial colonization in the murine urinary tract.
Topics: Animals; Benzhydryl Compounds; Escherichia coli Infections; Female; Glucosides; Mice; Mice, Inbred Strains; Urinary Tract; Urinary Tract Infections; Uropathogenic Escherichia coli | 2020 |
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Disease Progression; Enzyme Activation; Fibrosis; Glucosides; Inflammasomes; Male; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred C57BL; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Purinergic P2Y Receptor Antagonists; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ticagrelor; TOR Serine-Threonine Kinases; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients.
Topics: Benzhydryl Compounds; Blood Flow Velocity; Diabetes Mellitus, Type 2; Glucosides; Humans; Ultrasonography; Ultrasonography, Doppler, Color | 2020 |
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Prognosis; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Norway; Proportional Hazards Models; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2020 |
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Motivation; Sodium-Glucose Transporter 2 Inhibitors; Standard of Care; Stroke Volume | 2020 |
Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
Topics: Adrenal Gland Neoplasms; Animals; Benzhydryl Compounds; Canagliflozin; Cell Line, Tumor; Glucosides; Methylglucosides; Pheochromocytoma; Pituitary Neoplasms; Potassium Channels; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of sodium glucose co-transporter 2 inhibitors on genital infections in female patients with type 2 diabetes mellitus- Real world data analysis.
Topics: Adult; Benzhydryl Compounds; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Israel; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2020 |
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diet, High-Fat; Energy Intake; Glucagon; Glucagon-Secreting Cells; Glucosides; Homeodomain Proteins; Hydrocortisone; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice, Transgenic; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Trans-Activators | 2020 |
A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin.
Topics: Benzhydryl Compounds; Cells, Cultured; Endothelial Cells; Glucose; Glucosides; Humans; Kidney Tubules, Proximal; Models, Biological; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2020 |
Dapagliflozin Does Not Directly Affect Human α or β Cells.
Topics: Adolescent; Adult; Animals; Benzhydryl Compounds; Cells, Cultured; Female; Glucagon; Glucagon-Secreting Cells; Glucosides; Heterografts; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred NOD; Mice, Transgenic; Middle Aged; Signal Transduction; Species Specificity; Young Adult | 2020 |
Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Italy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment | 2020 |
Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucosides; Metformin; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice.
Topics: Adult; Age Factors; Aged; Benzhydryl Compounds; Blood Glucose; Cohort Studies; Diabetes Mellitus; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Benzhydryl Compounds; Disease Models, Animal; Energy Metabolism; Glucosides; Male; Mitochondria, Heart; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
Topics: Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Topics: Adult; Aged; Benzhydryl Compounds; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Female; Glucosides; Heart Failure; Hospital Costs; Humans; Incidence; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
An Escape From Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin Glargine; Metformin | 2020 |
SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?
Topics: Benzhydryl Compounds; Glucagon-Secreting Cells; Glucosides; Humans | 2020 |
Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Benzhydryl Compounds; Diet; Fatty Liver; Fructose; Glucosides; Humans; Inflammation; Interleukin-18; Interleukin-1beta; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Transaminases; Tumor Necrosis Factor-alpha | 2020 |
Regression of left ventricular hypertrophy with SGLT2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Humans; Hypertrophy, Left Ventricular; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Fluorescence spectroscopy for determination of dapagliflozin in pure form and its tablets formulation; Application to content uniformity testing.
Topics: Benzhydryl Compounds; Glucosides; Limit of Detection; Spectrometry, Fluorescence; Tablets | 2020 |
Benefit of dapagliflozin is independent of LVEF.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Humans; Sodium; Sodium-Glucose Transporter 2; Stroke Volume; Ventricular Function, Left | 2020 |
Dapagliflozin reduces left ventricular mass.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucosides; Humans; Hypertrophy, Left Ventricular | 2020 |
Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Biomechanical Phenomena; Bone Density; Bone Matrix; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Liraglutide; Mice; Osteogenesis | 2020 |
Dapagliflozin improves behavioral dysfunction of Huntington's disease in rats via inhibiting apoptosis-related glycolysis.
Topics: Animals; Apoptosis; Autophagy; Behavior, Animal; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Glycolysis; Huntington Disease; Inflammation; Male; Maze Learning; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers, Pharmacological; Drugs, Investigational; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2020 |
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
Topics: Benzhydryl Compounds; Body Mass Index; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endocrine Cells; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glucosides; Insulin; Insulin-Secreting Cells; Male; Mice; Proprotein Convertase 1; Regeneration; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin (Farxiga) - a new indication for heart failure.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Netherlands; Quality-Adjusted Life Years | 2021 |
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Female; Germany; Glucosides; Heart Failure; Humans; Male; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Spain; Ventricular Function, Left | 2020 |
Dapagliflozin for heart failure: is it a class effect?
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Topics: Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Models, Biological; Randomized Controlled Trials as Topic; Renal Insufficiency; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Quadruple Therapy Is the New Standard of Care for HFrEF.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Standard of Care; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume; Thailand; Ventricular Function, Left | 2021 |
Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis.
Topics: Benzhydryl Compounds; Cardiomegaly; Extracellular Fluid; Glucosides; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Models, Cardiovascular; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Pharmacology Focus: Dapagliflozin Use in Reduced Ejection Fraction Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2020 |
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2020 |
Antihyperglycemic Drug Approved to Treat Heart Failure.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Stroke Volume; United States; United States Food and Drug Administration | 2020 |
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Female; Fibrosis; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure, Diastolic; Hypertrophy, Left Ventricular; Incretins; Liraglutide; Mice, Inbred C57BL; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Ventricular Remodeling | 2021 |
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Mice; Pancreas; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
Topics: Atrial Fibrillation; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2020 |
The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Heart Failure; Humans | 2020 |
Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertrophy, Left Ventricular; Predictive Value of Tests; Ventricular Function, Left | 2021 |
SGLT2 inhibitors and renal complications in type 1 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Correction of anemia by dapagliflozin in patients with type 2 diabetes.
Topics: Anemia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Serum Albumin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Glucosides; Rats; Reperfusion Injury | 2020 |
Evaluation of dapagliflozin in the treatment of heart failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2021 |
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Topics: AMP-Activated Protein Kinases; Benzhydryl Compounds; Canagliflozin; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Glucosides; Hexokinase; Humans; Hypoglycemic Agents; Inflammation Mediators; Lipopolysaccharides; MAP Kinase Signaling System; NF-kappa B; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; Breast Neoplasms; Canagliflozin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Glucose; Glucosides; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Volume; Computer Simulation; Diabetes Mellitus, Type 2; Diuresis; Glomerular Filtration Barrier; Glucosides; Heart Failure; Hematocrit; Hemodynamics; Humans; Models, Theoretical; Natriuresis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Current and Emerging Issues in the Management of Heart Failure in Primary Care.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Topics: Aged; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Female; Glucosides; Humans; Male; Middle Aged; Myocardium; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2021 |
The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2020 |
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Overweight; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2021 |
Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; United States | 2021 |
Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'.
Topics: Benzhydryl Compounds; Cardiovascular System; Glucosides; Humans; Renal Insufficiency, Chronic | 2020 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
Topics: Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Apoptosis; Benzhydryl Compounds; Breast Neoplasms; Cardiotoxicity; Caspase 3; Cell Line; Cell Survival; Comorbidity; Diabetes Complications; Diabetes Mellitus, Experimental; Disease Models, Animal; Doxorubicin; Echocardiography; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Glucosides; Humans; Male; Middle Aged; Myocytes, Cardiac; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Retrospective Studies; Young Adult | 2021 |
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
Topics: Adolescent; Animals; Benzhydryl Compounds; Cell Line, Transformed; Cells, Cultured; Dialysis Solutions; Female; Glucose; Glucosides; Humans; Male; Mice; Mice, Inbred C57BL; Peritoneal Fibrosis; Peritoneum; RAW 264.7 Cells; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ultrafiltration | 2020 |
[Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Female; Glucosides; Glycemic Control; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Computational Biology; Disease Models, Animal; Fasting; Glucose; Glucosides; Immunohistochemistry; Insulin Resistance; Macrophages; Mice; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bayes Theorem; Benzhydryl Compounds; Bone Density; Canagliflozin; Data Mining; Female; Fractures, Bone; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmacovigilance; Retrospective Studies; Risk Factors; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2021 |
Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Drug Liberation; Emulsions; Glucosides; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Mice; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Plant Oils; Rats; Rats, Wistar; Sitagliptin Phosphate; Solubility; Surface Properties | 2021 |
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Incidence; Stroke Volume | 2021 |
Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Peripheral Arterial Disease; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Colitis, Ulcerative; Colon; Glucosides; Heme Oxygenase (Decyclizing); HMGB1 Protein; Male; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Rats, Wistar; Receptor for Advanced Glycation End Products; Signal Transduction; TOR Serine-Threonine Kinases; Trinitrobenzenesulfonic Acid | 2021 |
Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis
Topics: Animals; Antioxidants; Benzhydryl Compounds; Cell Line; Diabetes Mellitus, Type 2; Diet, High-Fat; Forkhead Box Protein O1; Gene Expression Regulation; Gluconeogenesis; Glucose; Glucosides; Humans; Male; Mice; Mice, Obese; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Random Allocation; Resveratrol; Sodium-Glucose Transporter 2 Inhibitors; Up-Regulation | 2021 |
Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Sodium, Dietary | 2021 |
Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Glucosides; Hyperglycemia; Male; Obesity; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Topics: Animals; Ascites; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drug Therapy, Combination; Furosemide; Glucosides; Hemodynamics; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in Patients with Chronic Kidney Disease. Reply.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality.
Topics: Benzhydryl Compounds; ErbB Receptors; Glomerular Filtration Rate; Glucosides; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes Mellitus, Type 2; Drainage; Female; Fournier Gangrene; Glucosides; Hospitals, Rural; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Obesity; Perineum; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2021 |
Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson's Disease Rat Model.
Topics: Animals; Benzhydryl Compounds; Glucosides; Glycogen Synthase Kinase 3 beta; Mice; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Parkinson Disease; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Reactive Oxygen Species; Rotenone | 2021 |
Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Glucosides; Inflammation; Kidney; Male; Rats; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2021 |
Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Diet, High-Fat; Endoplasmic Reticulum Stress; Gene Expression Regulation; Glucose Tolerance Test; Glucosides; Inflammation; Kidney; Magnetic Resonance Imaging; Male; Malondialdehyde; Obesity; Oxidative Stress; Pancreas; Rats, Wistar; Signal Transduction; TOR Serine-Threonine Kinases; Vildagliptin | 2021 |
Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells.
Topics: Benzhydryl Compounds; Calcium; Calcium Channels; Cell Cycle; Cell Death; Cell Line; Cell Proliferation; Cytosol; Gene Expression Regulation; Glucosides; Humans; Hydrogen Peroxide; Kidney Tubules, Proximal; Mitochondria; Oxidative Stress; Phenanthridines; Protective Agents; Protein Isoforms; Reactive Oxygen Species; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 | 2021 |
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans; Insulin; Ketosis; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis.
Topics: Animals; Apoptosis; Arginine; Autophagy; Benzhydryl Compounds; Glucosides; Male; Mice; Neoplasms; Nitric Oxide; Transforming Growth Factor beta1; Transforming Growth Factors | 2021 |
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Disease Risk Factors; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Glucosides; Humans; Hypertriglyceridemia; Male; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fluorescent Dyes; Glucosides; Kidney; Liver; Mice; Sodium-Glucose Transporter 2 | 2021 |
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years | 2021 |
Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Expert Testimony; Female; Glucosides; Heart Failure; Humans; Male; Poland; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
Slowing Progression in CKD: DAPA CKD and Beyond.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Glucosides; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Health Policy; Heart Failure; Humans; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; United Kingdom | 2021 |
Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.
Topics: Animals; Benzhydryl Compounds; China; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Immediate-Early Proteins; Male; Mice; Mice, Inbred C57BL; Protein Serine-Threonine Kinases; T-Lymphocytes, Regulatory; Th17 Cells | 2021 |
Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans | 2021 |
Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Hemodynamics; Male; Mitral Valve Insufficiency; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus.
Topics: Adipose Tissue; Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Gene Expression Regulation; Glucosides; Hypoglycemic Agents; Intra-Abdominal Fat; Lipids; Lipoproteins, HDL; Male; Rats; Rats, Wistar; Streptozocin | 2021 |
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Physicochemical characterization of dapagliflozin and its solid-state behavior in stress stability test.
Topics: Benzhydryl Compounds; Calorimetry, Differential Scanning; Glucosides; Powder Diffraction; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2021 |
SGLT-2 inhibition in IgA nephropathy: the new standard of care?
Topics: Benzhydryl Compounds; Glomerulonephritis, IGA; Glucosides; Humans; Immunosuppressive Agents; Kidney; Renal Insufficiency, Chronic; Standard of Care | 2021 |
Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Eating; Glucose; Glucosides; Hypothalamic Area, Lateral; Phosphorylation; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of taxifolin/dapagliflozin combination on colistin-induced nephrotoxicity in rats.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Beclin-1; Benzhydryl Compounds; Colistin; Drug Combinations; Gene Expression Regulation; Glucosides; Kidney Diseases; Male; MAP Kinase Kinase 4; Quercetin; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Bone Marrow Cells; Diabetes Mellitus, Experimental; Glucosides; Hematopoietic Stem Cells; Human Umbilical Vein Endothelial Cells; Humans; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin does not affect blood pressure variability in prediabetic prehypertensive subjects.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Humans; Prediabetic State; Prehypertension | 2021 |
Response to Comment on Díaz-Cruz et al. Effect of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial Blood Press Monit 2020; 25:346-350.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Humans; Prediabetic State; Prehypertension | 2021 |
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
Topics: Benzhydryl Compounds; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Standard of Care | 2021 |
Effects of dapagliflozin on energy metabolism.
Topics: Benzhydryl Compounds; Energy Metabolism; Glucosides; Humans | 2021 |
DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Retrospective Studies; Sitagliptin Phosphate; Spain; Treatment Outcome | 2021 |
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Primary Prevention; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis.
Topics: Acetic Acid; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Colitis; Dose-Response Relationship, Drug; Drug Delivery Systems; Glucosides; Male; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
Topics: Benzhydryl Compounds; Cells, Cultured; Connective Tissue Growth Factor; Diabetic Nephropathies; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Glucose; Glucosides; Humans; Kidney Tubules, Proximal; Phosphorylation; Signal Transduction; Smad2 Protein; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1 | 2021 |
Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2021 |
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis.
Topics: Benzhydryl Compounds; Catalysis; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |
[New Developments in Type 1 Diabetes].
Topics: Benzhydryl Compounds; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemia; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
Topics: Benzhydryl Compounds; Drug Approval; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; United States; United States Food and Drug Administration | 2021 |
Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Topics: Angiotensin II; Animals; Antifibrotic Agents; Benzhydryl Compounds; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardium; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; DNA, Mitochondrial; Dynamins; Gene Dosage; Glucosides; GTP Phosphohydrolases; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Obesity; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Random Allocation; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2021 |
Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibroblasts; Fibrosis; Glucosides; Male; Mesoderm; Rats; Signal Transduction; Smad4 Protein; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2021 |
Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis.
Topics: Benzhydryl Compounds; Chemistry, Organic; Glucosides; Glycosides; Humans | 2021 |
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Erythropoietin; Glomerular Filtration Rate; Glucosides; Kidney; Male; Microvessels; Oxygen; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and safety of dapagliflozin in the treatment of chronic heart failure: A protocol for systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Treatment Outcome | 2021 |
Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
Topics: Benzhydryl Compounds; Canagliflozin; Cell Membrane Permeability; Endothelial Cells; Glucosides; Guanidines; Humans; Inflammation; NADPH Oxidases; Oxidative Stress; Pyrazoles; Pyridones; Reactive Oxygen Species; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stress, Mechanical; Sulfones | 2021 |
Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diet, High-Fat; Glucosides; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Oleic Acid | 2021 |
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
Topics: Albumins; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Benzhydryl Compounds; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eosine Yellowish-(YS); Glucose; Glucosides; Hematoxylin; Inflammasomes; Insulins; Kidney; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Periodic Acid; Proto-Oncogene Proteins c-akt; Ticagrelor | 2022 |
Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts.
Topics: AMP-Activated Protein Kinases; Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Connexin 43; Gene Expression; Glucosides; Male; Myocardial Infarction; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Remodeling | 2021 |
Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway.
Topics: Benzhydryl Compounds; Diabetic Cardiomyopathies; Glucosides; Humans; MAP Kinase Signaling System; Molecular Docking Simulation; Network Pharmacology; Protein Interaction Mapping; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
Topics: Adrenal Glands; Animals; Benzhydryl Compounds; Cardiovascular Agents; Catecholamines; Glucosides; Heart Failure; Humans; Ketone Bodies; Models, Biological; Receptors, G-Protein-Coupled; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Structure-Activity Relationship; Sympatholytics | 2021 |
Dapagliflozin in patients with COVID-19: truth or dare.
Topics: Benzhydryl Compounds; COVID-19; Glucosides; Humans; SARS-CoV-2 | 2021 |
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Markov Chains; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Surveys and Questionnaires | 2021 |
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Is Dapagliflozin Cost-effective for Treating Heart Failure?
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, Protein-Restricted; Glucose; Glucosides; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
Topics: Animals; Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Electrocardiography; Erythropoietin; Glucosides; Male; MAP Kinase Signaling System; Myocardium; Rats, Wistar; Streptozocin | 2021 |
Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective.
Topics: Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Glucosides; Heart Failure; Humans | 2021 |
Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome.
Topics: Benzhydryl Compounds; Glucosides | 2021 |
The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Heart Failure, Systolic; Humans; Obesity; Prognosis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2021 |
Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2021 |
Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin.
Topics: Benzhydryl Compounds; Binding Sites; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Serum Albumin, Bovine; Sodium-Glucose Transporter 2 Inhibitors; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2022 |
Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 1; Glucosides; Hypoglycemic Agents; Insulin; Rats; Rodent Diseases | 2021 |
Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Philippines; Stroke Volume | 2021 |
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
Topics: Adiposity; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucosides; Insulin Resistance; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Dapagliflozin: The outcome of use as add-on therapy in real-life clinical setting -An Audit.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2021 |
Current Role of Dapagliflozin in Clinical Practice.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Determination of the Chemical Stability of Dapagliflozin by LC/DAD and MS/MS Methods.
Topics: Acetonitriles; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Reproducibility of Results; Tablets; Tandem Mass Spectrometry; Water | 2022 |
Study Projects Lifetime Benefits of Dapagliflozin in HFrEF.
Topics: Benzhydryl Compounds; Cardiotonic Agents; Cause of Death; Clinical Trials, Phase III as Topic; Glucosides; Heart Failure; Humans; Life Expectancy; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Stroke Volume | 2021 |
Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro.
Topics: Animals; Benzhydryl Compounds; Calcium; Glucosides; Hydrogen Peroxide; In Vitro Techniques; Liver; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxygen Consumption; Permeability; Rats; Rats, Wistar; Reactive Oxygen Species | 2021 |
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Sodium-Glucose Transporter 2 | 2022 |
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
Topics: Aged; Asia; Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Drug Costs; Female; Glucosides; Heart Failure, Systolic; Hospital Costs; Hospitalization; Humans; Male; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity.
Topics: Animals; Benzhydryl Compounds; Chemokine CX3CL1; CX3C Chemokine Receptor 1; Glucosides; Inflammation; Lipopolysaccharides; NF-kappa B; Rats; Reactive Oxygen Species; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2022 |
Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation.
Topics: Aged; Benzhydryl Compounds; Black or African American; Eligibility Determination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Female; Glucosides; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cell Line; Cyclic AMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Epithelial Cells; Female; Follow-Up Studies; Glucosides; Humans; Male; MAP Kinase Signaling System; Middle Aged; Renal Elimination; Retrospective Studies; RNA-Seq; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glucuronosyltransferase; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2022 |
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2021 |
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia.
Topics: Benzhydryl Compounds; Colombia; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Muscles; Natriuretic Peptide, Brain; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2021 |
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
Topics: Age Factors; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Retrospective Studies; Weight Loss | 2022 |
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Death, Sudden; Glucose; Glucosides; Heart Arrest; Heart Failure; Humans; Sodium; Stroke Volume; Ticks | 2022 |
[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycemic Control; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
[Dapagliflozin in the prevention and treatment of heart failure].
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Topics: Aged; Atrial Fibrillation; Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2021 |
Dapagliflozin improves exercise capacity in HFpEF.
Topics: Benzhydryl Compounds; Exercise Tolerance; Glucosides; Heart Failure; Humans; Stroke Volume | 2022 |
Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.
Topics: Animals; Benzhydryl Compounds; Diet, Carbohydrate Loading; Dietary Supplements; Disease Models, Animal; Fructose; Glucosides; Homeostasis; Insulin Resistance; Kidney; Kidney Tubules; Magnesium; Magnesium Deficiency; Magnesium Sulfate; Metabolic Syndrome; Rats; Sodium-Glucose Transporter 2 Inhibitors; TRPM Cation Channels | 2021 |
Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Glucose; Glucosides; Heart Failure; Mice; Sirtuin 1 | 2022 |
Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Benzhydryl Compounds; Glucosides; Glycation End Products, Advanced; Podocytes; TOR Serine-Threonine Kinases | 2022 |
Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real-world experience.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Treatment Outcome | 2022 |
SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
Topics: Animals; Benzhydryl Compounds; Citric Acid Cycle; Fibrosis; Glucosides; Inflammasomes; Kidney Diseases; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Succinates | 2022 |
Dapagliflozin in patients with COVID-19: mind the kidneys.
Topics: Benzhydryl Compounds; COVID-19; Glucosides; Humans; Kidney; SARS-CoV-2 | 2022 |
Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.
Topics: Benzhydryl Compounds; COVID-19; Glucosides; Humans; Kidney; SARS-CoV-2 | 2022 |
Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load.
Topics: Action Potentials; Administration, Intravenous; Animal Feed; Animals; Benzhydryl Compounds; Diet, High-Fat; Glucose; Glucosides; Hypoglycemic Agents; Insulin Resistance; Male; Rats, Wistar; Sciatic Nerve; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System; Time Factors | 2022 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Monocytes | 2021 |
The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats.
Topics: Animals; Atorvastatin; Autophagy; Benzhydryl Compounds; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Insulin; Kidney; Male; Rats; Rats, Wistar | 2022 |
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability.
Topics: Animals; Benzhydryl Compounds; Constriction, Pathologic; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose; Glucosides; Humans; Hypoglycemic Agents; Mice; Plaque, Atherosclerotic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2022 |
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
Topics: Actins; Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Liver; Glucosides; Insulin; Interleukin-1beta; Liver; Male; Malondialdehyde; NF-kappa B; Oxidative Stress; Rats; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2022 |
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hematocrit; Humans; Risk Factors | 2022 |
Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Benzhydryl Compounds; Gene Expression Regulation; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Hypoglycemic Agents; Inflammation Mediators; Macrophage Activation; Macrophages; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Toll-Like Receptor 4 | 2022 |
The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Inflammation; Lipopolysaccharides; Male; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; Standard of Care; Thailand | 2022 |
Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline.
Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Disease Models, Animal; Glucosides; Hypertension, Pulmonary; Male; Monocrotaline; Pulmonary Artery; Rats; Rats, Sprague-Dawley | 2022 |
Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Prospective Studies | 2021 |
Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzhydryl Compounds; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Risk Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2022 |
Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt/β-Catenin and CREB pathway.
Topics: Animals; Behavior, Animal; Benzhydryl Compounds; Cognitive Dysfunction; Cyclic AMP Response Element-Binding Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glucosides; Glycogen Synthase Kinase 3 beta; Memory Disorders; Neuroprotective Agents; Rats; Signal Transduction; Wnt3 Protein | 2022 |
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin | 2022 |
Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2022 |
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Glucose; Glucosides; Humans; Hypoglycemic Agents; In Situ Hybridization, Fluorescence; Metformin; MicroRNAs; RNA, Circular; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2022 |
SGLT2 inhibitors may prevent diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Heart Failure; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Prospective Studies; Quality-Adjusted Life Years; Spain | 2022 |
SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Gain of Function Mutation; Glucosides; Humans; Infant, Newborn; Infant, Newborn, Diseases; Insulin-Secreting Cells; KATP Channels; Male; Mice; Mice, Transgenic; Oxidative Stress; Protective Agents; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
Topics: Animals; Benzhydryl Compounds; Cardiomyopathies; Glucosides; Inflammation; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Obesity; Palmitic Acid; Rats; Sodium-Glucose Transporter 2 Inhibitors; Transcription Factor AP-1 | 2022 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Dapagliflozin on Adipose and Liver Fatty Acid Composition and mRNA Expression Involved in Lipid Metabolism in High-Fat-Fed Rats.
Topics: Adipose Tissue; Animals; Benzhydryl Compounds; Dietary Fats; Fatty Acids; Glucosides; Lipid Metabolism; Liver; Male; Rats; RNA, Messenger; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India.
Topics: Adipose Tissue; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver | 2022 |
Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs.
Topics: Animals; Benzhydryl Compounds; Dogs; Glucosides; Proline; Solubility; Swine; Swine, Miniature; Tablets | 2022 |
Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Apoptosis; Benzhydryl Compounds; Glucose; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Inflammation; Interleukin-6; Oxidative Stress; Reactive Oxygen Species; Sirtuin 1; Tumor Necrosis Factor-alpha | 2022 |
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis | 2022 |
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hypoglycemic Agents; Ketones; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Is Dapagliflozin future for CKD?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Topics: Benzhydryl Compounds; Brain; Cues; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Could SGLT2 inhibitors be the next 'game changer' in focal segmental glomerulosclerosis?
Topics: Benzhydryl Compounds; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Humans; Inflammation; Liraglutide; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin in young people with type 2 diabetes.
Topics: Adolescent; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2022 |
Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1α/HE4/NF-κB Pathway.
Topics: Acute Kidney Injury; Animals; Benzhydryl Compounds; Contrast Media; Diabetes Mellitus; Glucosides; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; NF-kappa B; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Male | 2022 |
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Glucosides; Humans; Hypertension, Pulmonary; Monocrotaline; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Sildenafil Citrate; Vascular Remodeling | 2022 |
Stability-indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Drug Stability; Glucosides; Metformin; Tablets | 2022 |
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzhydryl Compounds; Cardiotoxicity; Doxorubicin; Glucosides; Humans; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; STAT3 Transcription Factor | 2022 |
Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor.
Topics: Benzhydryl Compounds; COVID-19; Glucosides; Humans; Kidney; Paint; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyponatremia; Sodium; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Glucagon-Like Peptides; Glucosides; Humans; Insulin; Insulin Resistance | 2022 |
Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Endothelial Cells; Glucosides; Mice; Retina | 2022 |
Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Streptozocin | 2022 |
Skin Dryness Induced in the KK-Ay/TaJcl Type 2 Diabetes Mouse Model Deteriorates Following Dapagliflozin Administration.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyaluronic Acid; Hypoglycemic Agents; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2022 |
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiomyopathies; Fatty Acids; Female; Glucosides; Heart Failure; Humans; Ketones; Ketosis; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Dapagliflozin Safe and Effective for Heart Failure With Frailty.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Frailty; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2022 |
Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1/PGC-1α pathway in obese mice.
Topics: Animals; Benzhydryl Compounds; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Obese; Mitochondria; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Sirtuin 1 | 2022 |
Dapagliflozin partially restores reproductive function in MC4R KO obese female mice.
Topics: Animals; Benzhydryl Compounds; Female; Glucosides; Growth Hormone; Human Growth Hormone; Humans; Hyperphagia; Luteinizing Hormone; Mice; Mice, Knockout; Obesity; Receptor, Melanocortin, Type 4 | 2022 |
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus; Diabetic Nephropathies; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Medicare; Quality-Adjusted Life Years; Standard of Care; United States | 2022 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss | 2022 |
Dapagliflozin Attenuates Sympathetic and Pressor Responses to Stress in Young Prehypertensive Spontaneously Hypertensive Rats.
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Hypertension; Muscle Contraction; Rats; Rats, Inbred SHR; Sympathetic Nervous System | 2022 |
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Retrospective Studies | 2022 |
Dapagliflozin Alleviates Coxsackievirus B3-induced Acute Viral Myocarditis by Regulating the Macrophage Polarization Through Stat3-related Pathways.
Topics: Animals; Benzhydryl Compounds; Coxsackievirus Infections; Cyclic S-Oxides; Cytokines; Enterovirus B, Human; Glucose; Glucosides; Interleukin-6; Macrophages; Male; Mice; Mice, Inbred BALB C; Myocarditis; Sodium; Symporters; Tumor Necrosis Factor-alpha | 2022 |
SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Benzhydryl Compounds; Cardiomyopathies; Collagen; Diabetes Mellitus, Type 2; Fibrosis; Glucose; Glucosides; Heart Diseases; Inflammation; Mice; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats.
Topics: Animals; Benzhydryl Compounds; Cardiomyopathies; Doxorubicin; Glucosides; Rats; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha | 2022 |
Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Glucosides; Mitochondrial Dynamics; Myocardial Infarction; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley | 2022 |
Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue-molecules and SGLT2i dapagliflozin.
Topics: Adipose Tissue; Benzhydryl Compounds; Endothelial Cells; Female; Glucosides; Heart Failure; Humans; Neutrophils; Obesity; Phenotype; Stroke Volume | 2022 |
Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Economic | 2022 |
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Topics: Acetates; Animals; Antioxidants; Benzhydryl Compounds; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Endoribonucleases; Glucose Transporter Type 4; Glucosides; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Leukotriene Antagonists; Metformin; Muscle, Skeletal; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Response Elements; Streptozocin; Sulfides | 2022 |
A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation.
Topics: Animals; Benzhydryl Compounds; Carotenoids; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gastrointestinal Microbiome; Glucosides; Lactobacillus; Male; Oxidative Stress; PPAR gamma; Rats; Rats, Wistar; Streptozocin | 2022 |
Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy.
Topics: Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effects of Dapagliflozin in Combination with Metoprolol Sustained-Release Tablets on Prognosis and Cardiac Function in Patients with Acute Myocardial Infarction after PCI.
Topics: Benzhydryl Compounds; Biomarkers; C-Reactive Protein; Delayed-Action Preparations; Drug Therapy, Combination; Glucosides; Humans; Interleukin-6; Metoprolol; Myocardial Infarction; Percutaneous Coronary Intervention; Prognosis; Serum Albumin; Stroke Volume; Superoxide Dismutase; Tablets; Ventricular Function, Left | 2022 |
Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Ferroptosis; Glucosides; Mice; Mice, Inbred C57BL | 2022 |
Dapagliflozin for patients with heart failure and reduced ejection fraction.
Topics: Adult; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 2022 |
Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus; Fibrosis; Glucosides; Male; Rabbits; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan.
Topics: Cost-Benefit Analysis; Glucosides; Humans; Japan; Renal Insufficiency, Chronic | 2022 |
Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Cardiotoxicity; Doxorubicin; Fibrosis; Glucosides; Hypertrophy; Inflammation; Myocardium; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Ventricular Remodeling | 2022 |
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Echocardiography; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Stroke Volume | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Cholic Acid; Diet, High-Fat; Fibrosis; Glucosides; Inflammation; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats | 2022 |
Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients.
Topics: Benzhydryl Compounds; C-Reactive Protein; Cardiomyopathies; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Failure; Humans; Interleukin-6; Tumor Necrosis Factor-alpha | 2022 |
Dapagliflozin improves outcomes in HFmrEF and HFpEF.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Prognosis; Stroke Volume; Ventricular Function, Left | 2022 |
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Percutaneous Coronary Intervention; Prognosis; Receptors, Angiotensin; Retrospective Studies; Triglycerides | 2022 |
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; COVID-19; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Morbidity; Pandemics; Prospective Studies; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome; Vascular Stiffness | 2022 |
Dapagliflozin Inhibits Ventricular Remodeling in Heart Failure Rats by Activating Autophagy through AMPK/mTOR Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Atrial Natriuretic Factor; Autophagy; Autophagy-Related Proteins; Benzhydryl Compounds; Caspase 3; Glucosides; Heart Failure; Hypoxia; Myocytes, Cardiac; Rats; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Remodeling | 2022 |
An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.
Topics: Albumins; Animals; Benzhydryl Compounds; Caspase 3; Chemokines; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Interleukin-10; Mice; Network Pharmacology; PPAR gamma; RNA, Long Noncoding; RNA, Messenger; Sequence Analysis, RNA; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta | 2022 |
Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
Topics: Acetonitriles; Animals; Benzhydryl Compounds; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glucuronosyltransferase; Liver Neoplasms; Rats; Reproducibility of Results; RNA, Messenger; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib; Tandem Mass Spectrometry; Uridine Diphosphate | 2022 |
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States | 2022 |
Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans | 2022 |
Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Is Dapagliflozin a Cardiac Anti-Aging Drug?
Topics: Aging; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans | 2023 |
Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies | 2023 |
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Proportional Hazards Models; Stroke Volume | 2023 |
Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Function, Left | 2023 |
Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2023 |
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.
Topics: Aged; Benzhydryl Compounds; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
Topics: Benzhydryl Compounds; Frailty; Glucosides; Heart Failure; Humans | 2023 |
Using dapagliflozin in patients with heart failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans | 2023 |
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Heart Failure, Diastolic; Hospitalization; Humans; Male; Medicare; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2023 |
In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Heart Failure; Humans; Stroke Volume | 2023 |
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Stroke Volume; Ventricular Dysfunction, Left | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Topics: Benzhydryl Compounds; Cohort Studies; Death; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Topping Off the Pill Box: Dapagliflozin, Heart Failure, and Polypharmacy.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Polypharmacy; Stroke Volume; Ventricular Function, Left | 2023 |
Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents | 2023 |
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations.
Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Meta-Analysis as Topic | 2023 |